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CHAPTER!
INTRODUCTION
Embryonic and fetal development of the heart is a unique process
when compared to the development of other muscle tissue in that the
dividing muscle cells, or cardiomyocytes, are highly differentiated and
exhibit coordinated, contractile activity. However, these cardiomyocytes
lose their capacity to divide, and therefore, embryonic and fetal heart
development are the primary periods of active myocyte proliferation.
During the perinatal period of rat heart development, a rapid "transition"
occurs in the ventricle which involves the cessation of proliferation of the
cardiomyocytes. In this same perinatal transition period, the
cardiomyocyte undergoes a maturation process in which a change in
expression of individual isoforms of several contractile proteins occurs that
affects its contractile activity. Additionally, remodeling of the ventricle
occurs during the late fetal and early neonatal periods of development
involving both cardiomyocyte and non-cardiomyocyte populations. We have
hypothesized that the transforming growth factor-B (TGF-B) family of
receptors and ligands plays an integral role in these different processes of
the perinatal "transition" due to their characteristic anti-proliferative
activities as well as their ability to influence the expression of numerous
genes associated with ventricular remodeling.
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TGF-B ligands (TGF-B 1_3 ) transduce their actions through a
heterodimeric receptor complex containing the Type I and Type II TGF-B
serine/threonine kinase receptors (BRI and BRII, respectively). While BRI
appears to be constituitively expressed, we have shown by Northern blot
analyses that TGF-B 1 , TGF-B3 , and BRII expression in the rat ventricle is
low-to-undetectable during fetal development and increase dramatically ator-around birth. These patterns are temporally coordinated with the
cellular and extracellular changes that occur during the perinatal
transition period. These changes include the cessation of cardiomyocyte
proliferation, the isoform switch of several members of the contractile
machinery within the cardiomyocyte, the increase in extracellular matrix
accumulation, and an increase in angiogenesis, or blood vessel formation,
in the ventricle. Therefore, we would like to determine the direct roles
TGF-B may have in these developmental processes.
It is widely accepted that both TGF-B receptors are necessary for

most, if not all, actions of TGF-B signal transduction. BRII is the primary
ligand binding receptor and initiator of the TGF-B signaling cascade. It
has been shown that ablation of BRII kinase function is an effective way to
study the effects TGF-B has on cellular functions, and several of these types
of studies have been utilized to study the effects ofTGF-B on cardiomyocyte
growth and maturation. These studies have utilized a dominant negative
methodology in which an inactive BRII, either by eliminating the kinase
domain or through specific inactivating point mutations, was introduced
into the cell. When overexpressed, this mutant receptor interferes with the
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endogenous wild type BRII's function by limiting or eliminating its access
to bioactive ligand as well as available BRI, resulting in a blunted and/or
ablated response to TGF-B as the signal transduction pathway cannot be
activated by the truncated receptor.
This dominant-negative methodology was chosen to study the effects
of TGF-B in cardiomyocyte and ventricular development and provide a
system in which the roles of each receptor in cardiomyocyte development
can be elucidated. While the use of primary cardiomyocytes would be the
ideal cell type for such studies as they would be expected to closely reflect
events which occur in vivo, their lack of proliferative activity in vitro and
low receptivity to experimental manipulation have made them a nontenable methodology. Therefore, the model system chosen to study these
effects of TGF-B on a cardiomyocyte-like cell type was the use of two rat,
fetal ventricular myocyte-derived cell lines, BWEM and CLEM. To enable
us to evaluate the direct effects TGF-B may have on the cardiomyocyte, we
utilized the dominant negative methodology to eliminate the TGF-B
response in these cell lines. To do this, truncated, kinase-deficient human
BRII was stably expressed in the BWEM and CLEM rat myocyte-like cell
lines to create two clonal mutant cell lines, BW-Hl and CL-B5, with reduced
or absent BRII function.
Each of these cell lines, BWEM, CLEM, BW-Hl, and CL-B5, as well
as primary cultures of 18 day fetal cardiomyocytes were then used to study
the direct effects TGF-B may have on the myocyte population during
ventricular development. The goal of this dissertation project was to
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establish the role(s) TGF-B plays in modifying myocyte proliferation and
differentiation during the perinatal transition period. In addition to the
creation and characterization of the BRII dominant negative cell lines, the
data collected for this dissertation address the following questions:
(1) Does TGF-B inhibit cardiomyocyte proliferation?
(2) Does TGF-B play a direct role in cardiomyocyte differentiation by
inducing the "adult" isoforms of three contractile proteins, Troponin C,
Troponin I, and Troponin T?
(3) Does TGF-B promote ECM accumulation and angiogenesis
through the upregulation of cardiomyocyte produced PAI-1 and SPARC
peptides?

CHAPTER2
REVIEW OF THE LITERATURE
One of the most effective means of controlling tissue formation and
cellular function is the production of stimuli from cells which either act on
the cells themselves in a feedback mechanism (autocrine stimuli) or on
neighboring cells (paracrine stimuli). Growth factors are one type of
stimuli, and therefore, determining the role of growth factors in embryonic
and fetal development is an area of ongoing study. Changes in proliferative
activity, differentiation, cell shape, migration, cell adhesion, and cell death
are examples of the effects growth factors may elicit (Simmen and Simmen,
1991; Adamson 1993). Growth factors are important in such activities as
embryonic implantation (Simmen and Simmen, 1991), determining
dorsal/ventral patterning in the early embryo (Slack 1990; Christian and
Moon, 1993; Nusslein-Volhard 1991; de Vries et al., 1996), regulating
homeobox gene expression (Dawid et al., 1992), influencing proper limb
development (Fallon et al., 1994), and regulating cell growth and/or
differentiation (Adamson 1993; Murphy and Barron, 1993). The use of gene
ablations has provided examples of the importance of growth factors such
as the transforming growth factor-betas (Proetzel et al., 1995; Boivin et al.,
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1995; Kaartinen et al., 1995) and fibroblast growth factors (Amaya et al.,
1991; Ueno et al., 1992; Feldman et al., 1995) in development.
Development of the heart, like many other organs and systems,
appears to be under partial control by several growth factors which work in
an autocrine or paracrine manner. The presence of growth factors and
their receptors in the developing heart appears to be differentially regulated
in that they are expressed in both temporally and spatially discrete times
and sites. These growth factors are believed to be involved in several
separate, yet inter-related, processes: 1) cardiomyocyte proliferation and
differentiation, 2) the formation of biomechanical structures such as the
valves, 3) vasculogenesis; capillary angiogenesis and neovascularization,
and 4) non-muscle cell-produced extracellular matrix (ECM) formation.

Review of TGF-Bs
Identification of Ligands and Receptors
Among an expanding list of growth factors that appear to have an
active part in heart development are members of the transforming growth
factor-beta (TGF-B) superfamily. TGF-B is the prototypic member of this
large peptide growth factor family that includes the TGF-Bs, activins,
inhibins, bone morphogenetic proteins, mullerian inhibiting substance,
and products of the decapentaplegic (Drosophila) and Vgl (Xenopus) genes
(Massague 1990; Kingsley 1994). To date, five isoforms ofTGF-B have been
identified: TGF-B 1_3 (mammalian), TGF-B4 (avian), and TGF-B 5
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(amphibian) (Massague 1990). Although originally established as a novel
isoform, TGF-B4 has been shown to be the avian TGF-B 1 (Burt and Paton,
1992). Each of the three mammalian isoforms have nearly perfect amino
acid identity across species, and all five TGF-B isoforms have been highly
conserved throughout evolution, suggesting specific roles for each. In
addition, each TGF-B isoform shares a high degree of amino acid sequence
homology with each other in their mature, bioactive domain. In contrast,
each TGF-B isoform is associated and secreted with a large latency
associated protein (LAP) as well as a latent TGF-B binding protein
(Miyazono et al., 1988; Miyazono et al., 1990; Miller et al., 1992; MacKay et
al., 1992). These proteins are unique to each TGF-B isoform. In order for
"latent" TGF-B to be activated, these latency proteins must be released from
the bioactive TGF-B homodimer by processes that remain to be identified in

vivo, yet in vitro acidification, heat, or proteolytic cleavage has been shown
to be effective (Massague 1990; Ghosh and Brauer, 1996). Lastly, multiple
members of the TGF-B family are often co-expressed and co-localized, and
they generally elicit similar mechanisms of action on cells in culture.
While almost all TGF-B peptides identified exist as homodimers, limited
examples of TGF-B 112 heterodimers have also been identified in platelets and
bone (Cheifetz et al., 1987; Ogawa et al., 1992).
As with most, if not all, growth factors and cytokines, TGF-Bs exert
their effects through cell surface receptors. To date, nine distinct proteins
have been identified on the cell surfaces of a diverse array of cell types
which bind the TGF-Bs (Massague 1987; Sporn and Roberts, 1992). Three of
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these proteins in mammalian cells are classified as functional TGF-B
receptors: Type I (BRI), Type II (BRII), and Type III (BRiii). BRiii,
otherwise known as betaglycan, has been cloned from rat, chicken, human,
and porcine cells (Lopez-Casillas et al., 1991; Wang et al., 1991; Moren et
al., 1992; Barnett et al., 1994), and varies in size from 200-400 kD, dependent
on the level of glycosylation. However, the core protein is approximately 110
kD in size and is moderately conserved across species, having a 70-80%
identity at the amino acid level. This receptor appears to bind each of the
different TGF-B isoforms with a high affinity (Kd of 50-200 pM for B1_3 ,
Miyazono et al., 1994) and is expressed in and found on the surfaces of
virtually all cell types. However, this receptor is not a "classical" receptor
in that it does not have a intracellular signaling domain, and as such, its
exact role in TGF-B signal transduction has yet to be fully elucidated (see
below).
BRI and BRII have also been cloned from a variety of species and are
the prototypes of an ever growing family of serine/threonine (SIT) kinase
receptors. BRII has been cloned recently from cDNA libraries derived from
human, porcine, mink, rat, chicken, and mouse cell lines (Lin et al., 1992;
Wrana et al., 1992; Tsuchida et al., 1993; Lawler et al., 1994). Immediately
following the cloning of BRII, Type I receptor genes were cloned through
cDNA library screens utilizing sequences obtained from the kinase domain
of BRII. These screens have identified numerous genes which fall into the
Type I "family", but their exact identities were harder to determine due to
their promiscuous ligand binding abilities in concert with BRII (example:
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Ebner et al., 1993). However, a physiologically relevant, true BRI has been
identified from human (ALK-5), rat (R4), and murine (ESK2/mTFR40)
systems (Franzen et al., 1993; He et al., 1993; Suzuki et al., 1994b; Tomoda et
al., 1994).
The bulk of BRII can be divided into two domains: the extracellular
(EC) domain and the intracellular (IC) domain (Figure 1). While the TGF-B
ligands are almost perfectly conserved across species, the ligand-binding,
EC domain of BRII has only 80-85% amino acid sequence identity across
species, with the divergent areas considered not to be involved in ligand
binding activity. In contrast, the IC domain, of which the bulk is the SIT
kinase domain, is 96-100% identical across species at the amino acid level.
While the general structure of BRII is highly conserved, two variants have
been identified to date in human and murine cells. One contains a 25
amino acid insert in the EC domain (Suzuki et al., 1994a; Hirai and Fujita,
1996), while the other has an extended IC tail of -400 amino acids
(compared to 30 a.a. for its "normal" human counterpart; Kawabata et al.,
1995a).
Like BRII, BRI receptors are highly conserved with 100% amino acid
identity within the IC-SIT kinase domain and 90-97% overall sequence
identity (Figure 1). Contrasting with this high level of interspecies
conservation seen in the domains of BRI, the kinase domain of different
members of the type I family of receptors within the TGF-B superfamily
(aka type I activin receptors, type I BMP receptors, etc.) are less conserved
at the amino acid level (-65%), and interestingly, have relatively low amino

10
acid homology to the BRII kinase domain (-40%) (Tomoda et al., 1994).
These low homologies imply that the type I and type II receptors have
distinct functions within the signaling cascade, and that the different type I
receptors activate distinct pathways I downstream effectors.

TGF-BRJ

~~

-53kD

....
llJ

JC

.....

I
JC

501 aa

~~-

TGF-BRII -75kD
homology (human:rat)

82%

I
98%

567 aa

~ Signal Sequence

Im Extracellular Ligand-binding domain
•

Transmembrane Domain
Im ml GS Domain
•
Serine/Threonine Kinase Domain

Figure 1: Schematic Diagrams of BRI and BRII
Diagrams of each TGF-B receptor and the major functional domains
are depicted. Arrows indicate full intracellular (IC) domain, a majority of
which is the kinase domain, but also including activation domains such as
the well conserved GS domain in the type I receptors. Amino acid
homologies between the extracellular domain and kinase domains are
given for BRII.
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General Functions of TGF-B
The general biological functions of TGF-B can be broadly grouped into
three major, albeit overlapping, categories: 1) actions which affect cellular
proliferation and migration; 2) actions involved in cell adhesion and ECM
formation; and 3) actions that affect a cell's phenotype (Massague 1990;
Roberts and Sporn, 1992a). In general, all of these activities can be
mediated by any of the five TGF-B isoforms known to date.

Cellular Proliferation
While TGF-B is able to stimulate cell division in a distinct and limited
subset of cell types (Anchan and Reh, 1995, and references therein; Zhao
and Young, 1996), the TGF-B's have significant anti-proliferative activities
on almost all cell types in culture (Massague 1990; Sporn and Roberts,
1992). While such studies continue, the effects of TGF-B on cellular
proliferation appear to involve the regulation of the synthesis and/or
activities of proteins involved in the normal progression through the cell
cycle. For example, the retinoblastoma (Rb) gene is a critical cell cycle
regulatory protein which is inactivated by phosphorylation in late G 1 , and
this inactivation is necessary for entry into S phase and DNA replication
(Laiho et al., 1990). TGF-B 1 has been found to maintain Rb in its
unphosphorylated state leading to G 1 arrest (Laiho et al., 1990). Addition of
TGF-B 1 at the mid-to-late G 1 stage of the cell cycle did not have any effect on
the Rb which was already phosphorylated, but inhibited further
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phosphorylation, thus regulating the phosphorylation and not the
dephosphorylation of Rb (Laiho et al., 1990).
Of growing importance in the study of TGF-B's anti-proliferative
effects is the understanding of the multifaceted regulatory role TGF-B has
in regards to the many proteins which are involved in the cell cycle. TGF-B 1
has been found to regulate cyclin/cdk activities, one of which mediates Rb
phosphorylation (Lafon et al., 1995), which is needed during G 1 to S phase
transitions. While cyclin D mRNA levels appear unchanged in response to
TGF-B 1 , the mRNA levels of two other G 1 cyclins, cyclin E and cyclin A, are
reduced to almost undetectable levels in cells treated with TGF-B 1 (Geng
and Weinberg, 1993). The lower levels of cyclin A can be attributed to a
direct downregulation of mRNA synthesis by TGF-B (Feng et al., 1995). In
addition to cyclin synthesis, synthesis of the cyclin EID co-activator, cyclin
dependent kinase (cdk) 4, is suppressed by TGF-B 1 in a post-transcriptional
manner (Ewen et al., 1993; Ravitz et al., 1995). This suppression appears to
be critical in preventing the formation of active cyclin E/cdk4 complexes in
cells treated with TGF-B 1 • Inhibitors of cdk2 (cyclin A-associated) and cdk4
such as p27/Kipl and p21/Cipl/WAF-1 were identified as proteins which
were in excess in contact-inhibited or TGF-B 1 treated cells (Polyak et al.,
1994a; Polyak et al., 1994b; Toyoshima and Hunter, 1994). In mink lung
cells, WAF-1 synthesis was induced by TGF-B 1 (Raynal and Lawrence,
1995). However, excess Kipl was not caused by increased production of the
protein itself, but by decreased competition for binding from cyclin D/cdk4
complexes which resulted from down-regulated cdk4 synthesis in response
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to TGF-B 1• Additionally, another inhibitor of cdk4, pl5 1NK48 , was identified
which inhibits cdk4 and cdk6 (Hannon and Beach, 1994). pl5 1NK4B is
induced approximately 30-fold in response to TGF-B 1, and while it may not
result in the release of Kipl from cyclin D/cdk4 complexes, it inhibits cyclin
activity needed for progression through G 1. Additionally, it has been shown
that TGF-B 1 induction of Cipl and p15 1NK4B relies on Spl consensus binding
sites within their respective promoters, indicating that the activity of the Sp
family of transcription factors are also regulated by TGF-B 1 (Li et al., 1995;
Datto et al., 1995).

Cellular Differentiation
As cellular differentiation is usually coupled to the cell's withdrawal
from the cell cycle, TGF-B is a prime candidate when studying
differentiation factors. While inhibition of proliferation is not sufficient for
bronchial epithelial cells to undergo squamous differentiation, TGF-B was
identified as the serum factor that induced this differentiation, which
included decreased proliferation accompanied by morphological changes
(Masui et al., 1986). Similarly, TGF-B induces the differentiation of
endothelial cells in vitro into cells that appeared indistinguishable from
smooth muscle cells and expressed a-smooth muscle actin, a state which
was irreversible after prolonged exposure to TGF-B 1 (Arciniegas et al.,
1992). As TGF-B 1 can induce myocyte-like characteristics in endothelial
cells (Arciniegas et al., 1992), pericytes (Verbeek et al., 1994), epithelial cells
(Kurodaka et al., 1995), and fibroblasts (Ronnov-Jessen and Petersen, 1993),
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it is no surprise that TGF-B has been postulated to play a role in muscle
development.
In skeletal muscle development, progenitor cells proliferate as nondifferentiated myoblasts which do not express muscle-specific genes and
have no or limited contractile ability. Upon withdraw! from the cell cycle,
these cells terminally differentiate and fuse to form contractile myofibers.
This differentiation process can be triggered in vitro by maintaining the
cells in a low serum media. TGF-B 1 appears to be necessary for
differentiation as mutant myoblasts which are unable to respond to TGF-B 1
do not undergo differentiation under low serum conditions (Filvaroff et al.,
1994). This is in contrast to most of the previous studies relating TGF-B 1

activity to myoblast differentiation. In myoblasts treated with TGF-B 1 under
low serum conditions, the muscle-specific transcription factors MyoDl and
myogenin were inhibited or not expressed, which blocked contractile
protein expression and myoblast fusion into myotubes (Massague et al.,
1986; Olson et al., 1986; Florini et al., 1986; Vaidya et al., 1989; Brennan et

al., 1991). However, in vivo, differentiation occurs where mitogens, or
positive stimuli, are potentially high. Therefore, addition of TGF-B 1 to
myoblasts maintained in high serum (or mitogen enriched) media is also
able to induce myoblast differentiation (Zentella and Massague, 1992). This
mechanism(s) involved the inhibition of proliferation (one aspect being
downregulation of c-myc) and decreasing the levels of the myogenic
inhibitor of differentiation, Id. While the anti-proliferative activity of TGFB1 aides in the induction of differentiation, overexpression of MyoD alone
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releases the cells from their dependence on TGF-B 1 to differentiate (Filvaroff
et al., 1994).

ECM Formation. Cell Adhesion. and Angiogenesis
One of the classic effects ofTGF-B stimulation is the regulation of
ECM deposition. This regulation involves the stimulation of ECM protein
production and secretion, inhibition of protease synthesis and increasing
synthesis of protease inhibitors, and stimulation of integrin receptor
production which enhances the cell's ability to interact with the ECM and
surrounding cells (Roberts and Sporn, 1992a). Two classic ECM promoting
factors which are responsive to TGF-B actions are an ECM protein,
fibronectin, and a protease inhibitor, plasminogen activator inhibitor-1
(PAI-1). Increases in expression or promoter activity of the these two
genes, in addition to growth inhibition, are standards used to determine a
cell's ability to respond to TGF-B (e.g. Massague 1990; Chen et al., 1993;
Brand et al., 1993; Attisano et al., 1994; Reed et al., 1994). Other ECM
genes/proteins or ECM promoting factors which are induced by TGF-B
include the proal and proa2 chains of type I collagen, and tissue inhibitor
of metalloproteinases (TIMP) (Laiho et al., 1986; Ignotz et al., 1987; Wrana
et al., 1988; Overall et al., 1989; Reed et al., 1994). In addition to promoting
expression of "positive" factors of ECM biosynthesis, TGF-B inhibits or
decreases expression of factors associated with ECM degradation such as
collagenase, plasminogen activator, and stromelysin/transin (Laiho et al.,
1986; Edwards et al., 1987; Kerr et al., 1988).
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While most effects of the TGF-B 1 are transcriptional, posttranscriptional regulation such as increasing mRNA stability of collagen
and fibronectin has also been demonstrated (Wrana et al., 1991).
Specifically, regulation of Type I collagen expression demonstrates the
ability of TGF-B 1 to regulate both transcription and translation (Fine and
Goldstein, 1993). Type I collagen is made up of two subunits, al(I) and
a2(I). Upon TGF-B 1 treatment, al(I) mRNA levels increase resulting in

increased collagen protein production. This increase in al(I) is attributed,
at least in part, to increased protein binding to a TGF-B 1 activating element
within the al(I) promoter (Ritzenthaler et al., 1993). In contrast, a2(I)
mRNA levels are unchanged; by an as yet unknown mechanism, TGF-B 1
induces and/or increases translation from the "basal level" of this specific
mRNA resulting in an equal increase in both Type I collagen protein
subunits (Fine and Goldstein, 1993).
In addition to promoting ECM accumulation, TGF-B also promotes
cell adhesion to the ECM through the induction of several members of a
family of receptors called integrins which function as ECM receptors
(Ignotz and Massague, 1987; Heino and Massague, 1989; Wahl et al., 1993).
These ECM-binding integrins are responsible for transmitting signals from
the ECM into the cell and are thought to be expressed before the ECM
proteins are laid down, especially in fetal development (Borg et al., 1990).
Integrins are composed of one a and one B subunit, with the a subunit
specifying the particular ECM protein to which the receptor binds.
Depending on cell type, TGF-B can change a cell's affinity for different ECM
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proteins (e.g. increase a 2 , a 5 , and B1 while decreasing a 3 in osteosarcoma
cells) (Heino and Massague, 1989), or increase a cell's affinity for ECM in
general (monocytes and thymocytes) (Ignotz and Massague, 1987; Wahl et
al., 1993). Similar to the regulation of collagen synthesis, this upregulation
of mRNA and protein levels of the integrin subunits has a dual level of
control: increasing transcription rates and increasing the rate at which the
protein is processed and expressed at the cell surface (Ignotz and
Massague, 1987).
In contrast to these ECM promoting factors, in processes such as
tissue remodeling and wound repair, TGF-B exerts opposing effects. While
TGF-B 1 usually induces ECM accumulation, it can also transiently induce
degradation of ECM components by increasing the production of
proteinases such as type IV collagenase (Overall et al., 1991; Wahl et al.,
1993). This degradation allows cell detachment from and migration
through the ECM (Overall et al., 1991; Salo et al., 1991). The actions of type
IV collagenase are also limited by TGF-B 1 as it co-induces its inhibitor,
TIMP, to a greater degree, but at a slower rate, thus allowing detachment
and migration of cells and then promoting their reattachment and ECM
accumulation (Overall et al., 1991). TGF-B's ability to promote cell
migration is also one method in which TGF-B controls angiogenesis, or
formation of blood vessels. TGF-B 1 is able to stimulate an angiogenic
response when injected into chicken chorioallantoic membrane or
subcutaneously, with the new capillary cords growing toward the site of
TGF-B 1 injection (Roberts et al., 1986; Yang and Moses, 1990). This activity
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is similar to wound healing in that TGF-B 1 induces cell migration (possibly
having a chemotaxic role) and changes in ECM composition. Similar to the
negative control demonstrated with TIMP, TGF-B also limits angiogenesis
after promoting it by upregulating PAI-1, which inhibits plasmin, an
important enzyme in angiogenesis (MacGregor et al., 1995).
In addition to its ability to control angiogenesis through ECM
turnover, it has been proposed that TGF-B may also promote angiogenesis
by inducing cells to produce angiogenic factors (Roberts et al., 1986). One of
these factors is SPARC (§.ecreted nrotein that is ftCidic and r.ich in gysteine),
osteonectin, or BM-40. SPARC has been associated with tumor metastasis
and with tissues undergoing morphogenetic processes, particularly cells
undergoing proliferation, migration, and detachment from the ECM
(Mason et al., 1986; Sage et al., 1989; Wrana et al., 1991; Iruela-Arispe et al.,
1991a; Reed and Sage, 1996; Sage 1997). The effects SPARC is able to elicit in
these processes are broad, encompassing cellular proliferation (negative),
cytoskeletal rearrangements, cell adhesion, cell migration, and ECM
turnover (Sage 1997). As most of these processes are involved in the
formation of blood vessels, it is not surprising that SPARC has been found
to be actively synthesized by endothelial cells undergoing angiogenesis
(lruela-Arispe et al., 1991b; Lane et al., 1992). Therefore, TGF-B may
promote morphogenesis and angiogenesis through its ability to induce the
expression of SPARC in both fibroblasts and endothelial cells (Wrana et al.,
1988; Wrana et al., 1991; Reed et al., 1994), and this induction may be at the
transcriptional and/or post-transcriptional level (Wrana et al., 1991; Iruela-
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Arispe et al., 1995). Interestingly, intact SPARC has been found to have no
angiogenic activity on its own, but a cleavage product of SPARC as a result
of digestion with plasmin induces angiogenesis in vivo (Iruela-Arispe et
al., 1995). Therefore SPARC, as well as TGF-B, also limits its own
angiogenic activity as it has been found to increase PAI-1, an inhibitor of
plasmin activation (Reed and Sage, 1996).

TGF-B Signal Transduction Pathway
As previously mentioned, three receptors for TGF-B have been
identified to date, BRI, BRII, and BRIII. The cloning of these receptors has
provided a molecular and cellular means by which to study the interactions
and specific roles each plays in TGF-B signaling. While it appears that all
three mammalian isoforms of TGF-B ligands mediate their responses
through their interactions with BRI and BRII, the exact function of BRIII
in these processes is unclear. BRIII is able to bind all three isoforms of
TGF-B as well as members of another family of growth factors, fibroblast
growth factors (Andres et al., 1992), but as it does not have an intracellular
signaling domain, its actions remain unclear. Membrane bound BRIII
has been postulated to be involved in TGF-B ligand presentation to BRII
(particularly for TGF- B2 ) or ligand sequestration (Lopez-Casillas et al.,
1993; Lopez-Casillas et al., 1994). To support its role in ligand presentation,
BRIII has been shown to form hetero-oligomeric complexes with BRII
when TGF-B 1 is present (Moustakas et al., 1993; Henis et al., 1994), and

increases cells' responsiveness to TGF-B 1 (Lopez-Casillas et al., 1993). This
hetero-oligomeric complex may be disrupted upon ligand binding to BRll,
with BRiii being displaced by BRI. (Henis et al., 1994). Additionally, a nonmembrane bound form of BRiii has been found to be an antagonist to TGFB1 signaling as it binds extracellular ligand and does not allow subsequent
binding to cell surface BRll (Lopez-Casillas et al., 1994).
Nevertheless, most, if not all, actions of TGF-B are mediated through
BRI and BRll, which are the receptors containing the functional SIT kinase
domain. While BRI cannot bind TGF-B on its own, BRll binds TGF-B
ligands with varying affinities (Ka of 5-50 pM for B1 and B3 , Ka of 500 mM for
B2 , Miyazono et al., 1994). Therefore, BRll binds TGF-B and complexes with
BRI to initiate the signaling cascade (Wrana et al., 1992). This is clearly
demonstrated in cells resistant to TGF-B actions in that many do not
express one of these two receptors, and can be rescued by transfection with
expression vectors encoding for the missing receptor (Laiho et al., 1991;
Wrana et al., 1992; Markowitz et al., 1995). In addition, the kinase domain
of BRll is constitutively active and autophosphorylates its IC domain in a
ligand independent manner (Wrana et al., 1994a). This
autophosphorylating activity is independent of its ability to phosphorylate
BRI as mutants have been identified which can phosphorylate themselves
but not BRI (Carcamo et al., 1995). Additionally, BRll is also
phosphorylated by cellular kinases as a kinase defective BRll has also been
found to be phosphorylated, yet to a lesser degree than its active form
(Wrana et al., 1994a). Because BRll exists at the cell surface as homomeric

21
complexes in a ligand independent manner (Chen and Derynck, 1994),
cross-phosphorylation of BRII may also occur.
It appears that the sole purpose of TGF-B 1 binding to BRII is the

recruitment of BRI. Upon ligand binding to BRII, BRI is recruited to the
complex, and is directly phosphorylated by BRII in the GS domain (Wrana
et al., 1994a; Ventura et al., 1994; Vivien and Wrana, 1995). This domain is
a highly conserved, 30 amino acid domain found in most type I TGF-B
receptors (Wrana et al., 1994b ). It contains seven serine and threonine
residues, of which deletion or mutation of more than one results in an
inactive receptor (Wieser et al., 1995). As BRII exists in the cells as
homomeric complexes, it is no surprise that hetero-oligomeric complexes
containing two or more of each, BRI and BRII, have been found and are
thought to mediate TGF-B signaling (Bassing et al., 1994; Yamashita et al.,
1994). It is interesting to note that this complex formation and subsequent
phosphorylation of BRI is not dependent on ligand binding to BRI itself
(Vivien and Wrana, 1995). It has been shown that the intracellular
domains of BRI and BRII directly interact upon ligand binding to BRII, and
that this interaction is sufficient for BRI phosphorylation by BRII (Ventura
et al., 1994; Chen et al., 1995a; Feng and Derynck, 1996). The functionality
of the interaction between the intracellular domains is complex as an
activation-defective BRI and a kinase-defective BRI are able to
complement/rescue each other's defect when co-expressed and assembled
into a single complex with active BRII (Weis-Garcia and Massague, 1996).

2'2
A simple, multi-step mechanism of TGF-B receptor activation has
been proposed by Wrana et al. (1994a). In this four step process, any of the
TGF-B ligands binds to a pre-phosphorylated BRII, BRI is recruited into
this complex, BRI is phosphorylated by BRII and thus activated, and then
BRI is able to phosphorylate downstream effectors which mediate the
different responses to TGF-B (Figure 2).
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Figure 2: Postulated TGF-B Receptor Activation Sequence
TGF-B 3 binds to BRII (A), resulting in the recruitment of BRI (B).
Once the BRII-BRI complex is formed, BRII phosphorylates BRI in the GS
domain (C), which activates BRI resulting in activation of downstream
effectors (D).

In support of the 4-step hypothesis for TGF-B receptor activation
diagrammed in figure 2, a point mutation in the kinase domain of BRII has
been identified which results in BRII being unable to phosphorylate BRI,
while being able to autophosphorylate itself (Carcamo et al., 1995). The
inability of BRII to phosphorylate BRI results in a complete loss of TGF-B 1
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responsiveness and indicates that transphosphorylation of BRI by BRII is
essential for signal transduction. However, as illustrated above and
described previously, this mechanism of receptor activation is not as simple
as first anticipated. In addition to the complex interactions of the
intercellular domains of the two receptors, it is becoming apparent that the
different responses that can be elicited by TGF-B are determined by BRI and
the signal transduction pathway it activates. Deletion analyses have
determined that the juxtamembrane domain preceding the GS domain in
BRI is responsible for growth inhibition, but not the induction of ECMpromoting genes, PAI-1 and fibronectin (Saitoh et al., 1996), while deletion
of the juxtamembrane region preceding the kinase domain in BRII is
essential for all functions (Feng et al., 1995). Additionally, uncoupling of
growth inhibition and gene transcription can be demonstrated in cell lines
which have undetectable BRII or which express a kinase deficient BRII
(Chen et al., 1993; Lafon et al., 1995). In these cells, addition of TGF-B 1 does
not inhibit cellular proliferation, but does induce genes such as PAI-1, cjun, and TGF-B 1 • These results suggest that BRI is able to activate some
pathways without phosphorylation by BRII, but this issue remains
controversial.
While the "beginning'' or activation of the TGF-B signal transduction
pathway has been examined extensively, the events occurring between
ligand binding to the cell surface receptors and the cellular response are
only beginning to be understood through the discovery of proteins that act
downstream of or are physically associated with BRI or BRII. Two proteins
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have been identified by their association with the receptors themselves:
Farnesyl-protein transferase-a (FT-a) and TRIP-1 (Chen et al., 1995b;
Ventura et al., 1996). FT-a associates with BRI, is phosphorylated by BRI in

vitro (Kawabata et al., 1995b), yet appears unnecessary for TGF-B activity
(Ventura et al., 1996). Therefore, the role for FT-a and BRI interaction
remains unknown. Similarly, data has been collected which supports the
hypothesis that TRIP-1 may be involved in the TGF-B 1 signaling pathway
(Chen et al., 1995b). The TRIP-1 protein associates with BRII, but not other
type II SIT kinase receptors, in a ligand-independent fashion, and is
phosphorylated on threonine and serine residues, potentially by either, or
both, BRII or BRI. However, while the available TRIP-1 clues to
intracellular pathways, no mutants or knockout studies have been
performed to directly demonstrate its involvement in a TGF-B signaling
pathway.
In the world of tyrosine kinase receptors, the Ras-MAP (mitogenactivated protein) kinase signaling cascades are integral components of the
cell's intracellular responses to extracellular signals. Similarly, members
of these families of kinases are being identified as components of the
"downstream" TGF-B signal transduction pathway(s). Rae, a small GTPbinding protein assumed to be near the beginning of the cascade, exhibited
a 3.7-fold increase in activity after exposure to TGF-B, which led to
increased transcription from the PAI-1 promoter (Mucsi et al., 1996).
Additionally, activity of extracellular signal-regulated kinase-I (ERKl) was
also increased 4.5-fold after TGF-B 1 treatment, whereas other proteins such

as Ras, Rho, and MAP kinases such as Jun kinase (JNK) are not involved
(Mucsi et al., I996). While Rae and ERKI are activated by a wide variety of
signals, other members of the MAP kinase cascade have been identified
which appear to be more closely associated with signal transduction from
the receptors of the TGF-B superfamily. TAKI (TGF-B-activated kinase) is a
MAP kinase kinase kinase whose activity was stimulated in response to
TGF-B 1 and another TGF-B family member, BMP-4, resulting in increased
PAI-I promoter activity (Yamaguchi et al., I995). Additionally, another
protein, TABI (TAKI binding protein) was subsequently identified which
interacts with TAKI and may activate it by binding to its catalytic domain
(Shibuya et al., I996). The importance of TABI in the TGF-B signaling
cascade was demonstrated by the creation of a dominant negative TABI
mutant which was able to inhibit PAI-I promoter activity in response to
TGF-B 1 (Shibuya et al., I996).
While MAP kinase signal transduction cascades are a rapidly
expanding area of study in growth factor and cytokine actions, other signal
transduction pathways appear to be involved in some manner in TGF-B's
activity. The G-protein Gial was found to be necessary for cytoskeletal
reorganization in fibroblasts which occurs in response to TGF-B1' although
the exact mechanism of activation remains unknown (Kataoka et al., I993).
Two other common signaling molecules have also been associated with
TGF-B's activation of gene expression in human lung carcinoma cells:
phosphatidylcholine-phospholipase C (PC-PLC) and protein kinase C (PKC)
(Halstead et al., I995). When these proteins are inhibited by specific toxins,
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steady state mRNA levels of PAI-1 and fibronectin were not increased in
response to TGF-B 1 as was seen in untreated cells. In support of the
involvement of PKC in the increased mRNA levels of PAl-1 in response to
TGF-B 1, inhibition of PKC also eliminated the increase in PAI-1 promoter
activity in response to TGF-B 1 which was detected in control cells (Halstead
et al., 1995). While it appears that TGF-B 1 can activate transcription from
the PAI-1 promoter through several pathways, caution must be used in
these interpretations as it has been strongly implicated that PKC may act
upstream of MAP kinase (Blumer et al., 1994).
Most significantly, nuclear proteins which may mediate TGF-B's
ability to alter gene expression have also been discovered. Among the
transcription factors which appear to be regulated by TGF-B 1 are the
oncogenes c-jun,junB, c-fos, and c-myc (Coffey et al., 1988; Pertovaara et
al., 1989; Li et al., 1990; de Groot and Kruijer, 1990; Pietenpol et al., 1990).
WhilejunB and c-fos are significantly induced within 1-2 hours of TGF-B 1
treatment in all cell lines tested, changes in c-jun expression in response to
TGF-B 1 is cell type dependent (Pertovaara et al., 1989; Li et al., 1990; de
Groot and Kruijer, 1990). In contrast, c-myc expression is downregulated
in response to TGF-B 1 at the transcriptional level, a process, unlikejun and

fos induction, which requires protein synthesis (Coffey et al., 1988;
Pietenpol et al., 1990). This suggests that TGF-B 1 triggers the synthesis or
modification of a transcriptional inhibitor for the c-myc gene. It is of
interest to note that induction of jun and fos and the inhibition of c-myc
expression reflect TGF-B's ability to activate ECM gene transcription and

inhibit cell proliferation. Additionally, the induction of these immediate
early genes appears to occur through different pathways, as depletion of
PKC activity within a breast carcinoma cell line eliminates TGF-.8 1
induction of c-fos, but not c-jun (Lafon et al., 1995).
In addition to these "traditional" transcription factors, a family of
proteins is beginning to be defined which are transcriptional activators
specific to the TGF-B superfamily signaling pathway(s): Dwarfins.
Members of this family of cytoplasmic proteins have been identified from
Drosophila, C. elegans, human, and murine cells and appear to be involved
in the signaling pathways of the different members of the TGF-B
superfamily (Liu et al., 1996; Massague 1996; Savage et al., 1996; Yingling
et al., 1996; Hahn et al., 1996; Zhang et al., 1996; Lechleider et al., 1996).
This family of proteins contain DHl and DH2 (dwarfin homology 1 and 2)
regions which are homologous in function to SH2 and SH3 domains (Savage
et al., 1996; Yingling et al., 1996). These SH2 I SH3 are common in effector
proteins associated with tyrosine kinase-mediated signal transduction
pathways, and these domains along with the DHl I DH2 domains are
believed to be involved in protein-protein interactions that are often
regulated by phosphorylation. Different members within the dwarfin
family appear to mediate the effects from the different ligands and
receptors within the TGF-B superfamily. As the "prototype" member of this
family, Mad (Mothers against decapentaplegic) proteins and Mad-related
(MADR) proteins have been found to be important in BMP I dpp signaling
from mammals to drosophila (Liu et al., 1996; Newfeld et al., 1996;

Wiersdorff et al., 1996; Hoodless et al., 1996). Similarly, human and
murine Mad and MADR homologues have been identified which appear to
play direct roles in TGF-B signaling pathways (Yingling et al., 1996;
Lechleider et al., 1996; Zhang et al., 1996; Eppert et al., 1996). In murine
cells, Dwarfins A and C are phosphorylated in response to TGF-B 1 , but
neither is phosphorylated directly by BRI or BRII, thus appearing to act
further downstream in the pathway (Yingling et al., 1996). Similarly,
human Mad proteins, Bsp-1, DPC4, and h-MAD4, are also phosphorylated
in response to TGF-B 1, but are not associated with TGF-B receptors
(Lechleider et al., 1996; Zhang et al., 1996). However, h-MAD3 and MADR2
have been found to associate with BRI and be phosphorylated by BRI in vitro
(Zhang et al., 1996; Macias-Silva et al., 1996). To further support their roles
in TGF-B signaling, overexpression of Dwarfins A or C in 16 rat skeletal
muscle fibroblasts causes growth arrest and induction of PAI-1 (Yingling
et al., 1996), and deletion of Dwarfin A or mutation of MADR2 activity have
been demonstrated to block TGF-B 1 signaling (Zhang et al., 1996; Yingling
et al., 1996; Eppert et al., 1996).
Clearly, a significant amount of progress has been made in the
identification of several components of the TGF-B signal transduction
pathway, from the receptors on the cell surface to proteins within the
nucleus. In concert with their identification, examination of the function of
each protein in the pathway and the direct effects TGF-B exhibits in a
variety of cell types has been an area of ongoing study. While many of these
functions, such as its antiproliferative activity, are common to many cell
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types, several examples have been cited here where these effects are cell
type specific. Therefore, the role of TGF-B in processes such as organ
development is now being examined in vitro through the use of specific cell
types found within that organ as well as in vivo utilizing transgenic mice
which overexpress or do not express members of the TGF-B signal
transduction pathway. One organ system in which these types of
experiments are being utilized is the development of the heart.

TGF-B and Heart Development
Expression Patterns

TGF-B Ligands in the Heart
While most of what is known about the TGF-B ligands has been
ascertained from their genetic organization derived from their cloning,
biosynthesis, and pleiotrophic actions in vitro, determination of their
spatial and temporal patterns of expression in vivo is critical to elucidate
their functions in development. Expression patterns for the TGF-B ligands
during heart development have been best studied in rodent and avian
systems. These expression patterns, in general, are similar, but some
significant differences between species have been found. Expression
patterns of the three TGF-B ligands are very distinct, both temporally and
spatially, suggesting that while they have similar effects in vitro, they may
play very specific roles in vivo.
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TGF-B 1 expression was originally undetected in the chicken
embryonic heart or cultured myocytes obtained from embryonic hearts
(Jakowlew et al., 1991; Runyan et al., 1992), but these results are
misleading given the fact that TGF-B4 is the chicken isoform of TGF-B 1
(Burt and Paton, 1992). TGF-B4 can be localized to myocytes within the atria

and ventricles of the developing avian heart from as early as stage 22 (day 4)
through adulthood, with ligand expression increasing as the chick
matures (Jakowlew et al., 1991; Jakowlew et al., 1992). TGF-B 1 expression
during rodent heart development is better defined. The earliest expression
of TGF-B 1 mRNA is in cardiac precursor cells within the splancnic
mesoderm (Schneider and Parker, 1991). However, defined expression
patterns of TGF-B 1 later in heart development have also been documented
(Schneider and Parker, 1991; Roberts and Sporn, 1992a; Engelmann et al.,
1992). At 9 days post-coitum (dpc), TGF-B 1 is strongly localized to those
tissues which are undergoing epithelial to mesenchymal (e-m)
transformation, a phenomenon which occurs during the formation of the
heart valves (Schneider and Parker, 1991; Roberts and Sporn, 1992a). At 1112 dpc, TGF-B 1 can be detected in the ventricular myocardium in a uniform
manner with TGF-B 1 being localized to the myocytes themselves (Schneider
and Parker, 1991; Roberts and Sporn, 1992a; Engelmann et al., 1992). The
expression levels of TGF-B 1 increase significantly in the late fetal (18 dpc),
early neonate, and remain elevated in the mature rat heart (Engelmann et
al., 1992).
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TGF-B2 expression patterns suggest that it may play an important
role in heart development in chickens as well as rodents. However, these
expression patterns deviate markedly from one another. In the murine
heart, TGF-B 2 is expressed at 9.5-10.5 dpc in both the atrioventricular (AV)
region and in the pre-valvular myocardium (Schneider and Parker, 1991;
Akhurst et al., 1992). However, by 12.5 dpc, TGF-B2 expression cannot be
detected in the myocardium, yet is still highly expressed in the AV region,
particularly in the valves (Schneider and Parker, 1991; Akhurst et al.,
1992). In contrast to the distinct temporal and regional changes in TGF-B 2
expression in the mouse, TGF-B2 expression in the developing chicken
heart appears to be in both heart regions at Hamilton-Hamburger stages 1520 (this corresponds to the time in which differences were seen in mice)
(Jakowlew et al., 1991; Runyan et al., 1992) and decreases with age after
stage 29 (Jakowlew et al., 1994).
TGF-B3 expression appears to be the most limited of the three
primary TGF-B isoforms. In the chicken, TGF-B3 has a distinct localization
to the AV canal and has been implicated to be critical in the epithelialmesenchymal (e-m) transition associated with valve formation (see below)
(Runyan et al., 1992). Interestingly, TGF-B3 cannot be detected in the early
mouse heart at similar stages (Runyan et al., 1992; Akhurst et al., 1992)
suggesting a different isoform or family member may be involved in the e-m
transition I valve formation. TGF-B 1 and TGF-B 2 expression patterns
suggest they may "substitute" or compensate for TGF-B 3 in the mouse.
Later in heart development (11.5-16.5 dpc) TGF-B3 can be detected in the
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ECM and mesenchyme of the valves as well as the atrial and ventricular
myocardium (Schneider and Parker, 1991; Burton et al., 1993) and
continues to be expressed at relatively high levels in the ventricular
myocardium in the immediate postnatal period and through weaning
where the expression levels drop off markedly (Engelmann 1993).

TGF-B Receptors in the Heart
While expression patterns of the TGF-B ligands indicate where they
may be important for various developmental processes, an understanding
of the expression patterns of the TGF-B receptors is also necessary to fully
appreciate the role(s) TGF-B plays in development. The expression of the
three primary TGF-B receptors has been studied to varying degrees in
chicken (Barnett et al., 1994), murine (Lawler et al., 1994; Roelen et al.,
1994), and rat (Engelmann and Grutkoski, 1994) systems. In general, the
expression patterns observed in these three systems are similar within the
heart. While data are limited for early heart development, neither BRI nor
BRII could be detected by PCR analysis at 6.5-7.5 dpc. in the three mouse
embryo germ layers, but could be detected by 14 dpc through adulthood
(Lawler et al., 1994; Roelen et al., 1994). Similarly, expression of BRII and
BRIII can be detected in the chicken heart at low levels in the Stage 26
embryo in atrial and ventricular cells (Barnett et al., 1994). This expression
significantly increases between stage 26, day 6, and day 10, and greatly
increases upon hatching. It is interesting to note that in the fetal avian
heart, the protein levels of all three receptors (determined by receptor
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crosslinking) is approximately 10-fold higher in the atria than in the
ventricles, suggesting that TGF-B plays a significantly different or more
prominent role in the development of the atria than the ventricles in the
avian heart (Barnett et al., 1994). Expression of the three receptors was
studied extensively in the rat from the late fetal stage through adulthood,
and these results support and extend those obtained in the mouse and
chicken (Engelmann and Grutkoski, 1994). BRI and BRiii mRNA levels
were readily detected in total RNA from ventricular tissue of 18 dpc through
9-week postnatal animals, with only a modest age-related increase in
transcript abundance. However, BRII expression was age-restricted with
low-to-undetectable levels in the late fetal periods, but transcript levels
increased markedly at-or-around birth and increased through the
postnatal-to-mature stages of development (Engelmann and Grutkoski,
1994). Immunolocalization of BRII within the ventricle was primarily in
the cardiomyocytes, but surrounding non-myocytes also expressed the
receptor (Engelmann and Grutkoski, 1994). Additionally, there were no
significant differences in steady state transcript abundance between the
different regions of the mature heart (right ventricle, left ventricle, and
septum) (Engelmann and Grutkoski, 1994). Studies in the rat did not
address the expression of the TGF-B receptors in the atria, however it is
expected that mRNA patterns for the three isoforms would resemble those
seen in other rodents such as the mouse.
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TGF-B Effector Protein - Cardiac Expression in vivo
As important as it is for the ligands and receptors to be present in
order for a cell to respond to TGF-B, the factors that act downstream of the
receptors must also be present. To date, limited developmental or in vivo
expression data are available for the recently identified downstream
effectors of TGF-B signal transduction. Nonetheless, it has been found that
TRIP-1 is expressed in the heart, and that TRIP-1 expression in mouse
embryos and human fetal tissue samples correlates with BRII expression
(Chen et al., 1995b). This supports the postulated functional role it may
have in the TGF-B signaling pathway as well as the ability of the cells in
developing tissues to respond to TGF-B 1 • Developmental data on many of
the other postulated TGF-B effector proteins are not yet available. However,
of interest to our studies, it has been demonstrated that TAKl and TABl
transcripts are found in adult mouse and human heart RNA samples,
although not yet localized to the cardiomyocyte population (Yamaguchi et
al., 1995; Shibuya et al., 1996). Transcripts for the MAD proteins, in
general, are expressed ubiquitously in adult rat and human tissues,
including the heart (Yingling et al., 1996; Lechleider et al., 1996), and
steady-state Bsp-1 transcript levels in adult human tissues are highest in
heart and skeletal muscle, two non-mitotic, fully differentiated tissues
(Lechleider et al., 1996). Developmental expression data for the MAD
family of proteins appears to be limited to studies in Xenopus where Xmad
is uniformly expressed from fertilization through the tadpole stage,
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suggesting that it is not the limiting factor for BMP-2/4 mesoderm-inducing
activity in the developing embryo (Graff et al., 1996).

Regulation of TGF-B ligand and receptor expression
The distinct temporal and spatial expression patterns observed for
both TGF-B ligands and receptors suggest that each is regulated in an
independent manner that may occasionally overlap. Regulation of both
ligands and receptors may occur at both the transcriptional and posttranscriptional levels through the use of different promoters, regulatory
transcription factors, untranslated regions (UTRs), as well as posttranslational processing and protein turnover or "latency" of the ligands.
These regulatory mechanisms may respond to humoral, neurohumoral
and mechanical stimuli differently, supporting the hypothesis that each
TGF-B ligand and receptor may have distinct physiological and
development functions.
The production of mRNAs and proteins for TGF-B 1_3 and their
receptors is influenced by many diverse factors. One of these factors may be
the TGF-B ligand itself. In cardiac myocytes isolated from 10 day chicken
embryos, addition of TGF-B 1_3 results in an increase in steady state
expression levels of TGF-B 314 , but not of TGF-B2 (Jakowlew et al, 1992).
Autoinduction of TGF-B 1 is also seen in primary cultures of rat neonatal
ventricular myocytes after treatment with exogenous TGF-B 1 (MacLellan et
al., 1993; Flanders et al., 1995). Similarly, expression of BRI has also been
shown to be induced by TGF-B 1 in human lung fibroblasts and smooth
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muscle cells (Bloom et al., 1996). However, while several factors have been
identified that can downregulate BRII, the effects of TGF-B on expression of
BRII has yet to be determined. Autoregulation of TGF-B 1 activity through
the regulation of TGF-B 1 ligand and TGF-B receptor expression is just one
level of control. Another regulatory feedback loop can be demonstrated with
ECM proteins. Mammary epithelial cells plated on ECM have a much
lower level of TGF-B 1 transcripts than those plated on plastic, while TGF-B2
expression appears unaffected (Streuli et al., 1993). These data suggest a
mechanistic, positive feedback loop wherein low levels of ECM stimulate
TGF-B 1 expression which in return may stimulate ECM production. Once
ECM concentrations reach a critical level, they may downregulate TGF-B 1
gene expression; thereby downregulating ECM production and completing
the regulatory loop. Other factors that have been found to regulate TGF-B 1
gene expression in myocytes are retinoic acid, calcium, oestradiol, phorbol
esters, cAMP, and steroids (Burt et al., 1991; Roberts and Sporn, 1992b).
The role of these inducers, whether direct or indirect, and the signaling
pathways relevant to cardiomyocytes and heart development are still under
investigation.
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Roles for TGF-B in Heart Development
The roles that the TGF-Bs are thought to play in the development of
the heart, as mentioned above, involve three important aspects: 1) cellular
differentiation, 2) ECM deposition and tissue remodeling, and 3) cellular
proliferation. Limited studies have been performed on ventricular
cardiomyocytes in vitro which address each of these. However, a
significant amount of data have been collected on the role of TGF-B in valve
formation in the chicken, and gross anatomical effects of TGF-B on
development inferred through the use of knockout mice.

Epithelial-Mesenchymal (e-m) Transformation
The formation of mesenchymal tissue from an epithelial sheet is a
developmentally significant event and often is mediated by ECM proteins
(Huang et al., 1995). This phenomenon of the transformation of epithelial
cells to mesenchymal cells (e-m transformation) is especially important in
heart development since the valves and membranous portions of the atrial
and ventricular septum are derived from cells which are endothelial in
origin. This type of transformation is regionally specific within the heart
and occurs only in the atrioventricular (AV) canal. This process of e-m
transformation in the heart, as well as similar transformations earlier in
embryonic development, have been recently reviewed (Huang et al., 1995).
In order to study the e-m transformation in the heart, a collagen gel culture
system is employed in which explants (AV canal explants which contain
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myocardium and endothelium) from the embryonic heart can be cultured
and allowed to grow and differentiate in a 3-D system (Runyan et al., 1992).
In these cultures, the myocardium aggregates into a beating myoball, the
endothelium expands across the gel surface, and the mesenchymal cells
can migrate into the matrix of collagen. It is these migrating cells which
are the products of the e-m transformation.
As mentioned above, TGF-B 1 is expressed in the AV canal in the
chicken embryo at the time of the e-m transformation. A series of
experiments have determined that TGF-B 1 plays a role in this
transformation. In the first set of experiments, stage 14 AV canal explants
were cultured in the presence of TGF-B 1 and TGF-B2 +/-either b-FGF or
EGF (Potts and Runyan, 1989). However, when the "AV myoball" was
replaced with ventricular myocardium, e-m transitions occurred, while the
myocardium itself could not induce the transformation. Additionally, an
antibody immunoreactive against all three forms of TGF-B was added to the
cultures and was able to block the transformation (Potts and Runyan, 1989).
This suggested that a TGF-B family member along with a ventricularly
produced co-factor could induce the e-m transformation.
Since exogenous TGF-Bs are able to elicit similar functions when
added to cells in vitro, an alternative method was used to determine which
TGF-B isoform(s) is important for the e-m transformation. In this
approach, oligonucleotides complementary to the non-conserved 5'-ends of
the TGF-B ligand mRNA transcripts were used to block production of
endogenous TGF-Bs (Potts et al., 1991). These oligonucleotides were
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topically applied to the explants twelve hours after cultures were started,
after which the explants were allowed to "grow" for 12-18 hours when e-m
transformations normally occur. It was demonstrated that only the
oligonucleotides specific for TGF-B3 were able to inhibit transformation by
BO%, whereas oligonucleotides to TGF-B 1 and TGF-B 2 mRNA had no effect.

These data suggested that "only" TGF-B3 is essential for the e-m
transformation in the chicken heart as judged by the appearance and
migration of mesenchymal cells into the collagen matrix. The data further
demonstrated that even though an added substance can elicit a certain
function in vitro, it may not truly reflect what actually occurs in vivo.
To further support the importance of TGF-B's in chick heart valve
formation, similar studies were performed using antibodies to BRII (Brown
et al, 1996). Through the use of antibodies in the same explant system, it
was shown that TGF-B plays two distinct roles in valve formation: inducing
e-m transformation and controlling the migration of the newly transformed
mesenchymal cells. BRII antibodies added to explants from different
staged embryos (14-18) inhibited e-m transformation at least 50%. Those
that underwent transformation were thought to have been activated prior to
explant, and these transformed cells, while expressing mesenchymal
markers, migrate at a slower rate (approximately 50% of control cells).
Therefore, the role of TGF-B in valve formation in the chicken is two-fold: 1)
to induce transformation, and 2) to promote migration of the newly formed
cells. It would be of interest to use this system on mammalian models as
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the specific roles for each TGF-B isoform in heart development do not
completely coincide across species.

TGF-B Ligand and Receptor Knockouts and Developing Hearts
As the expression pattern for each TGF-B isoform is distinct, each
ligand appears to have a distinct role in heart development. Due to the
ability of each TGF-B isoform to mediate similar effects in vitro, data collect
from in vitro models or systems can give an unrealistic picture of what may
actually occur during in vivo heart development. Therefore, in vivo studies
are necessary to elucidate the distinct role each TGF-B isoform may have on
heart development, as well as those that may overlap with other isoforms or
TGF-B family members. Targeted overexpression of TGF-B 1 in transgenic
mice has allowed the examination of the role TGF-B 1 has in mammary
development (Arteaga et al., 1996), lung morphogenesis (Zhou et al., 1996),
renal disease (Kopp et al., 1996), skin tumor development (Cui et al., 1996),
and central nervous system development (Galbreath et al., 1995), but none
of these studies has addressed cardiac development.
Another method in which to study in vivo roles of TGF-B is through
the use of knockout mice. These in vivo gene knockout models have been
reported for TGF-B 1 and TGF-B3 • In these murine models, TGF-B 1 and -B 3
deficient mice were created by knocking out a TGF-B allele by homologous
recombination in embryonic stem cells (Shull et al., 1992; Kulkarni et al.,
1993; Kulkarni et al., 1995; Kaartinen et al., 1995; Proetzel et al., 1995). For
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both isoforms, heterozygous animals were phenotypically normal and
fertile, and thus were crossed to obtain homozygous null mutants(-/-).
While not all of the TGF-B 1 (-/-)mice were born (only 40-50%), those
that made it to term were indistinguishable from littermates and had no
gross developmental abnormalities upon external anatomical examination.
However, these animals developed a wasting syndrome and ultimately died
within the first three weeks due to cardiopulmonary failure. Upon more
detailed histological examination, it was noted that the primary cause of
death was a dysfunctional immune response system which is normally
held in check, at least in part, by TGF-B. Between 7-20 days after birth,
mononuclear inflammatory cells infiltrated the lungs and heart, both the
myocardium and pericardium, resulting in lesions, myocyte lysis, and
tissue necrosis.
While it appeared that TGF-B 1 was not essential for embryonic or
fetal heart development, this conclusion is premature as TGF-B 1 has been
proposed to be supplied by the mother through the placenta during fetal
development and breast milk during neonatal development (Letterio et al.,
1994). However, one observation was made in the myocytes of the-/- pups
which reflected one of the characteristic effects of TGF-B in general:
inhibition of proliferation. Several myocytes from a 5-day old "TGF-B 1 null"
mouse were found to have mitochondrial changes which were
characterized as being enlarged and having a decreased number of cristae,
suggesting extended proliferation in the absence of TGF-B 1 (Boivin et al.,
1995). Additionally, in animals in which the inflammatory response was
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pharmacologically suppressed, nuclear labeling (by bromodeoxyuridine)
indicated hyperplasia in cardiac tissue isolated from 5 week old animals
(Diebold et al., 1995). However, in TGF-B 1 null mice devoid oflymphocytes
(backcrossed onto a SCID background), any evidence of postnatal myocyte
proliferation was not seen (Diebold et al., 1995). This suggests that it is not
the absence of TGF-B 1 but the absence of lymphocytes, by a mechanism as
yet unknown, that has an effect on the extended proliferation of postnatal
cardiac myocytes (Diebold et al., 1995).
Like the TGF-B 1 null mice, TGF-B3 -null animals exhibited no gross
abnormalities in the heart (Proetzel et al., 1995; Kaartinen et al., 1995).
Nevertheless, these animals died within 24 hours after birth due to their
inability to breathe properly or suckle as a result of improper formation of
their cleft palate and abnormal development of their lungs. Therefore,
possible roles of TGF-B3 in early neonatal and adult development could not
be analyzed.
The importance of either TGF-B isoform in heart development
appears to be minimal according to the data from these transgenic murine
models, which is rather unexpected given the importance of TGF-B in valve
formation in the chicken. While it does not appear that the expression
patterns of the non-ablated TGF-B ligands change in the knockout models
(Proetzel et al., 1995), we can not rule out the apparent "rescue" effect other
TGF-B isoforms or TGF-B family members may have in compensating for
the missing isoform. Ideally, TGF-B receptor knockout models would
resolve this possible rescue by other isoforms. However, BRII knockout
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mice have been created, but provide no additional information about the
roles of TGF-B in heart development as this knockout is embryonic lethal at
10.5 dpc (Oshima et al., 1996). This embryonic lethality is not due, however,
to cardiac malfunction, which is consistent with the fact that BRII is not
expressed in the heart at these early timepoints. Conditional, tissuespecific TGF-B receptor knockout or dominant negative studies have
recently been initiated. Targeted expression of a truncated BRII to
epidermal cells have demonstrated the need for TGF-B to maintain the
proper proliferation rates important for skin development (Wang et al.,
1997). Similar studies using targeted expression of a dominant negative
BRII in the heart may better address the role TGF-B plays as a whole in
heart development, as well as cardiac structure-function relationships, but
would not address the importance of each individual ligand.

Coordinate Changes in Ventricular Development
The onset of TGF-B 1 , TGF-B 3 , and BRII expression in the ventricle
during the late fetal period of development and their subsequent increase in
steady-state transcript levels in the neonatal period temporally correlates
with several developmental phenomena critical to the formation of the
heart: 1) regulation of cardiomyocyte proliferation and differentiation, 2) the
formation of biomechanical structures such as the valves, 3)
vasculogenesis; capillary angiogenesis and neovascularization, and 4) nonmuscle cell-produced extracellular matrix (ECM) formation. While it has
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been determined that TGF-B 1 may regulate cardiomyocyte gene expression
through a signaling pathway that involves the activation of ras and
immediate early genes such as c-fos and c-jun (MacLellan et al., 1993),
other pathways also involved and their regulatory roles, if any, remain to be
fully elucidated. However, no matter what the pathway or mechanism of
action, the TGF-Bs are able to mediate changes in cardiomyocyte gene
expression, mRNA translation, and protein production.

Cellular Proliferation
It is a well established fact that the increase in ventricular size

during fetal development is due primarily to cellular proliferation
(hyperplasia), while the increase in size seen throughout the rest of the
organism's life is through the increase in mass of each individual
cardiomyocyte (hypertrophy) in concert with the proliferation and
migration of non-myocyte populations as ventricular remodeling occurs.
While ventricular myocytes divide during fetal development, the rate of
division falls off dramatically during the late fetal period, resulting in only
1-2% of the myocytes still dividing at birth (Zak 1973; Bugaisky et al., 1992).
While nuclear division occurs, as each myocyte in the rat heart generally
becomes binuclear and/or polyploid, the mitotic division rate continues to
decrease until all myocyte division ceases by 3-4 weeks postnatal (Zak 1973;
Bugaisky et al., 1992). This rapid decline in myocyte division in the late
fetal and early neonate temporally correlates well with the heightened
expression of the TGF-B ligands and BRII.
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As discussed previously, TGF-B has significant anti-proliferative
activities on most cell types in culture. It is important to note that studies
on cell cycle times and specific cell cycle components have not been
rigorously done in cardiomyocytes. Therefore, the role that TGF-B may play
in the regulation of cardiomyocyte proliferation at the level of specific cell
cycle-related proteins is speculative. However, TGF-B 1 has been shown to
have antiproliferative activities in neonatal cardiomyocytes (Kardami 1990;
Engelmann et al., 1992; Nair et al., 1995). These antiproliferative activities
utilize an alternative/complementary method than that described
previously involving specific components of the cell cycle: TGF-B is able to
interrupt the stimulation of proliferation by other growth promoting
stimuli.
Epidermal growth factor (EGF), acidic and basic fibroblast growth
factor (a-/b-FGF), and the insulin-like growth factors (IGF) -I and -II are
five "mitogenic" growth factors which are found within the heart at various
developmental stages, particularly during embryonic and fetal development
when most of the proliferative expansion of the cardiomyocyte population
occurs. Co-stimulation of embryonic chicken cardiomyocytes with TGF-B 1
and the mitogens b-FGF or IGF-II decreased or canceled out, respectively,
their stimulatory effects on subsequent DNA synthesis and cell division
<Kardami 1990). Downregulation of the expression of the receptors for bFGF by TGF-B 1 has been hypothesized to play a role in this inhibition. This
is supported by the finding that the FGF receptor, Flg, is expressed fetally,
but decreases to low/undetectable levels just after birth (Engelmann et al.,
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1993a), an expression pattern that correlates well with the increases in
TGF-B ligand and BRII expression. Results similar to those observed for
FGF in culture were seen in rat cardiomyocytes, both fetal and neonatal,
treated with IGF-1 or IGF-11 and TGF-B 1 (Engelmann et al., 1992). These
results demonstrate that one of the anti proliferative activities of TGF-B 1
involves interfering with other proliferative stimuli commonly found in the
developing heart. Another example of TGF-B modulating the activity of
another growth factor is that seen in co-treatment of neonatal rat
cardiomyocytes with TGF-B 1 and EGF (Nair et al., 1995). TGF-B 1 has the
ability to decrease the cAMP elevation resulting from EGF stimulation in a
time and dose-dependent manner. This decrease is bi-functional with TGFB1 decreasing the EGF receptor's kinase function as well as altering the
activity of the catalytic subunit of adenylyl cyclase (Nair et al., 1995).

Differentiation
In rodents, many muscle-specific, contract-!le proteins undergo an
isoform switch during the fetal-to-neonatal-to-adult transition period, and
for several of these proteins, this switch involves the replacement of a
skeletal muscle isoform with a cardiac form of the protein. Among the
proteins that have been shown to undergo isoform switching are myosin
heavy chain (MHC), actin, tropomyosin, troponin I (TNI), and troponin T
(TNT), and creatine kinase (Table 1).
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Table 1: Protein Isoform Switch in the Rodent Ventricle
Adult Isoform

Fetal Isoform
B-Myosin Heavy
Chain

(B-MHC)

a-Myosin Heavy
Chain

(a-MHC)

a-Skeletal Actin

(aSk-actin)

a-Cardiac Actin

(aCa-actin)

Skeletal
Troponin I

(sTNI)

Cardiac
Troponin I

(cTNI)

Fetal Cardiac
Troponin T

(ITNT)

Adult Cardiac
Troponin T

(aTNT)

Muscle Creatine
Kinase- Brain

(MCK-B)

Muscle Creatine
Kinase - Muscle

(MCK-M)

MHC has two isoforms in the rat heart: the fetal isoform, B-MHC,
and the adult isoform, a-MHC. B-MHC is the predominant isoform in the
embryonic and fetal heart, with a-MHC appearing later in gestation
(Lompre et al., 1991; Shwartz et al., 1992). Just after birth, a-MHC becomes
the predominant isoform with B-MHC not being detected by three weeks of
age. Similarly, two isoforms of actin are found developmentally in the
heart: a-skeletal actin (aSk-actin) and a-cardiac actin (aCa-actin). Both
isoforms are expressed in the fetal heart, but just after birth, aSk-actin is
downregulated so that by one week of age, it comprises only 30-40% of the
total actin in the ventricle, and continues to decrease until it represents
<5% of the total actin mRNA by two months of age (Zak et al., 1990; Lompre
et al., 1991; Shwartz et al., 1992).
TNC is the thin filament subunit which confers Ca++ sensitivity to the
myofibrils (Lompre et al., 1991). Two isoforms have been identified to date:
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fast skeletal TNC (sTNC) and cardiac/slow skeletal TNC (cTNC) (Parmacek
and Leiden, 1989; Parmacek et al., 1990). Similar to other contractile
proteins, this family undergoes an isoform switch as skeletal muscle
matures (Dhoot and Perry, 1979). Originally it was thought that fast
skeletal TNC was present in the embryonic heart (Gahlmann et al., 1988),
however low stringency washes led to the questioning of these results.
Similarly another skeletal isoform was identified in the heart (Dhoot and
Perry, 1979), but the cloning of TNC from cardiac muscle indicated that the
skeletal isoform detected was identical to cardiac TNC (Wilkinson 1980).
Subsequent studies have failed to locate sTNC in the heart at any age in
murine, avian, and rabbit systems, being expressed exclusively in skeletal
muscle (Toyota and Shimada, 1981; Gahlmann et al., 1988; Parmacek et al.,
1990). Not unexpectedly, cTNC has been found to be expressed at a low level
in the embryonic heart in chicken and mice (Toyota and Shimada, 1981;
Parmacek and Leiden, 1989; Parmacek et al., 1992). While a fetal isoform
has not yet been identified for cTNC, its expression appears to be regulated
developmentally as cTNC is upregulated within the heart during the
perinatal period.
TNI is the thin filament subunit which is a specific inhibitor of Mg++ stimulated ATPase of actomyosin (Lompre et al., 1991). TNI exists in three
isoforms, fast skeletal (fTNI), slow skeletal (sTNI), and cardiac (cTNI). In
mice, fTNI is expressed very early in heart development and is completely
absent by 16dpc (Zhu et al., 1995). However in the rat, the expression
patterns of sTNI and cTNI are more defined. sTNI appears to be the only
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isoform detected at lOdpc (Gorza et al., 1993). By lldpc mRNA for cTNI can
be detected, however cTNI protein could not be detected until 16-18dpc,
suggesting transcriptional and translational regulation of TNI isoform
expression (Ausoni et al., 1991; Gorza et al., 1993). After birth, cTNI
increases dramatically, being easily detected in 1-2 day neonatal hearts,
and by the third week of life, is the only isoform detected (Saggin et al., 1989;
L'Ecuyer et al., 1991; Ausoni et al., 1991; Murphy et al., 1991). Profiles of
TNI expression in human hearts are similar to those of rat (Bhavsar et al.,
1991; Hunkeler et al., 1991; Sasse et al., 1993).
Cardiac TNT is the thin filament subunit which binds directly to
tropomyosin (Lompre et al., 1991). It has two isoforms simply labeled as the
fetal cTNT (fTNT) and adult cTNT (aTNT). Unlike its thin filament
counterparts, the TNT isoform switch does not occur through the
differential expression of two separate genes. Cloning of each isoform
mRNA from rat, chicken, rabbit, and bovine cells reveal that the two
isoforms differed only in a 30bp insert present in the embryonic form
(Cooper and Ordahl, 1985; Jin and Lin, 1989). Genomic cloning confirmed
that the two isoforms were the result of a developmentally regulated
alternative splicing event of a singe exon, therefore each isoform comes
from the same primary transcript (Cooper and Ordahl, 1985; Jin et al.,
1992). While the mechanism by which this occurs is still unknown, the
developmental profile of the isoform switch in the rat has been well
established. The profile is similar to that for MHC and actin: fTNT being
expressed in the fetal heart with trace levels of aTNT, aTNT increasing

50

dramatically after birth with a concominant decrease in fTNT, and aTNT
as the sole isoform by 2-3 weeks of age (Saggin et al., 1988; Jin et al., 1990;
L'Ecuyer et al., 1991).
These changes in isoform expression coordinate well with the onset
of TGF-B 113 and BRII, but any direct correlation has yet to be made.
However, it has been shown that several additional factors can influence
the expression of a few of these genes. Thyroid hormone has been found to
affect the expression of cardiac genes such as MHC and the TNis, with the
isoform switching of the latter being delayed in hypothyroid rats (Lompre et
al., 1991; Bugaisky et al., 1992; Avery-Fullard et al., 1994). The mitotic
growth factors aFGF and bFGF are able to induce the fetal isoform of MHC
as well as sacroplasmic reticulum calcium ATPase (Sr-Ca++_ATPase),
while having opposing effects of aSk-actin and aCa-actin in cultured
neonatal rat cardiomyocytes (Parker et al., 1990a). Similarly, TGF-B 1
treatment of neonatal rat cardiomyocytes decreases the expression of aMHC and SR Ca++_ATPase, increases B-MHC and aSk-actin, while having
no effect on aCa-actin (Parker et al, 1990b; MacLellan et al., 1993). Whether
TGF-B 1 has these same effects on fetal myocytes has yet to be completely
determined.

Angiogenesis and ECM Biosynthesis
The fetal to neonatal to adult transition period is a time when the
ventricle undergoes significant remodeling, a process which involves the
migration of non-muscle cells into the ventricular wall, an increase in
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ECM formation and reorganization, and angiogenesis (Engelmann 1993).
As described previously, TGF-B, directly or indirectly, can influence each of
these processes. It has been shown that TGF-B receptor and ligand
expression coordinate well, both temporally and spatially, with changes in
ECM production (e.g. the collagens) and expression of the ECM receptors,
the integrins, during several morphological changes (Borg et al., 1990;
Engelmann 1993; Carver et al., 1994). Similarly, the increase in formation
of new blood vessels, as well as expanding those vessels which already
exist, are temporally correlated with TGF-B 1 expression (Sage et al., 1989).
As noted earlier, SPARC may play an integral role in each of these
processes (migration, ECM reorganization, and angiogenesis). To support
this hypothesis, SPARC, both protein and transcripts, have been localized to
organs or tissues undergoing morphogenesis, including the fetal and
neonatal (but not adult) heart (Sage et al., 1989; Reed and Sage, 1994).
Ventricular expression of SPARC has been determined developmentally,
and increases dramatically around the same time in which TGF-B 113 and
BRII appear (Engelmann 1993). However, whether these correlative
expression patterns have functional significance has not been determined.
It is important to note that the cellular migration, ECM formation,

and angiogenesis which occurs in ventricular development does not
directly involve the cardiomyocyte population. Most of the effects TGF-B
may have in this aspect of ventricular remodeling involve the migration of
fibroblasts and endothelial cells and induction of ECM protein expression in
fibroblasts and other non-myocyte cell types. However, TGF-B may play a
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role in cardiomyocyte regulation of these processes. While exogenous
SPARC has been shown to affect ECM interactions as well as induce
endothelial cells to undergo angiogenesis, it is probable that increases in
cardiomyocyte-produced SPARC in response to cardiomyocyte-produced
TGF-B would promote angiogenesis and other morphogenetic processes.

Similarly, it has been proposed that cardiomyocytes may be able to regulate
angiogenesis and cellular migration through the production of inhibitors of
ECM degradation enzymes, such as PAI-1, which are necessary for
migration and angiogenesis (MacGregor et al., 1995). Therefore, the
autocrine actions of TGF-B induced PAI-1 from cardiomyocytes may play a
dual paracrine role in the surrounding non-myocyte cell types: 1) by
promoting ECM accumulation by inhibiting its degradation, and 2) by
regulating cellular migration and capillary angiogenesis.
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Introduction of Cell Lines and Dominant Negative Mutants
Dominant negative (DN) mutants are defined as mutant polypeptides
which when overexpressed disrupt the activity of the wild-type (wt) gene
product (Herskowitz 1987). These DN mutants can disrupt function, in
general, in one of three ways: 1) DN can compete with wt for a rate-limiting
substrate, 2) DN can compete with wt for regulatory molecules or
transactivating molecules, and 3) DN can form inactive dimers or
oligomers with wt (Sheppard 1994). While several examples can be cited in
nature, DN mutants are becoming a widely used research tool which has
the advantage that one can study the function, or loss of function, of a
particular gene/gene product without having to inactivate each of its alleles
within the genome (Herskowitz 1987). Studies examining p21Ras function
have utilized the DN approach in C. elegans, Xenopus, and mammals (Han
and Sternberg, 1991; Whitman and Melton, 1992; Abdellatif et al., 1994).
These mutants disrupted vulval formation in response to EGF in C.

elegans, mesoderm formation in response to FGF in Xenopus, and gene
transcription in response to TGF-B 1 in mammals. Additionally, DN models
of two other cellular proteins, p53 and the estrogen receptor, have been
identified and studied (Unger et al., 1993; Ince et al., 1993). These mutants
are able to be activated or bind ligand, respectively, and dimerize with wt
partners, yet these resulting dimers do not contain their normal
transcriptional transactivating activities.
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An increasing use of the DN approach can be seen in the study of

tyrosine kinase-receptor activation and identification of its signal
transduction pathway components. In general, tyrosine kinase receptors
form homo-dimers or -oligomers upon ligand binding, auto- or transphosphorylate their intercellular domains, and transduce their signal(s).
The most frequent type of DN receptor mutation is a receptor with its kinase
domain deleted by truncation; however, point mutations which render the
receptor inactive have also been produced. Truncations of the receptors for
EGF, ANF, and IGF-1 have been shown to dimerize with their wt
counterparts, and the resulting dimers are unable to respond to growth
factor stimulation as no cross-phosphorylation and activation of the
receptors occurs (Kashles et al., 1991; Chinkers and Wilson, 1992; Prager et
al., 1992). Inactivation of the kinase domain in the insulin receptor was
found not only to interrupt signaling by insulin, but was also able to
interrupt the cells' response to IGF-1, which clearly demonstrated that
some responses to IGF-1 can be mediated through hybrids of IGF-1
receptors and insulin receptors (Frattali et al., 1992). In vivo studies
utilizing DN receptors have demonstrated the particular receptor's
importance in development. One naturally occurring DN mutation in the

c-kit gene, whose product binds Steel factor, has been identified in mice and
humans which results in anemia, sterility, and hypopigmentation
(Fleischman 1992). Deletion of the kinase domain of FGFRl abolishes all
FGF receptor function within the cell, and this mutant was used to
demonstrate the role of FGFs in mesoderm induction in Xenopus embryos

(Amaya et al., 1991; Ueno et al., 1992) and keratinocyte organization and
differentiation in transgenic mice (Werner et al., 1993).
Following in the tradition of using kinase deficient or inactive
tyrosine kinase receptors, the DN approach is now being utilized to study
the serine/threonine kinase receptors in the TGF-B superfamily. Just as a
truncated FGF receptor blocked mesoderm induction in Xenopus embryos,
a truncated, kinase deficient activin type II receptor (ActRII) was also used
to determine its role in mesoderm induction. These data showed that
activin is required for induction of mesoderm as well as anterior-posterior
and dorsal-ventral body patterns (Hemmati-Brivanlou and Melton, 1992).
In addition to ActRII, DN mutants of the type I receptors (ActRI and
ActRIB) have also been used to elucidate the signaling mechanism used by
activins. In these studies, a kinase deficient ActRIB receptor blocked
activin-induced transcription, while a kinase deficient ActRI did not have
any effect, demonstrating that these two receptors are functionally distinct
(Tsuchida et al., 1995). Similarly, kinase deficient type I and type II BMP
receptors have been used in vivo to demonstrate that BMPs are involved in
the induction of axial mesoderm and hematopoietic tissue in Xenopus
embryos (Ishikawa et al., 1995; Maeno et al., 1996) as well as mediating
interdigital cell death in embryonic chicken limbs (Zou and Niswander,
1996).
While in vivo data on TGF-B activities utilizing the DN approach are
limited to epidermal development (Wang et al., 1997), numerous studies in

vitro have used non-functional BRI and BRII to examine the mechanism of

signaling as well as effects TGF-B has on cellular functions. In an attempt
to uncouple the different effects of TGF-B signaling at the level of the
receptors, overexpression of a kinase deficient, dominant negative BRII
(BRII-DN) has been utilized. Since effects on cellular proliferation are a
hallmark of TGF-B activity, overexpression of BRII-DN in lung fibroblasts
was able to block TGF-B induced proliferative activities (+ in adult, - in fetal)
(Zhao and Young, 1996). In mink lung epithelial (MvlLu) cells, BRil-DN
expression resulted in an block in the anti-proliferative activity of TGF-B,
but not transcriptional upregulation of PAI-1 and fibronectin, suggesting
that there are BRI and BRII specific responses (Chen et al., 1993).
However, similar studies in primary cultures of neonatal cardiomyocytes
alongside MvlLu cells demonstrated that BRII-DN blocked the TGF-B
induction of skeletal a-actin and PAI-1 promoter activity in addition to TGF-

B's inhibition of a-myosin heavy chain transcription, suggesting that all
TGF-B effects are mediated through BRII (Brand et al., 1993; Brand and
Schneider, 1995). Finally, BRII-DN has also been utilized to study
developmental events such as capillary morphogenesis and myoblast
differentiation. In each case, interference with TGF-B signaling through
BRil-DN was able to disrupt processes such as apoptosis and capillary
morphogenesis in rat glomular capillary endothelial cells (Choi and
Ballermann, 1995) and myoblast differentiation and fusion into myotubes
(Filvaroff et al., 1994).
Although the TGF-B knockout studies indicate no gross
abnormalities in the hearts of the null mutants, the distinct expression
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patterns for the TGF-B ligands and receptors suggest a defined role each of
the TGF-B isoforms in development. Although compensation for missing
ligands in the knockout mice is possible, it is also possible that the roles the
TGF-Bs play in the heart are more subtle, affecting changes at the
molecular and cellular level. The onset of expression of TGF-B ligands and
BRII temporally correlates with the transition the mammalian heart goes
through as it progresses from its fetal-to-neonatal-to-adult stages of
maturation with regard to myocyte proliferation, myocyte differentiation,
and ECM formation/angiogenesis. Due to TGF-B's established antiproliferative activity and ability to influence ECM biosynthesis and
angiogenesis, we have postulated that ventricular TGF-Bs participate in the
three major developmental events ongoing during the neonatal ventricular
transition period: (1) inhibits cardiomyocyte proliferation in an autocrine
manner in the newborn, (2) influences differentiation of the cardiomyocyte
in an autocrine manner in the late fetal/early neonatal stages, and (3)
stimulates non-myocyte ECM biosynthesis/deposition and angiogenesis in
the postnatal period in a paracrine manner.
Because BRI and BRII are needed for most, if not all, actions of the
TGF-Bs, receptor manipulation appears to be the method of choice to define
the role(s) TGF-B may play in regulating myocyte proliferation and
influencing their differentiation and paracrine mechanisms of action.
Results from the DN TGF-B studies described above indicate that TGF-B
may be directly involved in several processes (proliferation, muscle protein
isoform expression, ECM biogenesis) which occur in or are associated with
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the cardiomyocyte population during heart development. However, due to
variability in responses between different cell types, only tenuous
relationships can be made as to TGF-B's direct effects on ventricular
development in vivo.
To begin to address the role(s) of TGF-B in ventricular development,
we have chosen to use the BRII-DN approach to evaluate changes that
occur in myocytes in response to TGF-B stimulation. While primary
cardiomyocyte cultures would be the cell culture system most applicable to
the in vivo situation, their general lack of proliferative activity,
heterogeneity, and transfection efficiency limit their in vitro utility. Two
ventricular myocyte-derived cell lines, BWEM and CLEM, are available in
which to study the aspects of TGF-B signaling in a myocyte background.
These cell lines were formed from 16dpc rat ventricular myocytes by
retroviral transformation with v-myc (Engelmann et al., 1993b). Unlike
their primary counterparts, these cell lines are non-contractile, which is
reflective of their lack of organized sarcomere-like structures. However,
these lines have maintained the expression of several genes which are
known to be expressed in embryonic and fetal cardiomyocytes: cTNC, acardiac actin, early growth response-1, creatine kinase-B, connexin-43,
myosin light chain-2v, and several muscle-specific transcription factors
(Engelmann et al., 1993b; Engelmann et al., 1996). These cell lines have
been used to create mutant myocyte lines with reduced or absent BRII
function in which the direct effects of TGF-B can be uncoupled and
evaluated in a myocyte background. Data are presented here on the
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creation and receptor expression/function in each of the parental and
mutant myocyte-like cell lines. Data are then presented in which these
lines were used to study the TGF-B signal transduction pathway and test
these hypotheses:
(1) TGF-B inhibits cardiomyocyte proliferation

(2) TGF-B plays a direct role in cardiomyocyte differentiation by inducing
the "adult" isoforms of three contractile proteins: TNC, TNI, and TNT.
(3) TGF-B promotes ECM accumulation and angiogenesis through the
upregulation of cardiomyocyte produced PAI-1 and SPARC peptides.

CHAPTER3
MATERIALS AND METHODS
Culturing of Cell Lines: BWEM and CLEM are myocyte cell lines derived
from 16-day fetal rat ventricular myocytes by v-myc transformation
(Engelmann et al., 1993b). Cells were maintained in 4% Fetal Clone Serum
(FCS-I, a bovine serum product, Hyclone Laboratories, Inc., Logan, UT) in
Dulbecco's Modified Eagle's Medium Nutrient Mixture F-12 Ham (DME/F12, Sigma Chemical Co., St. Louis, MO). Cells were passaged or split for
subsequent use by trypsinization (Trypsin-EDTA, Gibco-BRL, Grand
Island, NY).

Primary Fetal Cultures: 18 day gestation cardiomyocytes were obtained
from time-pregnant Sprague-Dawley rats (Zivic-Miller, Portersville, PA) as
previously described (Engelmann et al., 1990). Cells were plated on
collagen coated tissue culture plates and allowed to attach overnight in a 1:1
dilution of PC-1 (Ventrex, Portland, Maine):DME/F-12. After plating,
media was changed to a 1:2 dilution PC-l:DME/F-12, and timepoints and/or
transfections (see below) were started.
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Establishment of Stably Transformed Clonal Cell Lines: BWEM and CLEM
parental cell lines were transformed with pRSV2Neo (5 µg) (American Type
Culture Collection (ATCC), Rockville, MD) and the plasmid phBRIIDN
(Chen et al., 1993), which encodes a truncated, human BRII (25 µg). Both
parental lines were electroporated at 280 m V with a capacitance extender
option (BioRad, Hercules, CA), allowed to sit on ice 15 minutes, and plated
in 4% FCS-I for 14-16 hours (overnight). Resulting transformants were
then selected for with the antibiotic geneticin (400 µg/mL active G418, GibcoBRL). After the fifth passage, transformed lines were considered "stable"
and G418 was reduced to 200 µg/mL of active G418 for maintenance. After
20-25 passages, cells were collected from each set of transformants by
trypsinization, pelleted, and resuspended in Hank's balanced salt solution
(HBSS, Sigma Chemical Co.). Cells were stained with Hoechst dye and
single, G 0 cells were sorted using pulse-processing to exclude doublets and
collected into 96-well plates by fluorescence activated cell sorter analyses
(FACS, FACStar Plus, Becton-Dickenson, Mountainview, CA). Each well
contained 50% conditioned media from the parental line of origin to
facilitate their attachment and growth. All resulting single cell clones
were then expanded into full colonies. >50 of these colonies were screened
by Northern and Southern blot analyses, and a select group were
characterized in greater detail and contrasted to their parental sources.
One BWEM-derived clone, BW-Hl, and one CLEM-derived clone, CL-B5
were chosen for these more extensive and detailed studies.

Southern Blot Analysis: Genomic DNA was obtained from each myocyte
cell line or clone as previously described (Laird et al., 1991). DNA was
subjected to HindIII, Apal, or BamHI digestion, extracted twice with
phenol:chloroform, precipitated with isopropanol, resuspended in TE
(lOmM Tris-HCl, pH 8.0, lmM EDTA), and quantitated by ultraviolet (UV)
absorbance at 260 and 280 nm (U-2000 Double-Beam UVNis
Spectrophotometer, Hitachi Instruments, Inc., Danbury, CT). Equal
amounts of genomic DNA (25 µg) were loaded and electrophoresed on 0.6%
agarose TBE gels. After DNA was depurinated in 0.25M HCl for 15
minutes, DNA was denatured in 0.5N NaOH/ l.5M NaCl. The gel was then
neutralized in 0.5M Tris-HCl, pH 8.0/l.5M NaCl and transferred to nylon
membranes (Duralon-UV, Stratagene, La Jolla, CA) by overnight capillary
transfer. DNA was UV-crosslinked to the membranes after transfer (UV
Stratalinker, Stratagene) and used for hybridization analysis. Membranes
were blocked for 2 hours with cDNA hybridization buffer (50% formamide,
10% dextran sulfate, 1% sodium dodecyl sulfate (SDS), 1 M NaCl, 100
µg./mL herring sperm DNA) at 42°C in a Hybridization Incubator (Robbins
Scientific, Sunnyvale, CA). A cDNA probe specific for the CMV promoter
was obtained from the phBRIIDN plasmid by restriction digestion with Bgl
II and Hind III and isolation in low melt agarose, and labeled by random
prime labeling (Decaprime II Labeling Kit, Ambion, Austin, TX). The
probe was boiled in cDNA hybridization buffer for ten minutes just prior to
addition to hybridization tubes. After overnight hybridization at 42°C, blots
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were washed twice in 2X SSC, 0.5% SDS at room temperature for 20
minutes, followed by 10 minutes washes in O.lX SSC, 0.1 % SDS at 50-65°C in
5° increments. X-ray film (Biomar Blue Sensitive Autoradiographic film,
MARSH Biomedical Products, Inc., Rochester, NY) exposures were done at
-80°C for 24 hours.

TGF-B2 Treatments: Treatments with or without TGF-B 3 were begun after
suspended cells resulting from splitting and/or electroporation were
allowed to settle and reattach to the cell cultures plates 14-16 hours
(overnight). Plating media and dead cells were removed, and plates were
washed twice with HBSS. Unless otherwise indicated, 4% FCS-I (cell lines)
or 1:2 PC-l:DME/F-12 (fetal) media± TGF-B3 (Ken Iwata, Oncogene Science,
Uniondale, NY) was added to each plate and incubated at 37°C, 5% C0 2 •
Media was changed daily (mRNA/protein collection- cell lines) or spiked
with additional TGF-B3 (CAT assays, all fetal experiments) every 24 hours.
Cells were then washed twice with HBSS and samples collected.

Northern Blot Analysis: Total RNA from cell cultures was obtained by
scraping cell monlayers in guanidine isothiocyanate, the resulting
homogenate was then phenol/chloroform extracted, precipitated with
isopropanol, and the final RNA pellet was resuspended in formamide
(Chomczynski and Sacchi, 1987). Samples were quantified by UV
absorbance at 260 and 280 nm. Equal amounts of total RNA were loaded
and electrophoresed on denaturing 1.2% agarose gels. Separated RNA was
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hydrolyzed in dilute alkali, UV-crosslinked to nylon membranes after
overnight capillary transfer, and used for hybridization analysis. Probes
used for hybridization analyses were
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P-labeled using random prime

labeling of cDNA probes (Decaprime II Labeling Kit, Ambion) and terminal
deoxynucleotidyl transferase (Pharmacia Biotech, Piscataway, NJ) labeling
of oligonucleotide probes. Membranes were blocked in cDNA hybridization
buffer (see Southern blot analysis) or oligo hybridization buffer (6X SSC, IX
Denhardt's, 0.1 % SDS, 0.05% Na-pyrophosphate, and 100 µg/mL herring
sperm DNA) for 2 hours. Overnight hybridizations were performed at 42°C
for cDNA probes or at 51°C for oligo probes. Blots having cDNA probes were
washed as described for Southern blots. Blots hybridized with
oligonucleotide probes were washed 4x 10 minutes in 6X SSC, 0.1 % SDS at
room temperature, and twice at 50°C in the same solution. mRNA levels
were quantitated by phosphoimager analysis (lnstantlmager, Packard
Instrument Co., Meridan, CT). X-ray film exposures were done at -80°C for
the indicated times for each blot. Loading and RNA transfer equivalencies
were assessed by hybridizations with an 18S or 28S rRNA oligonucleotide
probe as previously described (Engelmann et al., 1989, Samarel and
Engelmann, 1991).

cDNA Probes: inserts isolated from plasmids containing cDNAs for:
rat TGF-BRI (R4) 3'UTR (He et al., 1993)
rat TGF-BRII (prBRII, extracellular domain)
(Tsuchida et al., 1993)
human hBRIIDN (extracellular domain)
cardiac Troponin C (cTNC, full length probe)
(Parmacek and Leiden, 1989)
murine skeletal Troponin C (sTNC, full length probe)
(Parmacek et al., 1990)
skeletal Troponin I (sTNI, full length probe)
(Murphy et al., 1991)
cardiac Troponin I (cTNI, full length probe)
(Murphy et al., 1991)
SPARC (full length probe, Mason et al., 1986).
Oligo Probes:
adult/fetal Troponin T, recognizes nt 942-974 (3'coding region)
(CCAR, Jin and Lin, 1989)
5' GGCAAGACCTAGAGCTGGGATTCACAGGGCAAG 3'
fetal Troponin T, recognizes exon 4 (PE4, Jin and Lin, 1989)
5' GGAAGACTGGAGCGAAGAAGAAGAAGACG3'
188 and 288 rRNA (25 nt) (Yu et al., 1992)
188 5' TCACCTCTAGCGGCGCAATACGAAT 3'
288 5' ACCTTTTCTGGGGTCTGATGAGCGT 3'
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£rotein Collection: Full cell extracts (FCE) were obtained from tissue
culture plates by scraping directly into freshly prepared 250 mM Tris-HCl,
pH 7.5, containing 3% sodium dodecyl sulfate (SDS), 1 mM sodium fluoride
(NaF), 1 mM sodium vanadate (NaV0 4 ), and 1 mM phenylmethylsulfonyl
fluoride (PMSF) (Tris-SDS solution). Conditioned media were collected
from tissue culture plates at indicated times and dead cells/debris were
removed by centrifugation at 2000 rpm for 5 minutes. Media proteins were
precipitated with 10% TCA, washed 4 times with ice cold acetone, and
allowed to dry. Proteins were resuspended in the Tris-SDS solution
described above. All samples (FCE and media) were boiled for six minutes
and allowed to return to room temperature. Samples were quantitated by a
standard BCA assay (Pierce, Rockford, IL). Samples were stored at -20°C
between uses. To avoid protein degradation, large sample volumes were
divided into several tubes to prevent repeated freeze-thaw cycles.

Western Blot Analyses: Samples were diluted in 250 mM Tris-HCl, pH 7.5,
containing 3% SDS. 5X dye solution (20% B-mercaptoethanol, 80% glycerol,
bromphenol blue) was added to each and heated at 65°C for 10 minutes.
Biotinylated standards (broad range, BioRad) were used at 1 µL per lane.
Samples were then loaded on a 10 or 12% SDS-PAGE gel and run for -2
hours at 105 volts at room temperature on a Mini-PROTEIN II Slab gel
apparatus (BioRad) according to manufacturer's protocol. Proteins were
transferred to nitrocellulose (BioRad) in transfer buffer containing 20%
methanol for 1.5 hours at 105 volts with the Mini Trans-Blot system

(BioRad) according to manufacturer's instructions. Membranes were then
washed with TBST (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.05% Tween2o) and used for western blot analysis. Membranes were blocked in TBST

containing 10% normal goat serum (NGS, Sigma Chemical Co.) and 2%
bovine serum albumin (BSA, Sigma Chemical Co.) for 2 hours at room
temperature (RT). Primary antisera (a.-SPARC,#5944, 1:5000 dilution, Sage
et al., 1989; a.-BRI, 1:1000 dilution, Santa Cruz Biotechnology, Inc., Santa
Cruz, CA) was added to the membranes (diluted in blocking buffer) and
incubated overnight at 4°C. Membranes were then washed 3 times at RT
with TBST (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.05% Tween-20).
Standard lanes were cut off from the remaining blot for separate 2° antibody
treatment. Alkaline phosphatase (AP) conjugated secondary antibody (arabbit or a-mouse, Santa Cruz Biotechnology, Inc.) was added to each
membrane and incubated at RT for 1 hour. Standard lanes were incubated
with streptavidin conjugated AP (BioRad). Membranes were then washed
at RT twice (5 minutes each) with TBST and twice (5 minutes each) with
deionized H 20. Blots were developed with the 5-bromo-4-chloro-3-indolylphosphate/p-nitro blue tetrazolium choloride color development system
(BCIP/NBT, 5 Prime--> 3 Prime, Inc., Boulder, CO) for 5-15 minutes.
Development was stopped by washing the blots with deionized H 20 and
blotting dry.
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Receptor-Ligand Crosslinking: TGF-B 1 crosslinking was performed as
previously described (Massague, 1987) with minor alterations. Cells were
plated at 1-2xl05 cells per 12-well or 35mm plate and allowed to incubate for
approximately 48 hours. As a control, 3-day old neonatal cardiomyocytes
were isolated by sequential collagenase digestions as previously described
in detail (Engelmann et al., 1990). lOOpM of 1251-TGF-B1 (Biomedical
Technologies, Inc., Stoughton, MA) was added to each dish in cold binding
buffer (128 mM NaCl, 5 mM KCl, 5 mM MgS0 4 , lmM CaCl2 , 50 mM
HEPES, pH 7.4, and 0.2% BSA) and incubated at 4°C for 4 hours. Receptor
bound ligand was then crosslinked with Disuccinimidyl glutarate (4.4
mg/mL in dimethyl sulfoxide) (Pierce, Rockford, IL) for 15 minutes at room
temperature. The crosslinking reaction was stopped by washing 4 times
with PBS (10 mM H 2NaP0 4 , pH 7.25, 150 mM NaCl).

Identification of TGF-B Binding Proteins/Receptors: Full cell extracts of
125

1-TGF-B crosslinked samples were collected directly into Laemmeli SDS-

PAGE buffer containing lmM DTT and boiled for 5 minutes. Fractions of
each sample were taken to quantify available radioactivity (COBRA II AutoGamma, Packard Instrument Co., Meridan, CT). Equal counts of
radioactivity for each sample were loaded and run on 10-12% SDS-PAGE
gels. The gels were dried and exposed to X-ray film at -80°C for 3-5 weeks.
Kaleidoscope standards (BioRad) were run on each gel for size
determination.

Identification of Receptors/Receptor Complexes: To more clearly observe
.BRII-DN and possibly provide evidence for BRII-DN:BRI association,
immunoprecipitations (IPs) were performed on
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1-TGF-B crosslinked

samples. Samples were collected into PBSTDS (10 mM Na2 HP04' 150 mM
NaCl, 1%Triton-X100, 0.1 % SDS, 1 mM NaF, 10 mM Na-deoxycholate, and
30 mM Na-azide) and immunoprecipitated (IP) with M2 a.FLAG
monoclonal antibody (M2) (Sigma, St. Louis) or a-BRI and Protein G
Plus/Protein A Agarose (Oncogene Sciences, Manhasset, NY). Final IP
pellets were resuspended in Laemmeli buffer containing 1 mM DTT and
equal volumes were loaded on 10-12% SDS-PAGE gels. Gels were dried and
exposed to X-ray film for 5 weeks at -80°C. Kaleidoscope standards (BioRad)
were run on each gel for size determination.

Growth Assays: 2-2.5xl0 5 cells were plated on 35 mm plates in 2% FCS and
allowed to settle and reattach for 4-5 hours. The cells were then washed
twice with HBSS and refed with media containing 0.5% FCS with 0-10
ng/mL TGF-B 3 • The number of attached cells was determined from nuclei
counts of these mononuclear cells at this time (T=O) for plating efficiency
(Engelmann and Gerrity, 1988). After 48 hours of continuous exposure
(without additional TGF-B 3 being added at 24 hours), nuclei were isolated
and counted (T=48). Duplicate plates were counted for each data point. The
data are expressed as the relative percentage of cell proliferation compared
to control cultures not exposed to exogenous TGF-B 3 •
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Luciferase Assays: 2-2.5xl0 6 cells were used for each electroporation. Cells
were collected by trypsinization, counted, pelleted, and resuspended in
electroporation buffer (20 mM HEPES, pH 7.05, 137 mM NaCl, 5 mM KCl,
0.7 mM Na2 HP04' 6 mM glucose). 25 µg p3TP-Lux (PAI-1, Wrana et al.,
1992) or BW147 (sTNI, Corin et al., 1994; Corin et al., 1995) and 5 µg pRSVZ
(ATCC) plasmid DNAs were added to the cells in a total volume of 800 µl for
each electroporation. Cells were electroporated at 240 m V with a
capacitance extender option (BioRad), allowed to sit on ice for 15 minutes
and then replated. Cells were allowed to recover/attach for 4-6 hours after
which the plates were washed with HBSS and refed with fresh media
containing 0-10 ng/mL TGF-B 3. After an additional 36 hours, luciferase
activity was measured from the cell lysates according to the
manufacturer's instructions (Enhanced Luciferase Assay Kit, Analytical
Luminescence Lab., Ann Arbor, MI). Data were normalized for
electroporation efficiency by determining B-galactosidase activity from each
sample and expressed as fold changes relative to untreated (O ng/mL TGFB3) controls.

CAT Assays: 4.5-5xl0 6 cells were used per poration. Cells were collected by
trypsinization, counted, pelleted, and resuspended in 800 µL electroporation
buffer. 25 µg reporter plasmid [cTNC (p-124SVOCAT, Parmacek et al.,
1994), sTNC (1.7/900-CAT, Parmacek et al., 1990), SPARC (639-SPARC,
McVey et al, 1988), TNT (303-CAT, Wang et al., 1994)] and 5 µg pRSVZ
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(ATCC) were used for each poration. Cells were electroporated at 240 m V,
allowed to sit on ice for 15 minutes and plated. Cells were allowed to
recover/attach overnight after which dead cells were washed off and
treatments were started. After 48-72 hours, proteins were collected,
quantitated by BCA, and CAT assays were performed using 150 µg protein
(cell line) or 40-70 µg protein (fetal) (Gorman et al., 1982). CAT activity was
quantitated by phosphoimager analysis (lnstant/mager, Packard
Instrument Co.). Data were normalized for poration efficiency by
determining B-galactosidase activity for each sample utilizing equal
amounts of cellular protein.

Transfection and Reporter Assays Utilizing Primary Fetal Myocytes:
Primary fetal cultures were transfected as previously described using
Lipofectin (Gibco-BRL) (Engelmann et al., 1990; Ciccarone and HawleyNelson, 1995). Briefly: 24 µg Lipofectin/mL final volume 1:2 dil. PCl:DME/F-12 was used for each transfection. Lipofectin and media were
combined and allowed to incubate at RT for -1 hour. Reporter plasmid (25
µg, BW147, 180-CAT, 1.7/900-CAT, 303-CAT, 639-SPARC) and pRSVZ (5 µg)
were mixed with lipofectin/media mixture and allowed to incubate at RT for
30 minutes. The resulting mixture was then added to plates and allowed to
incubate at 37°C, 5% C0 2 overnight. Lipofectin-media-plasmid mixture was
then removed, plates washed 3 times with HBSS, and TGF-B3 treatments
started. After 36 (luciferase) or 48 (CAT) hours, samples were collected and
activities were assayed as described above.
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Statistics: Using InStat Software and a P value of <0.05 as an index of
achieving statistical significance, Northern blot and luciferase data from
each parental line and mutant clone was analyzed using one way analysis
of variance (ANOVA) followed by Tukey-Kramer multiple comparisons test.
Unpaired T-tests were performed on all fetal data, and on cell line data
obtained from the CAT assays. Comparisons between parental cell lines
and their mutant clones at each dose ofTGF-B 3 were evaluated by one-way
ANOVA. Comparisons of the dose curves between each parental line and
its respective mutant were evaluated by two way ANOVAs using
SUPERANOVA software.

CHAPTER4
RESULTS

Creation and Initial Characterization of Cell Lines
Creation of Dominant Negative Cell Lines
As a model system for the study of the effects of TGF-B in ventricular

development, the BWEM and CLEM myocyte-like cell lines not only provide
a means to directly examine changes TGF-B may elicit, but also to examine
the mechanisms or pathways which mediate these effects. To more clearly
define the direct roles TGF-B may have in ventricular development and to
examine the specific roles of the Type I and Type II TGF-B receptors, we
chose to knock out BRII function in each of the myocyte cell lines utilizing
the dominant negative approach.
In order to create cell lines in which a response to TGF-B could be
abrogated, the expression plasmid phBRIIDN was introduced into the
BWEM and CLEM cell lines by electroporation. This plasmid contains a
cDNA encoding a truncated, kinase-deficient human BRII (see Figure 3)
whose expression is under the control of the cytomegalovirus (CMV)
promoter. As this plasmid did not contain a eukaryotic selection marker,
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pRSV2neo expression plasmid conferring genestine (G418) resistance was
co-transfected. After G418 selection was maintained through 5-7 passages,
four stable, clonal lines were established; two BWEM derived, BDN and
BDNT, and two CLEM derived, CDN and CDNT. Because G418 resistance
alone does not guarantee stable integration of phBRIIDN, the polyclonal
nature of these lines made interpretation of the resulting data (not shown)
troublesome. Therefore, single cell derived clonal sublines were
established by fluorescence activated cell sorting (FACS) from each of the
four polyclonal populations. To ensure each subline was derived from a
single cell (clonal), each well of the 96-well plate was screened within 24
hours of FACS sorting to select/verify those wells which contained a single
cell. Greater than 50 clonal cell lines were screened by Southern and
Northern blot analyses for phBRIIDN integration and BRII-DN expression,
respectively (e.g. Figure 4). From these analyses, four clones were selected
based on indices of high expression of the estimated 1 kb transcript for the
truncated receptor and were further characterized: BDNT 96 F8, BDNT 296
Hl, CDNT 296 B5, and CDNT 96 F5 (indicated by ** , Figure 4). These four
clonal lines (two from each parental line) are referred to as BW-F8, BW-Hl,
CL-B5, and CL-F5 from here on.
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TGF-BRII
SS
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75kD
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hBRIIDN -40kD
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Figure 3: Diagram of Wild Type and Mutant TGF-BRII
Schematic of the protein domains found in the wild type TGF-BRII
and the truncation mutant present in the phBRIIDN expression vector used,
to create the DN cell lines.
SS: Signal Sequence
TM: Transmembrane domain
F: FLAG Epitope tag.

EC: Extracellular domain
IC: Intracellular domain
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Figure 4: Screen of Clonal BRII-DN Mutants
Examples of Northern Blot analyses used to choose mutant cell lines
which incorporated phBRIIDN and expressed the BRII-DN transcript.
Arrow indicates expected size (-1 kb) for the BRII-DN transcript.
**Indicates those DN lines which were chosen for further study. 25 µg
total RNA loaded for each sample. Results shown are from 24 hr. exposure
to film at -80°C. Bars on right indicate migration of 288 and 188 rRNA
markers.
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Expression and Ligand Binding of Endogenous and Mutant Receptors
As previously described, BRI and BRII are necessary for most, if not
all, TGF-B-mediated responses. Therefore, expression and ligand-binding
ability of each receptor, in all of the cell lines is of utmost importance.
While the expression of the endogenous TGF-B receptors was not expected
to be affected by the transformation, we chose to verify their expression in
each of the mutant lines as well as their parental cell lines. Additionally, to
verify the stable integration and expression of BRII-DN after multiple
passages (>20), expression and ligand-binding ability of BRII-DN was
verified in the mutant cell lines.
To verify expression of BRI in the parental and mutant cell lines,
Northern blot and Western blot analyses for the endogenous BRI were
performed on RNA and protein, respectively, isolated from the mutant
clones as well as the parental cell lines (Figure 5 and 6 ). As expected,
transcript levels for BRI (-6 kb) were not affected by the transformation, nor
did they differ significantly between parental lines or clones (Figure 5).
Similar results were seen with Western blot analyses for BRI protein,
which has an estimated size of 53 kD (Figure 6). Therefore, since it appears
that BRI is avidly expressed in each of the cell lines, any lack of response to
TGF-B observed in the mutant cells should not be attributed to abnormal,
cell surface expression of BRI.
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Figure 5: Analysis of Endogenous BRI Expression
Northern blot hybridization analysis was performed to verify
expression of the endogenous rat Type I TGF-B receptor utilizing the rat
BRI (R4) cDNA insert as the probe. Bars represent migration markers of
288 and 188 rRNA. Results shown are from 24 hour exposure to film at
-80°C. 288 rRNA hybridization is shown.
Lane 1: BWEM
Lane 2: BW-F8
Lane 4: CLEM
Lane 5: CL-B5
*Each lane contained 25 µg of total RNA

Lane 3: BW-Hl
Lane 6: CL-F5
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Figure 6: BRI Western Blot Analysis
Total cellular proteins from cell cultures of each cell line were run on
10% SDS-PAGE gels and used for Western blot analyses. 25 µg of protein
was loaded per lane. Markers on right indicate size in kilodaltons as
determined by co-running biotinylated standards on the gel. Staining of gel
indicated that protein loading was consistent (data not shown).
Lane 1: BWEM
Lane 4: CLEM

Lane 2: BW-F8
Lane 5: CL-B5

Lane 3: BW-Hl
Lane 6: CL-F5
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Expression of the endogenous BRII in each of the cell lines was also
verified by Northern blot analyses. As mentioned previously, the
extracellular domain is less conserved across species (see figure 1, Chapter
2). This reduced homology results in low cross-reactivity between human
and rat. Therefore, using a probe corresponding to the extracellular
domain of rat BRII, Northern blot analyses were performed to verify
expression of the endogenous BRII. As expected, expression of the rat BRII
transcript (-5.2 kb) was detected in each of the cell lines (Figure 7). Due to
the low amino acid homology between the extracellular domains of BRII
across species (e.g. 82% between human and rat), most available antisera
for BRII are made against peptides found within the conserved kinase
domain using the published human sequence. However, detection of the
endogenous rat BRII by Wes tern blot analyses was not successful, as these
antisera identified multiple bands, none of which were prominent and at
the expected size of -75 kD (data not shown).
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Figure 7: Analysis of Endogenous BRII Expression
Northern blot hybridization analysis was performed to verify
expression of the endogenous rat Type II TGF-B receptor utilizing the rat
BRII cDNA insert as the probe. Bars represent migration markers of 288
and 188 rRNA. Results shown are from 24 hour exposure to film at -80°C.
288 rRNA hybridization is shown.
Lane 1: BWEM
Lane 2: BW-F8
Lane 4: CLEM
Lane 5: CL-B5
*Each lane contained 25 µg of total RNA

Lane 3: BW-Hl
Lane 6: CL-F5
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While the mutant cell lines were selected because of their high
transcript level for BRII-DN (Figure 4), the stable integration of and
expression from the BRIIDN plasmid was verified after multiple (>20)
passages in all four mutant clones by Southern (Figure Sa) and Northern
(Figure Sb) blot analyses, respectively. In addition to transcript size
differences between the endogenous rat (-5.2 kb) and mutant human BRII
(-1 kb) gene products, the relatively low level of homology (at the cDNA
level) of the extracellular domains of BRII across species allowed us to
easily distinguish between the endogenous rat and mutant human
receptors. As expected, results were negative for both the Southern and
Northern blot analyses of the parental cell lines (CLEM Southern data not
shown). Similar to the results obtained from Northern blot analyses
performed on RNA obtained from the mutant lines at an early passage , the
-1 kb human BRII-DN transcript was readily detected in each of the

mutant cell lines (Figure S). A larger (-5 kb) band is consistently detected
in the BWEM derived lines (both early and later passages). As these bands
coincide with the size of the endogenous rat BRII, crossreactivity was
considered to explain the bands. However, since this band does not appear
in the parental BWEM line, this does not appear to be the case. Therefore,
the larger bands have been hypothesized to be the result of improper readthrough of the plasmid during transcription or tandem integration of
plasmids in the genome. These hypothesis have not been tested further.
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Since the available antisera for BRII are made against peptides
derived from the kinase domain, detection of BRII-DN with these antisera
was impossible as these peptide sequences are deleted during truncation.
However, to aid in its detection, BRII-DN was constructed with an epitope
tag, FLAG. Western blot analyses utilizing antisera against this epitope
from several independent sources were attempted, but each epitope-directed
antisera detected several protein bands in the protein samples, none of
which was unique to the DN lines (data not shown). However, this antibody
proved to be useful for immunoprecipitations (see receptor-ligand
crosslinking).
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Figure 8: Integration of and Expression from phBRIIDN Vector
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Figure 8: Integration of and Expression from phBRIIDN Vector
(A) Southern Blot hybridization analysis of genomic DNA (30
µg/lane) after HindIII digestion. The CMV promoter fragment from the
phBRIIDN vector was utilized as a probe. Results shown are from a 24
hour exposure to film at -80°C.
(B) Northern Blot hybridization analysis for expression of the mutant
human Type II receptor utilizing the entire coding region (primarily the
extracellular domain) from phBRIIDN as a probe. Results shown are from
24 hour exposure to film at -80°C. Bars represent migration markers of 288
and 188 rRNA. 288 rRNA hybridization is shown for the Northern blot.
Lane 1: BWEM
Lane 2: BW-F8
Lane 4: CLEM
Lane 5: CL-B5
*Each lane contained 25 µg of total RNA

Lane 3: BW-Hl
Lane 6: CL-F5
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Cell surface expression and ligand binding abilities of the
endogenous and mutant TGF-B receptor proteins were confirmed by 125ITGF-B1 crosslinking. Although Northern and Western blot analyses
detected the expression of the TGF-B receptor transcripts and proteins,
these analyses did not verify ligand binding capabilities. Based on the
mRNA studies, endogenous protein levels for each rat TGF-B receptor did
not vary significantly between the cell lines or clones. To verify that these
proteins were functional, their ligand binding capabilities were determined
by standard ligand-receptor crosslinking methodologies. As shown in
figure 9a, crosslinking with 125 I-TGF-B 1 showed the presence and ligand
binding capabilities of the endogenous rat Type I (53 kD) and Type II (75 kD)
TGF-B receptors as well as the truncated, human Type II (-40 kD) TGF-B
receptor. In addition to the cell lines, results from a primary culture of two
day neonatal cardiomyocytes was included for comparison. Duplicate, 125 ITGF-B1 crosslinked samples were used for immunoprecipitation (IP) with
the M2 antibody against the FLAG epitope on BRII-DN to more precisely
evaluate expression of this receptor. In correlation with the mRNA
studies, the mutant, human BRII receptor, estimated to be -40 kD, was the
only receptor-ligand band immunoprecipitated with the M2 a-FLAG
antibody from lysates of the four mutant clones (overexposure of film shows
weak band in CL-F5 sample), while none were detected using lysates from
the parental cell line (Figure 9b).
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Figure 9: 1251-TGF-B 1 Receptor-Ligand Crosslinking
125
1-TGF-B 1 (100 pM) was crosslinked to cell monolayers of each cell
line to determine cell surface receptor expression and ligand binding
capability.
(A) Full cell extracts were collected directly into Laemmeli buffer
and run on 12% SDS-PAGE gels. Results shown are from a 3-week
exposure to film at -80°C.
Lane 1: Primary neonatal rat cardiomyocytes
Lane 2: BWEM
Lane 3: CLEM
Lane 4: BW-F8
Lane 5: BW-Hl
Lane 6: CL-F5.
(B) Cell lysates were immunoprecipitated with M2 a.FLAG with all of

the IP-materials loaded and run on 12% SDS-PAGE gels. Results shown
are from a 5-week exposure to film at -80°C.
Lane 1: BWEM
Lane 2: BW-F8
Lane 3: BW-Hl
Lane 4: CL-B5
Lane 5: CL-F5.
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In.itial Characterization of the Response to TGF-B
To initiate the characterization of each of the parental lines and
clones to TGF-B responses, we analyzed two "standard" effects that have
been shown to be elicited by all three mammalian isoforms of TGF-B in
other well characterized cell lines (such as MvlLu): 1) inhibition of
proliferation and 2) induction of transcription from the p3TP-Lux reporter
construct derived from the promoter region of the PAI-1 gene. In addition
to being standard TGF-B effects, the characterization of these responses to
TGF-B 3 in each cell line also provided data which addresses two parts of our
hypothesis: 1) TGF-B 3 can directly inhibit cardiomyocyte proliferation and
2) TGF-B3 can influence ventricular remodeling by supporting ECM
accumulation. As these effects are standard indicators of TGF-B
responsiveness, the BWEM and CLEM cell lines are expected to exhibit
significant changes in proliferation and PAI-1 induction after TGF-B3
treatment. In contrast, the established expression of BRII-DN in the
mutant cell lines should result in the elimination of TGF-B 3
responsiveness, and therefore, the elimination of any changes in
proliferation or PAI-1 expression after TGF-B3 treatment.
Growth assays were performed on each cell line using 0-10 ng/mL
TGF-B 3 • The parental cell lines BWEM and CLEM each demonstrated
maximum inhibition of proliferation at 1 ng/mL TGF-B3 (Figure 10).
Highlighting the individual nature of the two parental lines, the levels of
TGF-B inhibition differed between these two lines. At 1 ng/mL TGF-B 3 ,
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growth of the CLEM line was inhibited approximately 80% while growth of
the BWEM line was inhibited only about 50%. These levels of inhibition are
similar to those previously obtained in fibroblasts (-70%, Zhao and Young,
1996), capillary endothelial cells (-65%, Choi and Ballerman, 1995), and
mink lung epithelial cells (-90%, Chen et al., 1993).
Similar growth assays were performed on each of the dominant
negative cell clones. Two of these clones, BW-Hl and CL-B5, had a
significantly reduced sensitivity to TGF-B 3-mediated growth inhibition
(Figure 10, Table 2). The BW-Hl clone's sensitivity to TGF-B 3-mediated
growth inhibition was such that the dose necessary to reach the 50%
inhibition seen in its parental BWEM line at 1 ng/mL TGF-B3 was
approximately lOX higher (i.e. 10 ng/mL TGF-B3 ). In contrast, growth of
the CL-B5 clone was only modestly inhibited (approximately 20%) at 1-10
ng/mL TGF-B3 • The results for CL-B5 reflect those obtained in mink lung
epithelial cells where expression of the BRII-DN reduced proliferation only
10% compared to the 90% reduction observed in the parental cells (Chen et
al., 1993). These results indicate that expression of the human BRII-DN is
successfully competing out the endogenous rat BRII for available rat BRI
and reducing or virtually eliminating the growth inhibitory activities of
biologically active, recombinant TGF-B 3 •
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Figure 10: 48 Hour Growth Assays
48 hour growth curves for the BWEM parental and mutant clone
BW-Hl (A) and CLEM parental and mutant clone CL-B5 (B) in the presence
of 0-10 ng/mL of recombinant TGF-B 3 are shown. Mean data shown are
from 4-6 individual assays performed in duplicate and the error bars
represent SEM. "Control" refers to those cultures seeing no exogenous
TGF-B 3 •
* significantly different from parental line (see Table 1)

Table 2: Statistical Analysis of 48 hr. Growth Assay
One way ANOVA was used to determine significance between the
percent growth for each parental cell line and its respective mutant at each
dose of TGF-13 3 • Data are presented as mean± SEM.
ng/mL
0.1
1.0
10

Parental*
89.8± 15.3
51.0± 3.9
57.0 ± 4.4

Mutant*
87.8±1.8
86.8± 1.9
48.8±4.9

n value

BW's
BW's
BW's
CL's
CL's
CL's

0.1
1.0
10

59.0±7.6
22.8±7.6
26.7±13.4

92.8±3.l
85.4± 6.9
78.8± 7.9

0.004
0.0002
0.011

*Percent Growth Vs. Control (0 ng/mL TGF-B 3 , control=lOO)

0.897
0.0002
0.251
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As a second TGF-B response index evaluated in the clones, we
measured the ability of exogenous TGF-B 3 to induce transcription of a well
established TGF-B-responsive gene, PAI-1. Expression from the luciferase
reporter construct p3TP-Lux (Figure lla), which contains three TPA
responsive elements (TRE) and a portion of the PAI-1 promoter, was
determined. As expected, TGF-B 3 significantly induced luciferase activity
in a dose dependent manner in the two parental lines (Figure llb and llc,
Table 3). Interestingly, even though the BWEM line appeared less sensitive
than CLEM to TGF-B 3's growth inhibition, they showed a greater fold
induction of transcription from this promoter: 5.4 ± 0.4X induction for
BWEM vs. 3.9 ± 0.6X induction for CLEM at 10 ng/mL TGF-B3 , although this
variation is statistically non-significant (Table 4). While this level of
induction is dramatically lower than those observed in epithelial cells (2040-fold, Wrana et al., 1992; Carcamo et al., 1995; Brand and Schneider,
1995), it is similar to those obtained in fibroblastic cell lines (5-6-fold,
Carcamo et al., 1995). The level of induction (fold induction) seen in the
parental lines is comparable to the 4.8 ± 0.002X induction seen with
primary fetal cultures (Figure llb), but it appears that the activities
measured in the parental lines are higher than the fetal myocytes, but only
the difference between the fetal myocytes and BWEM cell line achieved
statistical significance (Figure llc, Table 4).
Similar luciferase assays performed on the BW-Hl and CL-B5 clones
showed a markedly decreased sensitivity to TGF-B3 induction of PAI-1
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promoter activity. At 10 ng/mL TGF-B 3 , there was only a 2.3 ± 0.3X
induction of PAI activity in the BW-Hl clone and only a 1.6 ± 0.2 X induction
of PAI-1 activity in the CL-B5 clone. These values are significantly different
(Table 5) from their respective parental lines at equivalent ligand
concentrations. Similar to what was seen in the BW-Hl growth assay, PAI1 reporter activity in the two DN clones at 10 ng/mL TGF-B3 were not
significantly different from the level of induction seen with only 1 ng/mL
TGF-B 3 in their respective parental lines. This -50% reduction in TGF-Bresponsiveness at 10 ng/mL TGF-B 3 is less prominent as similar
experiments in mink lung epithelial cells where expression of BRII-DN
resulted in an approximate 75% reduction in P AI-1 induction (Brand and
Schneider, 1995, Carcamo et al., 1995). However, these data substantiate
the postulate that the levels of BRII-DN expressed by these mutant clones
are rendering them approximately lOX less sensitive than their parental
lines to changes mediated by TGF-B 3 induced signal transduction
pathways.

Table 3: Statistical Analysis of TGF-B 3 Dose Response Curves of PAI-1

Induction
One way ANOVA was used to determine significance of the dose
response curve of PAI-1 promoter activity.
Cell Type
Fetal
BWEM
BW-Hl
CLEM
CL-B5

p-value
(fold induction)
0.0031
<0.0001
<0.0001
<0.0001
<0.0001

p-value
(raw)
0.0004
<0.0001
0.0991
0.1424
0.1428

r
93

Figure 11: PAI-1 Promoter Assays
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Changes in Plasminogen Activator Inhibitor-1

(PAl-1) Promoter Activity
(A) p3TP-Lux reporter construct. This construct contains 3 TPA
responsive elements (TRE) and the PAI-1 promoter region upstream of the
Iuciferase gene.
(B & C) 36-hr. luciferase assays. 18 dpc primary fetal myocyte
cultures (fetal), each parental line (BWEM and CLEM) and their respective
mutant clones (BW-Hl and CL-B5) were transfected with the p3TP-Lux
reporter plasmid and treated with 0-10 ng/mL of recombinant TGF-B 3 for 36
hours after which luciferase activity was assessed as described Chapter 3.
Lucif~rase data were normalized with B-galactosidase activity. Data for the
cell lines represent the mean value from 3-4 individual assays and the error
bars represent SEM. Data for the fetal cardiomyocytes represent the mean
value from 2 individual assays and the error bars represent SD.
(B) Relative changes in activity are presented as fold increases
when compared to untreated (O ng/mL B3 ) samples.
(C) Relative luciferase units are presented for each cell line to
demonstrate individual expression levels in the different cell lines.
Significance: * p:::; 0.05, **:::; 0.01, *** p:::; 0.001

Table 4: Statistical Analysis of Fetal and Parental PAI-1 Induction
Unpaired t-test was used to determine significance between results
obtained from the different cell types in the PAI-1 promoter assay.

Fetal vs. BWEM
Fetal vs. CLEM
BWEM vs. CLEM

p-value
(RLU-02
0.052
0.345
0.805

p-value
(RLU-102
0.012
0.354
0.592

p-value
(fold induction}
0.320
0.424
0.090

~

r
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Table 5: Statistical Analysis of PAI-1 Induction - Parental vs. Mutant
One way ANOVA was used to determine significance between the
PAI-1 induction for each parental cell line and its respective mutant at
each dose ofTGF-13 3 • Data are presented as mean± SEM.

BW's
BW's
BW's

ng/mL
0.1
1.0
10

Parental*
1.06±0.11
2.42 ±0.40
5.39±0.37

Mutant*
0.85±0.01
0.81±0.12
2.25±0.34

12 value
0.160
0.021
0.002

CL's
CL's
CL's

0.1
1.0
10

0.92±0.06
1.92 ±0.17
3.93±0.63

0.76±0.04
0.77±0.03
1.64±0.17

0.054
0.0002
0.006

*Fold Induction Above Control (O ng/mL TGF-B3 , control = 1.00)
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Effects of TGF-B:a on Gene and/or Protein Expression
Having established that the two mutant cell lines BW-Hl and CL-B5
are approximately 10-fold less responsive to TGF-B3 -mediated changes in
cellular proliferation and PAI-1 transcriptional induction, these mutant
lines were used, alongside their respective parental lines and primary
cultures of fetal cardiomyocytes, to identify the direct effects TGF-B may
have on ventricular myocyte development and on their paracrine-mediated
promotion of angiogenesis. To test the hypothesis that TGF-B promotes the
maturation and differentiation of the cardiomyocyte during the perinatal
transition period, the ability of TGF-B 3 to influence the expression, at pretranslational levels, of three contractile proteins, troponin C (TNC),
troponin I (TNI), and troponin T (TNT), were determined. As maintaining
receptor expression levels are important for TGF-B to mediate its effects
during this differentiation process, TGF-B 3 -mediated changes in TGF-B
receptor expression were also examined. Finally, the ability of TGF-B3 to
influence the production of the angiogenesis-related protein SPARC was
examined to address the third and final hypothesis that TGF-B promotes
angiogenesis in the ventricle .

Effect ofTGF-B:a on TNC Isoform Expression
As stated previously, two isoforms ofTNC have been identified to

date, skeletal (sTNC) and cardiac (cTNC). While sTNC has not been found
in the heart at any stage, cTNC can be detected in the heart throughout
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development. Unlike the other members of the troponin complex, no fetal
isoform of cTNC has been identified. However, while expression of cTNC is
low in the fetal heart, its transcript levels increase around birth, in concert
with the increase in expression of the TGF-B ligands and BRII. Therefore,
we hypothesized that TGF-B enhances the expression of cTNC in the late
fetal cardiomyocyte by upregulating transcription from this gene.
Additionally, to verify that the myocyte-like cell lines have maintained their
cardiac background and thus support their use as a model system, sTNC
expression was examined in the lines as well as primary fetal
cardiomyocytes. Therefore, expression of sTNC is expected to be low-toundetectable in these cells. In contrast, cTNC transcripts are expected to be
readily detected and increase significantly in response to TGF-B3 in a dose
dependent manner in each of the parental cell lines. Companion promoter
assays are expected to reflect these changes. As the mutant cell lines were
found to be 10-fold less responsive to TGF-B 3 in the transcriptional, PAI-1
promoter assay, it is expected that the induction of cTNC in these mutant
lines would be significantly less than their respective parental lines.
The two isoforms of TNC, sTNC and cTNC, are derived from separate
genes and are moderately homologous (-70%) to each other at the amino
acid level (Parmacek et al., 1990). The divergence can be found in three
separate domains and allows for discrimination between isoforms by
Northern blot analyses using isoform-specific cDNA probes. Total RNA
was collected from cultures of each cell type which were treated for 48-72
hours with TGF-B3 and was used for Northern blot analyses. As expected,
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TGF-13 3 treatment resulted in an increase in the steady state level of the 712
bp cTNC transcript in each of the cell lines, both parental and mutant, in a
time and dose dependent manner (Figures 12 and 13). However, there
appeared to be no difference in the level of induction at the transcript level
between the parental lines and their respective mutant clones (Figure 12,
Table 6). This was not expected as the mutants appeared to be 10-fold less
sensitive to TGF-13 3-mediated changes in transcription observed in the PAI1 reporter assay (see Chap. 5 for further discussion). In all four cell lines,
increases in steady state cTNC transcript levels were detected at 48 hours,
and reached an approximate 2-2.5-fold induction after 72 hours of TGF-13 3
(10 ng/mL). It can also be noted that inherent differences in the expression
levels of cTNC can be seen among the cell lines (Figure 13).

Table 6: Statistical Analysis ofTGF-133 Dose Response Curves of cTNC
Northern Blot Analyses
One way ANOVA was used to determine significance of the dose
response curves of cTNC steady state transcript levels for each cell type.
Two way ANOVA was used to determine differences between dose curves of
each parental cell line and its respective mutant.
Cell Type
Fetal

p-value (48hr.)
0.229

p-value (72hr.)
0.023

BWEM
BW-Hl
BWvs.BW-Hl

<0.0001
0.003
0.863

0.144
0.167
0.749

CLEM
CL-B5
CL vs. CL-B5

0.059
0.001
0.034

0.429
0.005
0.966

99
Figure 12: cTNC Northern Blot Analyses
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Figure 12: TGF-B3 Induced Changes in Steady State cTNC Transcript
Levels
Cultures of all four cell lines and primary cultures of 18 dpc
ventricular myocytes were treated with 0-10 ng/mL TGF-B 3 for 48 (A) and 72
(B) hours. Northern blots were hybridized with a cDNA probe for cTNC.
Fold induction of steady state transcript levels as compared to untreated
controls is shown. Results shown are from 3-4 individual assays.
Expression data were normalized to 18S rRNA oligo hybridizations. Error
bars represent SEM.
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Figure 13: Northern Blot Analyses of cTNC
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Figure 13: Northern Blot Analyses of cTNC
Primary cultures of 18 dpc ventricular myocytes and cultures of each
of the cell lines were treated with 0- 10 ng/mL TGF-Ba for 48-72 hours.
Northern blots were hybridized the cDNA probe for cTNC. Bars indicate
188 and 288 rRNA bands. Blots shown are from 24 hr. exposure to film at
-B0°C. 188 rRNA hybridizations shown below each blot.
(A) 18 dpc Fetal RNA. 3 µg total RNA loaded for each sample.
Lane 1: 48 hr. Control
Lane 2: 48 hr. +TGF-Ba
Lane 3: 72 hr. Control
Lane 4: 72 hr. +TGF-Ba
(B) Total RNA from each of the cell lines treated with or without 10

ng/mL TGF-Ba· 30 µg loaded for each sample as indicated.
(C) CLEM and CL-B5 RNA. Representative blot of dose response to
TGF-Ba· 30 µg total RNA loaded for each sample.
Lane 1: CLEM Control
Lane 2: CLEM 0.1 ng/mL Ba
Lane 3: CLEM 1 ng/mL Ba
Lane 4: CLEM 10 ng/mL Ba
Lane 5: CL-B5 Control
Lane 6: CL-B5 0.1 ng/mL Ba
Lane 7: CL-B5 1 ng/mL Ba
Lane 8: CL-B5 10 ng/mL Ba
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To determine if these changes in cTNC transcript levels involved
transcriptional upregulation, cTNC-CAT promoter assays were performed
after treatment with TGF-B3 for 48 (Figure 14) and 72 hours (data not
shown). Based on the results obtained from the Northern blot analyses, we
expected cTNC promoter activity to increase in response to TGF-B 3 •
However, cTNC promoter activity in the parental lines significantly
decreased by -40-50% at both 48 and 72 hours in response to exogenous TGF-

B3 treatment (Figure 14, Table 7). Similar to the PAI-1 promoter assays, the
negative transcriptional regulation of the cTNC promoter by TGF-B3
appeared to be inhibited in the DN mutant lines as no significant difference
in promoter activity was observed in BW-Hl and CL-B5 in response to TGF-

B3 (Figure 14, Table 7). However, similar to the Northern blot analyses, the
cTNC promoter results obtained for the mutants and their respective
parental lines were not significantly different (Table 7). These data suggest
a complex, multi-level mechanism(s) wherein TGF-B regulates cTNC
production in the cell lines by both positive and negative influences.
However, these phenomena appear to be a characteristic of the cell lines as
the changes in promoter activity and transcript levels in primary fetal
cultures do not exhibit these same effects after TGF-B 3 treatment, having
very little, or no response to exogenous TGF-B3 (Figures 12 and 14).
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Figure 14: cTNC Promoter Assays
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Figure 14: TGF-B 3 Induced Changes in Cardiac Troponin C (cTNC)
Promoter Activity
(A) p-124SVOCAT reporter construct. This construct contains 124 bp
of the cTNC 5' flanking region plus 32 bp of the first exon upstream of the
CAT gene. Within this segment are 5 cardiac-specific binding elements:
GATA-4 binding site, cardiac enhancer factor-2 (CEF-2), and three cardiac
promoter factors (CPF-1-3).
(B & C) 48 hour CAT Assays. 18 dpc primary myocyte cultures
(fetal), each parental line (BWEM and CLEM) and their respective mutant
clones (BW-Hl and CL-B5) were transfected with the p-124SVOCAT reporter
plasmid and treated with 0 or 10 ng/mL of recombinant TGF-B 3 for 48
hours. Samples of each were assessed for CAT activity as described in
Chapter 3. Data were normalized with B-galactosidase activity. Data
represent the mean value from 3 individual assays and the error bars
represent SEM.
(B) Relative changes in activity are presented as fold increases
when compared to untreated (O ng/mL B3 ).
(C) Raw data are presented as the per cent conversion of 14 Cchloramphenicol per lOµg protein (fetal) or 150 µg protein (cell lines).
Significance: * p:::;; 0.05, ** p:::;; 0.01

Table 7: Statistical Analysis of cTNC Promoter Assays
Unpaired t-tests were used to determine significant differences
between treated and untreated cultures and between each parental line and
its respective mutant.
p-value
(fold induction)
0.534

p-value
(raw2
0.823

BWEM
BW-Hl
BWEM vs. BW-Hl

0.025
0.540
0.282

0.383
0.926
0.205

CLEM
CL-B5
CLEM vs. CL-B5

0.004
0.165
0.101

0.005
0.231
0.186

Cell Txne
Fetal
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To support the use of the BWEM and CLEM myocyte-like cell lines as
a model system for cardiomyocyte development, experiments were
performed to examine the effects of TGF-B on sTNC expression. As sTNC is
not normally expressed in the cardiomyocyte, sTNC transcript levels and
promoter activity are expected to be low to undetectable, and decrease in the
presence of TGF-B 3 • As expected sTNC transcript levels were low,
requiring extended exposure times for detection, but unexpectedly, the
BWEM cell line exhibited significant upregulation in the 700 hp sTNC
transcript levels after 72 hours exposure to TGF-B 3 (Figure 15, Table 8). The
results obtained for the mutant BW-Hl line are significantly different from
its parental BWEM line (Figure 15, Table 8). Similar to the Northern blot
analyses, no significant changes were observed in sTNC promoter activity
at 10 ng/mL TGF-B 3 in the primary fetal cardiomyocyte cultures and each
cell line (Figure 16, Table 9). However, caution should be taken when
interpreting the promoter data as basal activity in each cell type was
exceedingly low. These nearly undetectable levels of sTNC transcripts and
promoter activities are reflective of the fact that sTNC is not normally
expressed in cardiac myocytes, and therefore supports the use of these cell
lines as a cardiomyocyte model.
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Table 8: Statistical Analysis ofTGF-B 3 Dose Response Curves of sTNC
Northern Blot Analyses
One way ANOVA was used to determine significance of the dose
response curves of sTNC steady state transcript levels for each cell type.
Two way ANOVA was used to determine differences between dose curves of
each parental cell line and its respective mutant.
p-value (48hr.)
Cell Type
BWEM
0.271
BW-Hl
0.671
BWvs.BW-Hl
0.506
CLEM
CL-B5
CL vs. CL-B5

0.001
0.127
0.071

p-value (72hr.)
0.012
0.161
0.006
0.266
0.651
0.442
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Figure 15: sTNC Northern Blot Analyses
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Figure 15: TGF-B 3 Induced Changes in Steady State sTNC Transcript
Levels
Cultures of all four cell lines were treated with 0-10 ng/mL TGF-B 3 for
48(A) or 72 (B) hours. Northern blots were hybridized with a cDNA probe
specific for sTNC. Data are presented as fold induction of transcript levels
as compared to untreated controls. Results shown are from 3 individual
assays. Data were normalized to 188 rRNA oligo hybridizations. Error
bars represent SEM.
* indicate responses significantly different from control (O ng/mL B3)

Table 9: Statistical Analysis of sTNC Promoter Assays
Unpaired t-tests were used to determine significant differences
between untreated and treated samples for each cell line.
Cell Type
Fetal

BWEM
BW-Hl
CLEM
CL-B5

p-value
(fold induction)
0.164
0.928
0.015
0.403
0.793

p-value
(raw)
0.811
0.976
0.154
0.366
0.547
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Figure 16: sTNC Promoter Assays
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Figure 16: TGF-B3-lnduced Changes in Skeletal Troponin C (sTNC)
Promoter Activity
(A) 1.7/900-CAT reporter construct. This construct contains 1.7 kb of
the sTNC promoter inserted in front of the CAT gene and a 900 hp enhancer
element found within the first intron inserted downstream of the CAT
gene.
(B & C) 48 hour CAT Assays. 18 dpc primary myocyte cultures
(fetal), each parental line (BWEM and CLEM) and their respective mutant
clones (BW-Hl and CL-B5) were transfected with the 1.7/900-CAT reporter
construct and treated with 0 or 10 ng/mL of recombinant TGF-B3 • for 48
hours. Samples of each were assayed for CAT activity as described in
Chapter 3. Data were normalized with B-galactosidase activity. Data
represent the mean value from 3 individual assays and the error bars
represent SEM.
(B) Relative changes in activity are presented as fold increases
when compared to untreated (0 ng/mL B3 ) samples.
(C) Raw data are presented as the per cent conversion of 14Cchloramphenicol per 10 µg protein (fetal) or 150 µg protein (cell
lines).
*indicates response significantly different from control (0 ng/mL B3 )
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Effect ofTGF-B.a on TNI Isoform Expression
Unlike TNC, the two TNI isoforms, skeletal (sTNI) and cardiac
(cTNI), are present in the heart at distinct times during development. The
transition from sTNI expression to cTNI expression occurs during the
perinatal transition period. Therefore, we hypothesized TGF-B promotes
this sTNI-cTNI transition, and thus the maturation and differentiation of
the cardiomyocyte, through the upregulation of transcription of the adult
isoform, cTNI, and downregulation of the fetal isoform, sTNI. To test this
hypothesis, sTNI promoter assays and Northern blot analyses of sTNI and
cTNI transcript levels were performed.
Similar to the TNCs, the two TNI isoforms, sTNI and cTNI, are
derived from separate genes with distinct regulatory sequences within their
respective promoters. While a promoter construct was not available for
cTNI, a luciferase-based construct containing the 4.2 kb 5' flanking region
and exon 1 of the sTNI gene (see Figure 17 a) was used to assay the effects of
TGF-B 3 on sTNI expression. In support of the hypothesis, TGF-B 3 (up to 10
ng/mL) caused a small, but significant decrease in sTNI promoter activity
in primary fetal cardiomyocytes, but not in any of the cell lines (Figure 17b,
Table 10). As previously seen with the growth assays, inherent differences
can be seen in basal promoter activity between the BWEM and CLEM
parental cell lines and their respective DN clones (Figure 17c). To assess
the relationship of these data to a more in vivo-like system, cDNA probes
were available and utilized to determine steady state sTNI and cTNI
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transcript levels in 18 dpc primary fetal cardiomyocyte cultures treated
with 10 ng/mL TGF-B 3 for 48-72 hours. In contrast to what was observed in
the promoter assays, TGF-B 3 significantly (p

= 0.027) increased the 1.05 kb

sTNI transcript level after 72 hours (Figure 18, Table 11). Additionally,
TGF-B3 significantly (p:::;; 0.001) decreased the cTNI (1.2 kb) transcript levels
in the fetal cultures to -25% of the control levels after 72 hours of treatment
(Figure 18). This would suggest that sTNI would become more abundant
than cTNI after exposure to TGF-B 3 , possibly resulting in a change in Ca++
affinity in the troponin complex. This conclusion would be tentative as
Northern blots demonstrating sTNI expression used more RNA and
required a longer exposure time (see Figure 18 legend). Nevertheless, these
results suggest that TGF-B 3 does not promote cardiomyocyte maturation
and differentiation with regards to TNI isoform expression.

Table 10: Statistical Analysis ofTGF-B3 Dose Response Curves of sTNI
Promoter Assays
One way ANOVA was used to determine significance of the dose
response curves of sTNI promoter activity in response to TGF-B3 for each
cell type.
p-value
p-value
(raw)
(fold induction)
Cell Type
0.003
0.394
Fetal
0.849
BWEM
0.986
0.262
BW-Hl
0.961
0.823
0.604
CLEM
0.933
0.974
CL-B5
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Figure 17: sTNI Promoter Assays
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Figure 17: TGF-B3 Induced Changes in Skeletal Troponin I (sTNI)
Promoter Activity
(A) BW14 7 reporter construct. This construct contains 4.2 kb of the 5'
flanking region of the sTNI gene as well as the first exon inserted in front of
the luciferase gene.
(B & C) 36 hour luciferase assays. 18 dpc primary fetal myocyte
cultures, each parental line (BWEM and CLEM) and their respective
mutant clones (BW-Hl and CL-B5) were transfected with the BW147
reporter plasmid and treated with 0-10 ng/mL of recombinant TGF-B 3 for 36
hours. Each sample was collected and luciferase activity was assessed as
described in Chapter 3. Luciferase data were normalized with Bgalactosidase activity. Data represent the mean value from 3 (fetal) or 5-6
(cell lines) individual assays and the error bars represent SEM.
(B) Relative changes in activity are presented as fold increases
when compared to untreated (0 ng/mL B3 ) samples.
(C) Relative luciferase units are presented for each cell line to
demonstrate individual expression levels in the different cell types.
*indicates response significantly different from control (O ng/mL B3 )
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Figure 18: TNI Northern Blot Analyses
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Figure 18: TGF-B 3 Induced Changes in Steady State Skeletal (sTNI) and
Cardiac (cTNI) TNI Transcript Levels
Primary cultures of 18 dpc fetal ventricular myocytes were treated
with 0 or 10 ng/mL TGF-B 3 for 48-72 hours. Northern blots were hybridized
with cDNA probes for cardiac TNI (cTNI) and skeletal TNI (sTNI).
(A) Fold induction of transcript levels compared to untreated
controls. Results shown are from 3 individual assays. Data were
normalized to 18S rRNA oligo hybridizations. Error bars represent SEM.
* indicates response significantly different from control (0 ng/mL B3)
(B) Representative Northern blots of each TNI isoform. 5 µg (sTNI)
and 3 µg (cTNI) total RNA loaded for each sample. Bars indicate 18S and
28S rRNA bands. Blots shown are from 3 day (sTNI) and 24 hr (cTNI)
exposures to film at -80°C. 18S rRNA hybridization shown below each blot.

Lane 1: 48 hr. Control
Lane 3: 72 hr. Control

Lane 2: 48 hr. +TGF-B 3
Lane 4: 72 hr. +TGF-B 3

Table 11: Statistical Analysis ofTNI Northern Blot Analyses
Unpaired t-tests were used to determine statistical difference between
control and treated (10 ng/mL TGF-B3 ) 18 day fetal primary myocyte
cultures.
Time/Probe
48hr. cTNI
72hr. cTNI
48hr. sTNI
72hr. sTNI

p-value
0.018
<0.001
0.281
0.027
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Effect ofTGF-B2 on TNT Isoform Expression
In contrast to TNC and TNI, the two cardiac TNT (cTNT) isoforms,
fetal and adult, are products of the same gene and are produced by the
alternative splicing of a single 30 hp exon (exon 4 in the rat). This exon is
present in the 1.14 kb transcript for the fetal isoform of cTNT, and
subsequently absent in the adult isoform. While TGF-B has been shown to
affect transcriptional and translational activity as well as mRNA stability
in several different systems, no reports have been made on possible effects
the TGF-Bs could have on alternative splicing, and thus the cTNT isoform
switch. Therefore to address TGF-B's role in cardiomyocyte differentiation
in regards to the troponin complex, the effects of TGF-B3 on cTNT isoform
expression were evaluated in primary fetal cardiomyocytes and the four cell
lines. As with the other two troponin proteins, we hypothesized that TGF-B
would increase the transcript levels of the adult isoform of cTNT, and
therefore decrease the level of the fetal isoform.
While promoter analysis is not indicative of cTNT isoform switching,
assays were performed not only to determine if TGF-B3 has an effect on
overall transcriptional activity from the cTNT gene, but also to verify the
use of the myocyte-like cell lines as a model for cardiomyocyte development.
As transcriptional activity is not expected to influence the alternative
splicing of the cTNT hnRNA, TGF-B 3 is not expected to cause a significant
change in cTNT gene transcription. However, TGF-B 3 (10 ng/mL) appeared
to downregulate transcription from this promoter in the parental cell lines,
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but not in the primary fetal cardiomyocytes or mutant cell lines (Figure 19b,
Table 12). It should be noted that the promoter activity in the fetal
cardiomyocytes was significantly (p = 0.001) higher than in any of the cell
lines (Figure 19c).
To examine the effect TGF-B3 has on cTNT isoform expression,
Northern blot analyses were performed to detect relative changes in cTNT
isoform production as the result of alternative splicing. We have
hypothesized that the role for TGF-B in cardiomyocyte differentiation is to
upregulate the adult isoform of each type of troponin. While the effect on
TNC and TNI expression would theoretically be a direct regulation of
transcriptional activity, the regulation of cTNT splicing could be regarded
as an indirect effect. Nevertheless, we expect that treatment of the cells
with TGF-B 3 will result in the accumulation of the adult isoform of cTNT.
Northern blot analyses were performed using oligonucleotide probes
which detected either total cTNT transcript levels or just the fetal isoform.
As expected from results obtained from Northern blots of ventricular tissue,
cTNT transcripts were readily detected in total RNA from primary fetal
myocyte cultures (Figure 20b). Consistent with the promoter assay data, 10
ng/mL TGF-B 3 had no significant effect on the level of total cTNT
transcripts in primary fetal myocytes after 48 and 72 hours (Figure 20a,
Table 13). Using an oligonucleotide probe corresponding to the alternatively
spliced exon present only in the fetal isoform, the effect of TGF-B 3 on its
steady state transcript levels were determined. The results indicate TGF-B3
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(10 ng/mL) did not significantly alter the expression of the fetal isoform
after 48 and 72 hours of treatment (Figure 20a, Table 13). Reflective of the
significantly lower promoter activity in the cell lines as compared to the
fetal cardiomyocytes, Northern blot analyses on the cell lines proved
limiting as neither cTNT isoform could be detected in the cell lines when
using 30 µg total RNA, but could be detected if PolyA+ RNA was used (data
not shown). These results indicate that TGF-B 3 does not affect the
alternative splicing or accumulation of the adult isoform of cTNT in the
fetal cardiomyocyte as originally hypothesized. Additionally, these data
and the data obtained from the TNI studies indicate that there appears to be
significant limitations on the use of the BWEM and CLEM myocyte-like cell
lines for the study of cardiomyocyte development (see discussion, Chapter
5).

Table 12: Statistical Analysis of TNT Promoter Assays
Unpaired t-tests were used to determine significant differences
between control and treated (10 ng/mL TGF-B 3 ) cultures as well as between
BWEM and fetal cells.
p-value
(fold induction)
Cell Type
Fetal
0.163
N.D.*
Fetal vs. BWEM
0.004
BWEM
0.721
BW-Hl
0.026
CLEM
0.052
CL-B5

* N.D. = not determined

p-value
(raw)
0.474
0.001
0.368
0.727
0.629
0.537
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Figure 19: cTNT Promoter Assays
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Figure 19: TGF-B3 Induced Changes in Cardiac Troponin T (cTNT)
Promoter Activity
(A) 303-CAT reporter construct. This construct contains 303 bp of the
cTNT promoter inserted upstream of the CAT gene. As noted, this
promoter contains several known muscle-specific transcription factor
binding sites (CArG, MEF-2, M-CAT).
(B & C) 48 hour CAT assays. 18 dpc fetal primary myocyte cultures,
each parental line (BWEM and CLEM) and their respective mutant clones
(BW-Hl and CL-B5) were transfected with the 303-CAT reporter plasmid
and treated with 0 or 10 ng/mL of recombinant TGF-B3 for 48 hours.
Samples were collected and assayed for CAT activity as described in
Chapter 3. Data were normalized with B-galactosidase activity. Data
represent the mean value from 3 individual assays and the error bars
represent SEM.
(B) Relative changes in activity are presented as fold increases
when compared to untreated (O ng/mL 3 3 ).
(C) Raw data are presented as the per cent conversion of 14Cchloramphenicol per 10 µg protein (fetal) or 150 µg protein (cell
lines).
* indicates response significantly different from control (0 ng/mL B3)
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Figure 20: cTNT Northern Blot Analyses
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Figure 20: TGF-B 3 Induced Changes in cTNT Steady State Transcript
Levels
Primary cultures of 18 dpc fetal ventricular myocytes were treated
with 0 or 10 ng/mL TGF-13 3 for 48-72 hours. Northern blots were hybridized
with the oligonucleotide probes, CCAR (detects adult and fetal isoforms)
and PE4 (detects only fetal isoform).
(A) Fold induction of transcript levels compared to untreated
controls. Results shown are from 3 individual assays. Data were
normalized to 188 rRNA oligo hybridizations. Error bars represent SEM.
(B) Representative Northern blots of each cTNT isoform. 8 µg total
RNA loaded for each sample. Arrow indicates fetal cTNT band. Bars
indicate 18S and 288 rRNA bands. Blots shown are from 4 day exposure to
film at -80°C. 188 rRNA hybridizations shown below each blot.

Lane 1: 48 hr. Control
Lane 3: 72 hr. Control

Lane 2: 48 hr. +TGF-B3
Lane 4: 72 hr. +TGF-B 3

Table 13: Statistical Analysis of TNT Northern Blot Analyses
Unpaired t-tests were used to determine the statistical difference
between control and treated (10 ng/mL TGF-13 3 ) primary 18-day fetal
myocyte cultures.
Time/Probe
48hr. Total TNT
72hr. Total TNT
48hr. Fetal TNT
72hr. Fetal TNT

p-value
0.248
0.561
0.129
0.563
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Changes in TGF-B receptor expression in response to TGF-B.a
The presence of biologically active ligand and BRII appear to be rate
limiting factors for the TGF-B signaling processes to function within the
ventricle during the fetal development period (Engelmann et al., 1992;
Engelmann 1993, Engelmann and Grutkoski, 1994). As the TGF-B ligands,
TGF-B 1 and -B3 , and BRII begin to be expressed at approximately the same
time and increase dramatically at or around birth, the regulation of one or
several of these "limiting" components of the TGF-B signaling pathway by
TGF-B itself would augment its role in the developmental process.
Therefore, changes in TGF-B receptor expression in response to TGF-B 3
treatment were determined in the five different cell types. As BRI appears
to be constitutively expressed, its expression level is not expected to be
affected by the presence of TGF-B3 • In contrast, the dramatic increase in
BRII expression suggests that its expression may be induced by TGF-B in a
pseudo-autoregulatory loop similar to that seen for the ligand TGF-B 1 (Kim
et al., 1990).
In support of the developmental data, BRI transcript levels were not
significantly affected by TGF-B 3 treatment after 72 hours (Figure 21a, Table
14). However in contrast to that suggested by the developmental data, 72
hours of continuous TGF-B 3 treatment resulted in a significant (p < 0.05),
dose-dependent decrease in BRII transcript levels in the BW-Hl and CLEM
cell lines (Figures 21b and 22, Table 14), with a 25-40% decrease relative to
untreated cultures at a dose of 10 ng/mL TGF-B 3 • While there were no
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significant differences between BWEM and BW-Hl cell lines, the results
obtained for CLEM and CL-B5 were significantly (p

= 0.013) different.

These

differences between the two DN lines is reflective of the changes observed in
the growth assays, with BW-Hl having overcome the DN effect at 10 ng/mL
TGF-B 3 while CL-B5 remained minimally unresponsive to TGF-B3
treatment. As the antiproliferative effect of TGF-B has been uncoupled
from its transcriptional effects, these results suggest that the regulation of
BRII by TGF-B 3 is indirect and may share or have similar regulatory
pathways as those used to block proliferation. Prolonged exposure to TGFB3 was necessary as a significant decrease in transcript levels was not
observed after only 48 hours of exposure (data not shown). In contrast to the
cell lines, primary fetal cardiomyocytes exhibited a more modest, nonsignificant decrease in BRII levels after 72 hours of TGF-B3 (10 ng/mL)
treatment (Figure 21b, Table 14), which may be reflective of the trend seen
in these studies in which they appear less responsive to TGF-B3 than the
cell lines (see discussion, Chapter 5).
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Figure 21: TGF-B Receptor Northern Blot Analyses
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Figure 21: TGF-B 3 Induced Changes in Steady State Type I and Type II
TGF-13 Receptor Transcript Levels
Cultures of all four cell lines and primary cultures of 18 dpc fetal
ventricular myocytes were treated with 0-10 ng/mL TGF-B 3 for 72 hours.
Northern blots analyses were performed and data were normalized to 18S
rRNA oligo hybridizations. Data are presented as fold induction of
transcript levels as compared to untreated controls.
(A) BRI. Blots were hybridized with the cDNA probe for rat BRI (R4).
Results shown are from 2 individual assays. Data error bars represent SD.
(B) BRII. Blots were hybridized with the cDNA probe for rat BRII.
Results shown are from 3-4 individual assays. Data error bars represent
SEM.
* indicates response significantly different from control (O ng/mL B3 )

Table 14: Statistical Analysis ofTGF-B 3 Dose Response Curves of TGF-B
Receptor Northern Blot Analyses
One way ANOVA was used to determine significance of the dose
response curves of TGF-B receptor steady state transcript levels for each cell
type. Two way ANOVA was used to determine significance differences
between the dose curves of each parental line and its respective mutant.
p-value
{BRI2
N.D.*

p-value
{BRII2
0.319

BWEM
BW-Hl
BWvs.BW-Hl

0.995
0.350
0.907

0.066
0.030
0.816

CLEM
CL-B5
CL vs. CL-B5

0.824
0.041
0.446

0.001
0.132
0.013

Cell Type
Fetal

* N.D. = Not Determined
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Figure 22: Northern Blots ofTGF-B Receptors
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Figure 22: Northern Blots ofTGF-B Receptors
Primary cultures of 18 dpc fetal ventricular myocytes and cultures of
each of the cell lines were treated with 0-10 ng/mL TGF-B3 for 48-72 hours.
Northern blots were hybridized with the cDNA probe for BRI (R4) or BRII.
Bars indicate 188 and 288 rRNA bands. 188 rRNA hybridizations shown
below each blot.
(A) 18 dpc Fetal RNA. 3 µg total RNA loaded for each sample.
Results shown are from 48 hr. exposure to film at -80°C.
Lane 1: 48 hr. Control
Lane 2: 48 hr. + 10 ng/mL TGF-B 3
Lane 3: 72 hr. Control
Lane 4: 72 hr. + 10 ng/mL TGF-B3
(B) TGF-BRI expression. BWEM and BW-Hl RNA. Representative
dose response curve for BRI transcript expression. 30 µg total RNA loaded
for each sample. Results shown are from 48 hr. exposure to film at -80°C.
Lane 1: BWEM Control
Lane 2: BWEM 0.1 ng/mL B3
Lane 3: BWEM 1 ng/mL B3
Lane 4: BWEM 10 ng/mL B3
Lane 5: BW-Hl Control
Lane 6: BW-Hl 0.1 ng/mL B3
Lane 7: BW-Hl 1 ng/mL B3
Lane 8: BW-Hl 10 ng/mL B3
(C) TGF-BRII expression. Total RNA from each of the cell lines
treated with or without 10 ng/mL TGF-B 3 • 30 µg loaded for each sample as
indicated. Results shown are from 24 hr. exposure to film at -80°C.
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Changee3 sin SPARC expression in response to TGF-B:a
TH.he formation of new blood vessels, or angiogenesis, is a crucial part
of the ve-entricular remodeling which occurs during the perinatal transition
period ..... We have hypothesized that TGF-B promotes this angiogenesis
through _the induction of the angiogenic factor, SPARC. As TGF-B has been
shown to-o induce SPARC both transcriptionally and translationally, we have
chosen to;:;o examine the effect of TGF-B3 on SPARC transcript and protein
productio.ion. While we expect the end result to be a significant increase in
SPARC g protein production, it is difficult to predict a priori whether that
increase e is the result of increased transcript production, increased
translati i-ion from existing transcripts, or both.
Tooo examine the effect TGF-B may have on SPARC transcript levels,
we exam:.o.ined changes in SPARC promoter activity and steady state
transcriJXm)t levels after treatment with TGF-B3 for 48 hours. Using a
promotenr construct containing 639 hp of the 5' flanking region of the SPARC
promotem plus 11 hp of exon 1, transcriptional activity was determined in
primary !

fetal myocyte cultures and each of the cell lines in response to 0

and 10 n1.ng/mL TGF-B 3 (Figure 23). Interestingly, the results appeared to be
cell specii:ific. A modest, but significant, increase of -20% in promoter
activity

~as

detected the fetal myocyte cultures, while a significant decrease

was deteoected in CLEM (-30%) cultures (Figure 23a, Table 15). As a direct
result of - - this, the only significant differences between a parental line and
its respec:>~ctive mutant was between CLEM and CL-B5. Additionally, basal
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promoter activity in each of the mutant lines appeared higher than their
respective parental lines, however, this difference was only significant for
the CLEM and CL-B5 cell lines (Figure 23b, Table 15). In contrast to the
promoter data, a dose-dependent increase of -25-40% was observed in the
steady state -2.2 kb transcript levels in the BWEM and fetal myocyte
cultures (Figures 24 and 25, Table 16).
Since the changes in SPARC transcript levels are minimal, possible
changes in translation rates from existing SPARC transcripts in response
to TGF-B 3 were examined. As SPARC is readily secreted by cells in culture
after translation, proteins obtained from media conditioned by the cells for
48 hours± 10 ng/mL TGF-B 3 were used for Western blot analysis. Similar to
the Northern blot analyses, no significant changes in the amount SPARC
protein secreted were observed in these conditioned media samples (Figure
26). Similar Western blots analyses were performed on the cellular
proteins of the cultures from which the media were obtained, and no
increases in intracellular SPARC protein levels were detected (data not
shown). Therefore, it does not appear that TGF-B 3 promotes angiogenesis
through the induction of cardiomyocyte produced SPARC.
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Figure 23: SPARC Promoter Assays
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Figure 23: TGF-13 3 Induced Changes in SPARC Promoter Activity
(A) 639SPARC-CAT promoter construct. This construct contains 639
bp of the SPARC promoter inserted in front of the CAT reporter gene.
(B & C) 48 hour CAT assays. 18 dpc fetal primary myocyte cultures,
each parental line (BWEM and CLEM) and their respective mutant clones
(BW-Hl and CL-B5) were transfected with the 639SPARC-CAT reporter
plasmid and treated with 0 or 10 ng/mL of recombinant TGF-13 3 for 48
hours. Samples were collected and assayed for CAT activity as described in
Chapter 3. Data were normalized with B-galactosidase activity. Data
represent the mean value from 3 individual assays and the error bars
represent SEM.
(B) Relative changes in activity are presented as fold increases
when compared to untreated (O ng/mL B3 ).
(C) Raw data are presented as the per cent conversion of 14 Cchloramphenicol per 10 µg protein (fetal) or 150 µg protein (cell
lines).
* indicates response significantly different from control (0 ng/mL B3 )

Table 15: Statistical Analysis of SPARC Promoter Assays
Unpaired t-tests were used to determine significant differences
between control and treated (10 ng/mL TGF-B 3 ) samples and between each
parental cell lines and its respective mutant.
Cell Type
Fetal

p-value
(fold induction)
0.013

BWEM
0.313
BW-Hl
0.535
BWEM vs. BW-Hl N.D. *
CLEM
CL-B5
CLEM vs. CL-B5

*

0.009
0.387
0.019

N.D. = Not Determined

p-value
Craw)
0.662
0.808
0.654
0.332
0.041
0.834
0.001
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Figure 24: TGF-B 3 Induced Changes in Steady State SPARC Transcript
Levels
Cultures of all four cell lines and primary cultures of 18 dpc fetal
ventricular myocytes were treated with 0-10 ng/mL TGF-B 3 for 48 hours.
Northern blots were hybridized with a cDNA probe for SPARC. Data are
presented as fold induction of transcript levels as compared to untreated
controls. Results shown are from 3 individual assays. Data were
normalized to 18S rRNA oligo hybridizations. Error bars represent SEM.
*indicates response significantly different from control (0 ng/mL B3 )
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Table 16: Statistical Analysis of TGF-B 3 Dose Response Curves of SPARC
Northern Blot Analyses
One way ANOVA was used to determine significance of the dose
response curves of SPARC steady state transcript levels for each cell type.
Two way ANOVA was used to determine significant differences between
the dose response curves for each parental line and its respective mutant .

. Cell Type
Fetal

p-value
0.002

BWEM
BW-Hl
BWvs.BW-Hl

<0.001
0.082
0.295

CLEM
CL-B5
CL vs. CL-B5

0.069
0.581
0.919
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Figure 25: Northern Blot Analyses of SPARC Expression
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Figure 25: Northern Blot Analyses of SPARC Expression
Primary cultures of fetal cardiomyocytes and cultures of each of the
cell lines were treated with 0 or 10 ng/mL TGF-Ba for 48 hours. Northern
blots were hybridized the cDNA probe for SPARC. Bars indicate 18S and
28S rRNA bands. Blots shown are from 24 hr. exposure to film at -80°C. 18S
rRNA hybridizations shown below each blot.
(A) 18 dpc Fetal RNA. 3 µg total RNA loaded for each sample.
Lane 1: 48 hr. Control
Lane 2: 48 hr. +TGF-Ba
Lane 3: 72 hr. Control
Lane 4: 72 hr. +TGF-Ba
(B) BWEM and BW-Hl RNA. 30 µg total RNA loaded for each

sample.

Lane
Lane
Lane
Lane

1: BWEM Control
3: BWEM 1 ng/mL Ba
5: BW-Hl Control
7: BW-Hl 1 ng/mL Ba

Lane 2:
Lane 4:
Lane 6:
Lane 8:

BWEM 0.1 ng/mL Ba
BWEM 10 ng/mL Ba
BW-Hl 0.1 ng/mL Ba
BW-Hl 10 ng/mL Ba

(C) CLEM and CL-B5 RNA. 30 µg total RNA loaded for each sample.
Lane 1: CLEM Control
Lane 2: CLEM 0.1 ng/mL Ba
Lane 3: CLEM 1 ng/mL Ba
Lane 4: CLEM 10 ng/mL Ba
Lane 5: CL-B5 Control
Lane 6: CL-B5 0.1 ng/mL Ba
Lane 7: CL-B5 1 ng/mL Ba
Lane 8: CL-B5 10 ng/mL Ba
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Figure 26: SPARC Western Blot Analyses
Conditioned media proteins from cultures treated for 48 hours± 10
ng/mL TGF-B 3 (72 hr. sample also collected for 18 dpc fetal myocyte
cultures) were run on 12% SDS-PAGE gels and used for western blot
analyses to detect the 43 kD SPARC protein secreted by the cells. 5 µg of
protein was loaded per lane. Markers on right indicate size in kilodaltons
as determined by co-running biotinylated standards on the gel. Staining of
gel indicated that protein loads was consistent, except for CLEM+ B3 (data
not shown).

CHAPTERS
DISCUSSION
We and others have postulated that TGF-Bs are active participants in
late fetal and neonatal ventricular development. This is based on the
temporal and spatial expression patterns of the TGF-B ligands and
receptors which coincide with established changes in myocyte proliferation
and differentiation as well as ongoing ventricular remodeling in the
postnatal heart. To determine the role TGF-Bs may play on cardiomyocyte
growth and development at the cellular and molecular level, we have
chosen to use two ventricular myocyte cell lines, BWEM and CLEM, as our
experimental system. As a means to more clearly define and evaluate the
direct effects of TGF-B on the cardiomyocyte, mutant myocyte cell lines have
been created which exhibit reduced BRII function due to a dominant
negative method of inactivation. These mutant lines, along with their
parental counterparts and primary fetal myocyte cultures, were used to
study the direct effects TGF-B may have on several developmental changes
which occur in the ventricular myocyte population prior to and/or shortly
after birth. These results are summarized in Table 17.

140

141

Table 17: Summary of Results (10 ng/mL TGF-B3 )
Assay

l&l
Fetal

BWEM

BW-Hl

CLEM

CL-B5

Notes

Growth

ND

.l.50%

.l.50%*

.l.80%

J.20%

*10-fold less
sensitive

PAI-1 PA

t4.8x

t5.4x

t2.3x*

t3.9x

tl.6x*

*10-fold less
sensitive

cTNCNB

J.

+

+

+

+

cTNC PA
sTNCNB
sTNC PA

J.
ND

+

J.

Increase -2.5
fold, no DN diff.
no DN diff.
BWEM/BW-Hl
sig. diff.

H

J.

H

sTNI PA

J.

H

H

H

H

sTNINB

t

ND*

ND*

ND*

ND*

*Undetectable
in total RNA

cTNI NB

J.

ND*

ND*

ND*

ND*

*Undetectable
in total RNA

J.

H

J.

e.cTNTNB

ND*

ND*

ND*

ND*

*Undetectable
in total RNA

rt.cTNTNB

ND*

ND*

ND*

ND*

*Undetectable
in total RNA

H

H

cTNT PA

BRINB
BRII NB

ND

J.

H

SPARC PA

t

H

SPARC NB

t

t

SPARCWB

J.

CLEM/CL-B5
sig. diff.

J.

CLEM/CL-B5
sig. diff.
no sig. DN diff.
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Table 17: Summary of Results:
Results obtained from each experiment at 10 ng/mL TGF-B 3 (vs.
untreated) are given for each cell type.
Table Legend:
NB: Northern blot analyses

I:

Statistically significant increase

PA :

.!. :

Statistically significant decrease

Promoter assays

WB : Western blot analyses
f-+ :
ND : Not done
+:
t : t. cTNT = total cTNT, f. cTNT = fetal cTNT

No statistically significant change
Changes at select time points

Creation and Initial Characterization of
Clonal Dominant Negative Cell Lines:
A eukaryotic expression vector containing a cDNA encoding a kinase
deficient, human BRII (Figure 3) was introduced into the parental v-myc
derived myocyte cell lines. Using G418 selection and screening of single
cell clones derived from our initial polyclonal transformants, four mutant
myocyte cell lines (BW-F8, BW-Hl, CL-B5, and CL-F5) were chosen for
further study. Integration of and expression from the truncated, human,
Type II TGF-B receptor (phBRIIDN) in the mutant lines and its absence in
the parental lines was verified by Southern (Figure Ba) and Northern
(Figure 8b) blot hybridization analyses, respectively. The variations in
signal intensity on the Southern blot between the BW and CL mutant lines
represent differences in the number of integrations of the plasmid into the
host genome. Additional studies utilizing alternative restriction enzymes
indicate that at least 3-4 individual integrations occurred in the BW-Hl line
(data not shown) while CL-B5 appears to have only a single integration of
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phBRIIDN. Similarly, multiple integrations and/or aberrant
transcriptional read-through of the cDNA within the plasmid may be
responsible for the larger Northern blot transcript(s) detected when using
the human BRII-DN cDNA insert as a probe during the hybridizations.
Nonetheless, these data clearly show that we have successfully created and
isolated clonal BRII mutant cell lines which have stably incorporated the
phBRIIDN plasmid and express the BRII-DN transcript at high, readily
detectable levels.
Additionally, Northern (Figures 5 and 7) and Western (Figure 6) blot
analyses showed that expression of the endogenous rat BRI and BRII is
similar in the parental and transformed cell lines. These data indicate that
the cellular transformation mediated by G418 selection and subsequent
expression of the human BRII-DN cDNA does not affect the transcript or
protein levels for any of the endogenous rat TGF-B receptors. Of greatest
importance, BRI expression data inferred that its availability for
heterodimerization would be equivalent in the parental lines and mutant
clones. As partial confirmation of this, ligand-binding by BRI and BRII
(both wild type and mutant) was verified by receptor crosslinking analyses
(Figure 9). Similar to the Northern and Western blot analyses, the
crosslinking results showed that cell surface expression of the endogenous
rat receptors was similar between the parental lines and mutant clones.
Since BRI has been shown to bind TGF-B ligands only in the presence of
BRII, the strong crosslinking signal by the endogenous BRI suggests that
ligand-binding to BRII and/or BRII-DN is under-represented by the

144
intensity of the image. What is represented with the iodinated ligand
predominantly associating with BRI rather than BRII or BRII-DN may
reflect binding of non-isotopic ligand or non-uniform separation of labeled
vs. unlabeled TGF-B dimers during the stringent reduction step just prior
to loading samples on the gels. Nonetheless, we interpret these data to
indicate that the detected BRII-DN transcripts are translated into a ligandbinding, truncated, epitope tagged human BRII in the four mutant rat
myocyte cell clones. Additionally, we have demonstrated that the levels of
expression of the endogenous BRI and BRII genes in the cell lines are
comparable to that seen in primary neonatal cardiomyocytes,
strengthening the usefulness of these lines for our studies. It does appear
that the neonatal cardiomyocytes expressed a significantly greater amount
of BRIII than any of the cell lines. Since this is not a "signaling" molecule
and our present interests do not include TGF-B2 , of which ligand binding to
BRII is enhanced by ligand presentation by BRIII (Lopez-Casillas et al.,
1993), the lower BRIII expression in the cell lines does not represent a
limitation to the studies at hand.
Characterization of the direct effects TGF-B elicits in the parental
and mutant cell lines was carried out by assaying two fundamental TGF-Bmediated responses which represent the "gold standard" in the literature:
inhibition of proliferation and induction of PAI-1 promoter activity. Data
from our growth assays show that the mutant clones are significantly less
sensitive (-lOX, BW-Hl) or virtually insensitive (CL-B5) to TGF-B3-mediated
growth inhibition relative to their respective parental BWEM and CLEM
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lines (Table 17). As expected, TGF-B 3 induced transcription from the PAl-1
promoter construct, p3TP-Lux, in a dose-dependent manner in the parental
BWEM and CLEM cell lines. Even though the activity from the p3TP-Lux
plasmid was significantly higher in the cell lines than the activity seen in
the primary fetal cardiomyocyte cultures, the fold induction above the basal
(untreated) activity was comparable (Table 17), supporting the use of these
cell lines as a model to study effects of TGF-B on cardiomyocyte growth and
differentiation during heart development. PAI-1 was also induced in a
dose-dependent manner in the mutant clones, BW-Hl and CL-B5.
However, the concentration needed to elicit a response in the mutant clones
is significantly greater than in the parental lines, requiring an
approximately 10-fold higher concentration of bioactive TGF-B ligand to
elicit similar levels of PAl-1 induction. Therefore, the expression of BRIIDN in the two mutant cell lines was able to reduce the cells' ability to
respond to TGF-B 3 , and suggests that this dominant negative inhibition can
provide a means in which to examine the different aspects of TGF-B signal
transduction in a cell line of cardiomyocyte origin.
While total ablation of any TGF-B response in the clones would have
been ideal, incomplete inhibition through the expression of BRII-DN was
not unexpected. Since the dominant negative BRII did not interrupt the
expression of the endogenous TGF-BR genes, any endogenous BRII present
is still capable of initiating a response if it binds ligand as part of a
heteromeric receptor complex. In Xenopus embryos, ratios of 1:10 or 1:100
wild type to mutant FGF receptors were needed to see any level of inhibition
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(Amaya et al., 1991). While the exact ratio of BRII-DN to BRII was not
determined, it appears that the ratio of wild type to mutant BRII falls
within the level which exhibits partial inhibition. While not a receptor,
dominant negative mutations in the Ras protein demonstrate that different
levels of activation/phosphorylation are required for the different responses
a protein can elicit (Han and Sternberg, 1991). Therefore, if sufficient TGFB ligand is present to saturate the mutant receptor or bind the native,
functional BRII at a desired "threshold" level, one specific response (such
as transcription) will be seen while another (growth inhibition) will not
(Brand and Schneider, 1995). While the model presented for TGF-B signal
transduction is widely used (see Chapter 2, Figure 2), it is a simplified
model which does not address the formation of hetero-oligomers of BRI and
BRII upon ligand binding (Yamashita et al., 1994; ten Dijke et al., 1996). As
these oligomeric complexes contain at least two molecules of each type of
receptor (BRI and BRII), the "thresholds" may involve the ability of a
complex containing just one functional BRII (and one BRII-DN) to contain
enough activity to trigger one response, while two functional receptors are
required for another. Similarly, the association of downstream effectors
with this complex may also rely on the interactions of the intracellular
domains, with the presence of a truncated mutant possibly interrupting an
effector's stable interaction with and activation by BRI or BRII.
Nevertheless, the presence of BRII-DN in our mutant cell lines has
rendered them -10-fold less sensitive to exogenous TGF-B3 than their
parental lines.
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This reduced sensitivity, as opposed to total ablation of TGF-B
responsiveness, in these lines may actually prove to be advantageous. As
all TGF-B responses are mediated through BRII and BRI heterodimerizations, a different threshold (a.k.a. different levels of stimulation by
ligand) may be required for each individual response. Therefore, these
lines may be useful for the characterization of these thresholds in a
myocyte-like background. Additionally, the data from the CLEM and CL-B5
lines suggest that the signal transduction pathways utilized by the two
responses examined, proliferation and PAI-1 induction, are distinct and
would appear to involve significantly different thresholds for activation.
This could be one explanation for the virtual insensitivity to inhibition of
proliferation in CL-B5, even at 10 ng/mL TGF-B3 , while there is only an
approximate 10-fold reduction of sensitivity to TGF-B3 as measured by PAI-1
promoter induction.
Through this initial characterization of the cell lines, data have been
collected that support two fundamental parts of our hypothesis: 1) TGF-B 3
can inhibit cardiomyocyte proliferation, and 2) by inducing the expression
of PAI-1, TGF-B 3 indirectly promotes the accumulation of ECM by
inhibiting its degradation. As previously discussed, similar effects of TGFB on proliferation and PAI-1 induction have been observed in primary
neonatal cardiomyocyte cultures. Therefore, our results were not
unexpected, and extend these findings to fetal cardiomyocyte cultures and
the myocyte cell lines which closely reflect the late fetal stage of myocyte
development. However, as standard assays for TGF-B responsiveness in
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any cell, these results clearly demonstrate that the parental myocyte-like
cell lines are responsive to TGF-B 3 and that the mutant clones have altered
(reduced) sensitivity to normal, inhibitory levels of TGF-B 3. Therefore, these
lines are a suitable model in which to examine the effects of TGF-B as it
appears that components of the TGF-B signal transduction pathway are not
restricted in the parental or mutant cell lines. Additionally, the differences
in the signaling pathways or thresholds necessary to elicit the different
responses suggests there are several mechanisms by which TGF-B can
influence cellular functions in a variety of cell types, including myocytes.
These mechanisms may involve processes such as post-translational
modification, regulation of translational activity, or direct transcriptional
activation. Given the wide variety of second messenger pathways (e.g. Gproteins, MAP kinases, PLC) which have been linked to TGF-B activity, it
would not be wise to dismiss any of these mechanisms a priori. The
mutant cell lines may prove useful in the identification and/or separation of
these pathways in the myocyte background. As the induced effects of TGFB3 were clearly discernible at 10 ng/mL TGF-B3 in the parental cells, this
dose was used for those experiments in which a dose response curve was
not practical or feasible. This is most important for the CAT-based reporter
assays in which small changes are not as readily detected as the luciferasebased systems. As most of the effects examined are transcriptional, the
greater than 50% reduction in transcriptional activity in the mutant lines
as compared to their parental counterparts in the PAl-1 reporter assay
should provide a difference in which the DN-effect could be identified.
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Effects of TGF-B~ on Fetal Cardiomyocyte
Differentiation/Maturation
The ability of secreted proteins, such as growth factors, to influence
the differentiation and maturation of cardiomyocytes is not a new
phenomenon. It has been previously shown that innervation of heart tissue
results in a switch in expression of the troponin isoforms to the adult
forms, and that conditioned media from nerve cultures were able to induce
the same changes (Toyota and Shimada, 1983). Similarly, thyroid hormone
and the stimulation of the a 1-adrenergic receptor have also been found to
activate the fetal gene program in cardiomyocytes (Long et al., 1990;
Bugaisky et al., 1992). Therefore, as TGF-B ligand and BRII mRNA
appears and increases during the same period in which many contractile
proteins are undergoing the transition from a "fetal" isoform to its "adult"
counterpart, we hypothesized that TGF-B would promote the differentiation
and maturation of the fetal cardiomyocyte by upregulating the adult
isoforms and/or downregulating their fetal counterparts. Therefore, we
examined the ability ofTGF-B3 to influence the expression of the different
isoforms of three contractile proteins: TNC, TNI, and TNT.
As hypothesized, TGF-B3 treatment resulted in a dose-dependent
increase in steady state mRNA levels for cTNC (2-2.5-fold increase at 10
ng/mL TGF-B 3) after 72 hours in all four of the cell lines, both parental and
mutant (Table 17, Figure 12). The increases observed in the mutant lines
were not expected to be the same as the increases which occurred in their
parental counterparts given the mutant cell lines' 10-fold decrease in
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sensitivity to TGF-B 3 stimulation determined in the growth and PAI-1
promoter assays. Conflicting results were obtained from the cTNC
promoter assays in each of the parental lines, indicating a 40-50%
downregulation of transcription from this gene after exposure to 10 ng/mL
TGF-B3 ; yet only a 10% decrease in the mutant lines (Table 17). These
conflicting results between the Northern blot analyses and the promoter
assays could be explained by the fact that the reporter construct contains a
relatively small fragment of the cTNC promoter (Figure 14a), and the
increases observed in transcript levels could be the result of TGF-B3
induction of cTNC transcription through the use of an enhancer region or
positive promoter element located outside this region and which remains
intact for the native cTNC gene. However, this construct does appear to
have a negative promoter element which is responsible for the decrease in
transcription from this promoter in response to TGF-B 3 •
It is interesting to note that the downregulation of transcription from

this cTNC promoter construct was not as pronounced in the mutant lines,
demonstrating a decrease of only -10% as compared to the 40-50% decreases
observed in the parental lines. This decreased sensitivity to TGF-B 3 mediated transcriptional changes agrees with the data obtained from the
PAI-1 promoter assays. The higher transcription rates for cTNC in the
mutant lines when compared to their parental counterparts would lead to
the prediction that the cTNC steady state mRNA levels would be greater in
the mutant lines than in the parental lines after 72 hours. However, steady
state mRNA levels increased at levels similar to their respective parental
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lines. This suggests that TGF-B 3 is able to regulate cTNC transcript levels
on at least two overlapping levels, transcriptional and post-transcriptional,
both of which appear to be disrupted in the mutant lines.
One post-transcriptional mechanism that can partially explain these
results is one which involves an increase in cTNC mRNA stability in
response to TGF-B 3 , thereby allowing a steady increase in cTNC mRNA
accumulation even though transcription rates are reduced. The 3' UTR of
cTNC contains a 10 hp sequence (M. Parmacek, personal communication)
found to confer TGF-B 1-mediated mRNA stability to the mRNA for RHAMM
(;receptor for

hy.~Juronan

mediated motility gene, Amara et al., 1996).

Therefore, studies utilizing the transcriptional inhibitor actinomycin D
were initiated to address the effects TGF-B 3 may have on cTNC mRNA
stability. Unfortunately, a relatively long half life of the cTNC mRNA in the
myocyte cell lines (-15 hours, data not shown; Zhu et al., 1991) and reduced
cell viability in the presence of actinomycin D for extended periods of time
restricted our ability to clarify this issue. Alternative approaches such as
metabolic labeling and gel shift analyses could be considered to more
clearly define any role TGF-B 3 may have on cTNC mRNA stability.
Additionally, a more thorough examination (e.g. nuclear run-on
analyses or the use of larger promoter constructs) of the transcriptional
regulation of cTNC should be attempted to clarify or verify the effects of
TGF-B 3 • Identification of TGF-B-responsive elements (BRE), both positive
and negative, may be able to explain the results obtained in the myocyte cell
lines and possibly negate a role for TGF-B in cTNC mRNA stability. As
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previously discussed, TGF-B is able to influence the expression of several
contractile genes in primary myocyte cultures. As contractile gene
expression involves both cardiac/muscle-specific factors as well as
ubiquitous factors, the regulation of their activity by TGF-B is of great
importance. While TGF-B has been shown to increase general
transcription factors such as c-jun and c-fos, less is known about its effects
on cardiac transcription factors. One transcription factor which may be of
particular interest is GATA-4, a zinc-finger protein which appears to be
important for cTNC transcription and can drive its expression in nonmuscle cells (Ip et al., 1994). Since GATA-4 is inducible by factors such as
retinoic acid (Arceci et al., 1993), one could postulate that this factor, as well
as other muscle-specific factors, could be regulated by growth factors such
as TGF-B.
Although the complex regulation of cTNC expression that occurs in
the cell lines is intriguing and deserves further attention, these studies do
not lie within the focus of this dissertation. As a focus of this dissertation, it
must be stressed that the data obtained from the primary fetal
cardiomyocyte cultures indicated that cTNC promoter activity and mRNA
levels are not significantly affected by 10 ng/mL TGF-B 3 , with the cTNC
mRNA levels decreasing slightly after 72 hours of TGF-B 3 treatment. Thus,
the effects observed in the lines may be cell line specific and may not fully
represent what occurs in vivo.
To further test the hypothesis that TGF-B promotes differentiation
and maturation through the induction of the "adult"/cardiac isoforms and
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downregulation of "fetal"/skeletal isoforms of contractile proteins, the effect
of TGF-B3 on the expression of cTNI, sTNI, and sTNC was examined. As
sTNC is not normally expressed in the heart, the low promoter activities
observed in the primary cultures were not unexpected. The similar results
observed in the cell lines suggest that they have maintained their cardiacspecific background, and therefore, support their use as a cardiomyocyte
model system. However, mRNA transcripts for sTNC were detectable in
the cell lines, albeit at very low levels. As cTNC is avidly expressed in all of
the lines, both parental and mutant, and low stringency washes were
required for successful sTNC hybridizations, cross-hybridization of the
sTNC cDNA probe to cTNC transcripts similar to that reported in heart
tissue remains a possibility. However, the insignificant change in
transcript levels detected for sTNC after 72 hours of TGF-B 3 treatment does
not support that possibility. Therefore, the sTNC probe identified a
transcript distinct from cTNC, and suggests that sTNC is transcribed at a
low, negligible level in the cell lines.
In contrast to our hypothesis, it appears that TGF-B3 may have a
negative effect on the maturation of the cardiomyocyte. While sTNI
promoter activity in the primary fetal cultures is slightly reduced (-15%) in
response to 10 ng/mL TGF-B3 , a slight increase (10-15%) was detected in
sTNI transcript levels at 48 and 72 hours. In concert with these results, a
25% decrease in cTNI transcript levels was observed in primary fetal

myocyte cultures after 72 hours of treatment with 10 ng/mL TGF-B 3 (Table
17, Figure 20). In contrast, sTNI promoter activity, did not significantly
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change in any of the cell lines, even at 10 ng/mL TGF-B3 , however, the
individuality of the cell lines is once again demonstrated as the basal
activity in the BWEM lines was higher than that observed in the CLEM
lines, with little difference between the mutants and their parental lines.
The implications of the changes observed in the primary cultures and the
results obtained in the cell lines are discussed below.
While the transition between the two cTNT isoforms primarily occurs
just after birth, we hypothesized that TGF-B3 promotes the differentiation of
the cardiomyocyte through the upregulation of the adult isoform of cTNT.
Additionally, we used promoter assays to determine if TGF-B 3 has an effect
on overall transcriptional activity from the cTNT gene and to verify the use
of the myocyte-like cell lines as a model for cardiomyocyte development.
Promoter analyses demonstrated that 10 ng/mL TGF-B3 did not increase
transcription from the cTNT promoter construct in either primary fetal
myocyte cultures or the cell lines (Table 17). However, while cTNT
promoter activity was high in the primary cardiomyocyte cultures, cTNT
promoter activity was significantly lower in all of the cell lines. Similarly,
cTNT transcripts were readily detectable in total RNA collected from
primary cardiomyocyte cultures, yet undetectable in the cell lines by
Northern blot analyses using 30 µg total RNA. These results along with the
results obtained for TNI suggest that the cell lines have limited utility as a
cardiomyocyte developmental model. These limitations are discussed
further below.
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To directly examine effects of TGF-B3 on the expression of the
different isoforms of cTNT, Northern blot analyses were performed on RNA
collected from primary fetal cardiomyocytes treated with 0 or 10 ng/mL
TGF-B3 • Consistent with the promoter data, the transcript levels of total
cTNT expression did not change after 48 or 72 hours of treatment with TGF-

B3 (Table 17). To test the hypothesis that TGF-B promotes fetal myocyte
maturation, we examined the ability of TGF-B3 to influence the alternative
splicing of the cTNT transcript to favor the production of the alternatively
spliced, adult isoform in late fetal cardiomyocytes (18 dpc). A probe specific
for the fetal isoform of cTNT was used to determine any changes in the ratio
of fetal to adult isoforms. The results revealed that TGF-B 3 did not
significantly affect the transcript levels of the fetal isoform and, thus, the
adult isoform in the fetal cardiomyocyte cultures. This is in contrast to
what was observed in neonatal cardiomyocytes. Northern blot analyses of
RNA obtained from primary cultures of 2-day neonatal cardiomyocytes
treated with 1 ng/mL TGF-B 1 for 48-72 hours demonstrated an increase in
total cTNT expression and an increase in the alternatively spliced adult
isoform of cTNT (Dr. J. Lin, personal communication). As previously
discussed, TGF-B 1 and TGF-B3 elicit nearly identical effects in vitro, and as
such, it would be unlikely that these differences could be attributed to the
TGF-B isoform used. Since cTNT isoform switching predominantly occurs
during the immediate post-natal period, these data suggest that TGF-B can
augment the switch in its natural developmental time frame, but cannot
induce the switch prematurely in the fetal cardiomyocyte. Alternatively,
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the differences observed between the fetal and neonatal primary myocyte
cultures could be attributed to a developmental change in the TGF-B signal
transduction pathway (see below for further discussion). While selective
degradation of the fetal cTNT transcript may result from TGF-B3 treatment,
these data provide evidence suggesting TGF-B may have the ability to
influence gene expression at a post-transcriptional level by directly or
indirectly affecting the alternative splicing of a specific gene product.
Since the expression of TNC, and possibly other contractile genes, is
predominantly controlled by the production and accumulation of mRNA
transcripts (Gahlmann et al., 1988), it appears that TGF-B3 has little effect
on the expression of TNC, TNI, or TNT isoforms in fetal cardiomyocytes.
The downregulation observed for the adult isoform of TNI (cTNI) by TGF-B3
is an extension of what has been observed in neonatal cardiomyocytes
treated with TGF-B. In these cells, several "fetal" proteins, aSk-actin, BMHC, B-tropomyosin, and ANF, are induced while the adult isoform of
myosin, a-MHC, is downregulated (Schneider and Parker, 1990; Schneider
et al., 1992; Lembo et al., 1995). These changes in expression resemble
those that occur in the hypertrophic response to pressure overload
commonly induced in vivo by aortic banding or in vitro by stretching of
myocytes in culture (Schneider and Parker, 1991; Komuro et al., 1991;
Chien et al., 1991; Schneider et al., 1992) but not in exercise or thyroid
induced hypertrophy (Long et al., 1990). Additionally, the absence of
change in sTNI expression in the cell lines or small changes in expression
in the primary fetal myocyte cultures treated with TGF-B 3 corresponds to
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the lack of re-expression of sTNI in the ventricle in the adult heart
challenged by pulmonary hypertension or ischemic heart disease (Sasse et
al., 1993).
These similarities in changes in myocyte gene expression induced by
TGF-B and pressure overload have resulted in a postulated role for TGF-B
in the hypertrophic response of the adult myocyte. It has been
demonstrated that TGF-B expression is upregulated in vivo in response to
pressure overload (such as that induced by aortic banding) (Komuro et al.,
1991; Schneider et al., 1992; Lembo et al., 1995), but not through the
induction of hypertrophy utilizing other methods (Klein et al., 1995). In this
regard, TGF-B is considered to be part of a complex mechanism in which
changes in the cells' environment can be transmitted to the cells, either
directly influencing changes in gene expression and/or protein production,
or by augmenting the "signal" imposed by the pressure overload. In
addition to its apparent role in mediating a stress response, the TGF-Bs
have been implicated to play a role in recovery from myocardial infarction.
While TGF-B 1 is undetectable in the damaged myocytes, the viable myocytes
surrounding the injured cells exhibit increased TGF-B 1 expression
(Schneider and Parker, 1990; Lembo et al., 1995). Due to its established
roles in ECM biosynthesis and tissue repair, TGF-B 1 has been postulated to
play a role in the induction of compensatory hypertrophy of the myocytes
surviving or surrounding an infarct as well as building up the ECM to
increase tensile strength of the damaged area (Schneider and Parker, 1990;
Lembo et al., 1995). This is similar to what is observed during wound
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repair in skin tissue, where TGF-B ligands and receptor expression is high
in the tissues surrounding a wound, and absent within the wound and the
migrating epithelium (Gold et al., 1997).
In light of the data regarding TGF-B treatment of neonatal
cardiomyocytes as a model for pressure overload hypertrophy, the results
obtained in the cell lines and fetal cardiomyocytes suggest that our original
hypothesis for the direct role of TGF-B in ventricular development in
regards to modulating myocyte maturation is false and needs to be
modified. The data obtained for the TNT isoform switch suggests that TGFB may be able to promote the "adult" phenotype after birth, but not in the
developing fetal heart. The inability of TGF-B3 to induce similar changes in
cTNT expression in 18 day fetal myocytes as was observed in the neonatal
myocytes suggest two possible scenarios. The first option is that the
developmental program for the isoform switching that occurs in the heart
cannot be prematurely induced by TGF-B3 , but once the isoform switch is
initiated, TGF-B 3 has the ability to augment the change. However, the lack
of response observed for cTNC and the downregulation of cTNI in the fetal
myocytes cannot be attributed to TGF-B acting "out of frame" as the isoform
switch is already underway for these proteins during the late fetal period,
which encompasses the age at which the primary myocytes were collected.
This suggests an alternative scenario: the fetal myocytes lack or have a low
abundance of a rate-limiting factor in the TGF-B 3 signal transduction
pathway. While BRII expression is limiting in vivo at 18 dpc, Northern blot
analyses of RNA obtained from primary fetal myocyte cultures suggests
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neither receptor is rate limiting in vitro (Figure 22). However, other
members of the signal transduction pathway may be limiting. Since
members of the TGF-B signal transduction pathway have only recently
begun to be identified, this possibility cannot be addressed at this time.
However, the ability of the primary fetal myocytes to increase PAI-1
transcription in response to TGF-B 3 suggests these cells contain some of the
necessary components to mediate transcriptional regulation by TGF-B. As
PAI-1 is not a cardiac specific gene, a cardiac- or muscle-specific factor,
such as a transcription factor or a positive or negative trans-acting
regulator, which can be modulated by TGF-B may not be present or exist at
a low level in the fetal myocyte, and which is developmentally upregulated
in the neonatal myocyte conferring TGF-B responsiveness. This could
explain the overall lack of or low response to exogenous TGF-B3 treatment
observed in the studies described.
Similar arguments can be used to explain the differences observed
between the cell lines and the fetal myocytes. As transformed cell lines,

BWEM and CLEM have lost some aspect(s) of their cardiac-specific
transcriptional machinery demonstrated by the fact that they do not express
contractile proteins such as myosin heavy chain. As demonstrated here,
similar losses in expression have occurred for two other contractile
proteins, TNT and TNI, being readily detected in primary fetal myocyte
cultures but low or undetectable in the cell lines. Additionally, as
transformed cell lines, BWEM and CLEM express v-myc and potentially
several other unique transcription factors. As an extension of this, the

160
BRII-DN cell lines, having been transformed again with two exogenous
plasmids which integrated randomly, may have yet another molecular
milieu which may or may not be attributed to the expression of BRII-DN.
The altered transcriptional machinery available in the nucleus of all of
these cell lines may confer differential responses to exogenous TGF-B3 than
those responses elicited in the primary cells. Using cTNC as an example,
the decrease in promoter activity detected in the cell lines may be the result
of the activation of a TGF-B-responsive regulatory protein that binds to a
negative element in the cTNC promoter construct. However, the primary
fetal myocytes did not demonstrate a similar decrease in cTNC promoter
activity in response to TGF-B 3 • This suggests that the cell lines have
acquired or upregulated a negative regulator not normally present in the
cardiomyocyte. Finally, differences in responses, specifically the level of
response, between the cell lines and the primary myocytes may be the result
of differential expression of the receptors. While BRII receptor expression
is not rate limiting in any of the lines, the low expression levels of BRiil in
the cell lines may be one possible factor responsible for the differences
observed between the cell lines and fetal myocytes. Even though membrane
bound BRiii is thought only to present ligand to BRII, BRiii can be shed
from the cell surface and act to sequester TGF-B dimers (Attisano et al.,
1994). As BRiii is highly expressed in primary fetal myocyte cultures as
well as in vivo, heightened sequestration of exogenous TGF-B3 may be
responsible for the lower responses seen in the primary myocyte cultures.
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Based on a lack of effect on the filament isoform expression, it
appears that the developmental effects of TGF-B 3 on the fetal cardiomyocyte
are minimal. In as much as the studies described here only address the
direct effects TGF-B 3 has on the expression of these three contractile
proteins, indirect effects cannot be ruled out. As a modulator of ECM
formation, cell-cell interactions, and cell-ECM interactions, TGF-B may
promote cardiomyocyte differentiation and/or maturation through the
induction of morphological changes complemented by its ability to induce
cellular quiescence by its potent anti-proliferative properties retained in all
cell types examined.

Effects of TGF-B.a on Angiogenesis
A number of growth factors have been found to regulate angiogenesis
in vivo and, as discussed previously, one of these is TGF-B. While TGF-B

has been hypothesized to work as a chemoattractant and regulator of
capillary morphogenesis and apoptosis (Choi and Ballermann, 1995), TGFB may also control angiogenesis by regulating the production of an
angiogenic factor, SPARC. In order to test the hypothesis that TGF-B
promotes angiogenesis in the ventricle by increasing cardiomyocyteproduced SPARC, cultures of primary fetal cardiomyocytes and each of the
cell lines, wild type and mutant, were used to measure the changes in the
expression of SPARC and the release of its gene product into the media
upon exposure to TGF-B 3 • Although lower than expected, 10 ng/mL TGF-B 3
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induced a 20-40% increase in steady state SPARC transcript levels in all of
the cell lines as well as the primary fetal myocytes. Therefore, it appears
that TGF-B 3 minimally upregulated SPARC production through
transcription. Post-transcriptional upregulation in the absence of any
transcriptional induction has been demonstrated for SPARC in other cell
types (Wrana et al., 1991). Therefore, if our hypothesis that TGF-B
significantly increases SPARC production by cardiomyocytes and therefore
promotes angiogenesis in the ventricle is correct, TGF-B 3 would have to
mediate its effects translationally as the increases in transcripts were
minimal. To determine whether TGF-B 3 increased translation from preexisting SPARC transcripts, Western blot analyses were performed using
conditioned media proteins to detect changes in the levels of SPARC
secreted by the cells. Measuring the amount of SPARC protein secreted
into the media has been a standard determinant of the translation from
SPARC transcripts by a cell in culture (lruela-Arispe et al., 1991b; Wrana
et al., 1991). As such, Western blot analyses indicated that no further
upregulation of SPARC secretion occurred through increased translation
from the existing SPARC transcripts in response to TGF-B 3 in any of the
cell types. While promoter data for the fetal and BWEM lines support these
data, the CLEM and CL-B5 lines have conflicting results. Similar to the
cTNC study, CLEM exhibited a decrease of -35% in promoter activity, while
there was no significant change in activity in the CL-B5 line in response to
TGF-B 3 • However, unlike cTNC, it would be difficult to explain these results
in terms of mRNA stability as SPARC has a half life of -50 hours (Wrana et
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al., 1991). It is also of interest to note that the basal promoter activities for
CL-B5 are significantly higher than those for CLEM (Figure 23c). This is
reflected in the Western blot analyses (Figure 25) in which it appears that
CL-B5 secreted higher levels of SPARC protein as compared to CLEM.
However, this is not reflective of the relative transcript levels. In contrast to
CL-B5, there is no significant difference between BW-Hl and BWEM for
SPARC promoter activity, transcript or protein levels. The higher basal
promoter activity in CL-B5 may be attributed to an altered transcription
factor or regulatory protein content in this mutant line. While the results
obtained from these experiments vary slightly from cell line to cell line, a
general conclusion can be drawn that TGF-B 3 does not significantly
upregulate SPARC expression in and secretion from the fetal
cardiomyocytes or the myocyte-like cell lines.
It should be noted that the basal expression of SPARC, both mRNA
and protein, is very high in both the primary myocytes and the cell lines. It
has also been shown that secreted SPARC protein in vivo is rapidly
degraded, and thus, the majority of SPARC found in tissues is stored
within the cell until it is needed (Sage et al., 1989; Reed and Sage, 1996).
Therefore, it would be unwise to conclude that cardiomyocyte-produced
SPARC plays no role in promoting angiogenesis or that TGF-B doesn't have
a role in this process. However, it can be concluded that TGF-B3 does not
significantly increase SPARC production by the cardiomyocyte under the
conditions examined. As SPARC is stored in cytoplasmic granules in vivo,
TGF-B may provide a regulatory "trigger" which releases SPARC into the
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extracellular space when appropriate, selectively increasing the level of
SPARC into the ECM. As discussed previously, SPARC mediates most of
its actions, particularly angiogenesis, only after cleavage by proteases such
as plasmin. This provides another mechanism for TGF-B to promote
angiogenesis in relation to SPARC. As a modulator of ECM remodeling,
TGF-B has been shown to increase the production of several secreted
proteases. Since some of these same proteases may be involved in SPARC
activation, TGF-B may promote angiogenesis by inducing the production
and/or secretion of these SPARC activators from the cardiomyocytes. It
should also be stressed that TGF-B may also promote SPARC
production/secretion and angiogenesis in the ventricle by inducing similar
changes by paracrine mechanisms of action in the surrounding nonmyocyte cells whose numbers increase dramatically around and after
birth.

Use of Myocyte-like Cell Lines and Their Respective Mutants
The BWEM and CLEM myocyte-like cells lines are, theoretically, a
model system in which aspects of cardiomyocyte development and musclespecific activities can be evaluated. As stated previously, these cell lines
present certain limitations since they have lost some myocyte-specific
markers, such as the expression of myosin heavy chain, and their
spontaneous contractile activity after their transformation with v-myc.
While other contractile proteins such as cTNC are readily detected in these
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lines, in the experiments described here, transcripts for two other thin
filament proteins, TNI and TNT, were found to be very low or undetectable
using total RNA. Similarly, the basal promoter activities for the reporter
constructs of these two contractile proteins examined were significantly
lower than those observed in the primary cultures. As such, these low
transcript levels and basal promoter activities are difficult to interpret,
especially when a downregulation in expression level or activity is
anticipated or observed. Conversion of these promoter constructs to the
more sensitive luciferase based reporter may result in the accumulation of
data from the cell lines, as well as the primary myocytes, which are more
clearly defined and easier to interpret. Additionally, as demonstrated for
cTNC, the results obtained in these cell lines may not reflect what occurs in
the primary fetal cardiomyocytes. Therefore, the use of these cell lines as a
cardiomyocyte developmental model has limitations dependent on the
particular aspect being examined.
It has been demonstrated that these cell lines are useful in

examining aspects of cardiomyocyte developmental function such as the
roles cardiac and muscle-specific transcription factors play in contractile
gene expression (G.L. Engelmann, unpublished data). Having low TNI
and TNT transcript levels, these cells lines may be useful to identify
transcription factors involved in the activation of these or other genes
directly related to the contractile machinery of the beating cardiomyocyte.
Theoretically, through the introduction of exogenous transcription factors
by transfection of selective expression vectors, those factors involved in TNT
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or TNI transcription may be identified by their ability to increase levels of
these transcripts to those seen in primary cardiomyocytes. Since these cells
are much easier to manipulate than primary fetal and neonatal
cardiomyocytes, both knock-out and knock-in experimental systems are
available as tools to study molecular events involved in cardiomyocyte gene
regulation in a myocyte-like background.
As described here, these cell lines can be useful to study and possibly
identify components of the TGF-B signal transduction pathways in a
myocyte-like background. While not the focus of this dissertation, the
results obtained for cTNC in regards to the dual mechanisms of control
revealed by promoter and Northern blot analyses suggest that these cell
lines, both parental and mutant, provide a system in which the
mechanism(s) used to elicit the pleiotrophic effects of TGF-B can be
examined in greater detail. As cell numbers are not a rate-limiting factor,
co-treatment of cell cultures with TGF-B along with drugs, toxins, or other
chemicals can be used to interrupt various known signaling mechanisms
(G-proteins, kinases, etc.) and identify those pathways that may elicit the
specific TGF-B response. Using the transcriptional and posttranscriptional regulation of cTNC expression as a model, these types of
experiments could identify the type of pathways which regulate the two
different responses. Additionally, with the recent, and future,
identification of proteins which are involved in the signaling pathways of
the TGF-B superfamily, the dominant negative mutant cell lines could be
used to identify those proteins which may confer a specific response.
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Overexpression of an active form of these proteins in the DN lines may
result in the rescue of only one, transcriptional or post-transcriptional,
mechanism of cTNC regulation; an effect which may not be easily
discernible in the parental lines; and very difficult to examine in an in vivo
situation.

Conclusion
It appears that the role of TGF-B in the late fetal/ early neonatal

period of heart development is not as direct as we originally hypothesized.
We and others have provided in vitro data which supports the first part of
our hypothesis: biologically active TGF-B can directly inhibit proliferation
of ventricular cardiomyocytes. While the expression patterns of TGF-B 1,
TGF-B 3 , and BRII temporally coincide with the changes in cTNC, TNI,
TNT, and SPARC expression in the developing ventricle, they do not appear
to be functionally related to each other. It is important to keep in mind that
the increased production of TGF-B ligand as detected at the transcript and
protein level during this period may not be an indicator of TGF-B bioactivity
as TGF-B is usually secreted as a latent complex. In situ data have been
obtained from avian embryonic hearts which demonstrate that a majority of
TGF-B 3 located in the ECM is in its latent form (Ghosh and Brauer, 1996).
Therefore, functional activity of TGF-B in heart development may be
regulated by carefully restricting its level of activation, and not by its
general expression levels or that of its required receptor, BRII.
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As a mediator of the hypertrophic response to pressure overload,
TGF-B may also be a mediator of the mechanical stress that will be exerted
after birth as the newborn has to adjust to an air breathing environment.
As such, the onset of expression of TGF-Bv3 and BRII during the late fetal
period may serve to prime the myocardium for a proper response to this
stress or other physiological stimuli after birth. The onset/increase of
expression of BRII deems the cells competent to respond to TGF-B
activation. Similarly, as the majority of TGF-B released into the ECM is
biologically inactive, or latent, the onset/increase in expression of TGF-B 113
in the late fetal period provides a large "stock" of TGF-B which can be
readily activated as conditions require. While the exact mechanism of
activation in vivo is unclear, TGF-B can be activated in vitro by extreme pH,
heat, or proteolytic enzymes.
In contrast to our hypothesis which states that TGF-B affects
ventricular remodeling through the promotion of ECM accumulation and
angiogenesis, it would appear that cardiomyocyte-derived TGF-B may act
more as a negative regulator for these processes, keeping each in check.
Through the induction of PAI-1, TGF-B both promotes and inhibits
ventricular remodeling, allowing ECM accumulation, yet inhibiting the
transient breakdown of ECM components needed for remodeling and
cellular migration. Similarly, the induction of PAI-1 may actually inhibit
angiogenesis with regards to the mechanism of activation of SPARC. As
mentioned previously, SPARC must be cleaved by plasmin to induce
angiogenesis, and PAI-1 inhibits the formation of active plasmin.
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Therefore, TGF-B, while having some pro-angiogenic activities, also
provides a regulatory mechanism to keep the process in check.
Interestingly, TGF-B through two separate mechanisms, appears to
keep its own activity in check. While TGF-B 1 has been found to autoinduce
its expression (MacLellan et al., 1993; Flanders et al., 1995), co-induction of
PAI-1 inhibits the activation of plasmin, one of several proteolytic enzymes
found to release bioactive TGF-B from its latent form, thus downregulating
TGF-B's activity. Secondly, as demonstrated here, TGF-B3 appears to
downregulate a critical component of its own signal transduction
machinery by reducing the steady state transcript levels of BRII after
prolonged exposure. TGF-BRs have been found to undergo rapid
internalization upon ligand binding, being replaced almost immediately by
new receptors (Massague and Kelly, 1986; Centrella et al., 1996). As a
result, downregulation of the steady state transcript levels for BRII may
gradually slow down its replenishment at the cell surface, thereby
downregulating the cells' ability to respond to TGF-B. Therefore, it appears
that a complex web of positive and negative controls involving TGF-B exist
which could play a regulatory role in the proper development of the
cardiomyocyte and maintenance of ventricular tissue architectural and
functional homeostasis.
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